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Abstract
Complications with the current smallpox vaccine and the threat of a new smallpox 
epidemic have dramatically increased efforts to identify new antiviral compounds 
against orthopoxviruses. CpG oligodeoxynucleotides were investigated here for 
their ability to confer protection against vaccinia virus (VACV) in a model of 
orthopoxvirus infection in pre- and post-exposure settings.
Intranasal delivery of the B-class CpG 7909, prior to intranasal challenge with 
VACV, previously resulted in complete protection in a Balb/C mouse model of 
infection. Immunological analysis found that pre-stimulation with CpG resulted in 
the local release of pro-inflammatory cytokines such as IFN-a, IFN-y, TNF-a and 
IL-6 along with chemotactic messengers such as CCL2. In addition, activated 
innate effector cells such as macrophages, neutrophils, and dendritic cells were 
identified in high numbers in the lungs of CpG treated mice prior to infection. 
This heightened immune response persisted throughout early VACV infection in 
CpG-treated animals compared to that observed in un-stimulated control mice. 
Mice treated with CpG-B 7909 also initiated a second wave of immune activation 
late in infection indicative of a more rapidly formed adaptive response. Treatment 
and infection of B-cell Knock-out (KO) mice and neutrophil ablated mice 
suggested neither B-cells nor neutrophils alone were crucial in conferring CpG- 
mediated protection against VACV.
The success of CpG-B 7909 as a prophylactic against VACV led to its 
investigation as a post-exposure therapeutic. Intranasal treatment with CpG-B
7909, 24 hours after VACV challenge, boosted the pro-inflammatory response 
initiated after VACV infection in the lung. This response involved increased 
macrophage, neutrophil, dendritic cell and NK cell responses and increased levels 
of pro-inflammatory cytokines, interferons and chemokines. This enabled 
protection of 60% of VACV infected mice. Multiple dosing of CpG post-VACV 
exposure did not increase levels of protection.
The effectiveness of delivering CpG-B 7909 intranasally and identification of 
macrophages as a highly activated cell-type during CpG-mediated protection, led 
to the investigation of alveolar macrophages following CpG stimulation. Using in 
vitro macrophage cell-lines, A-class (CpG-A) and semi-soft C-class (CpG-sC) 
CpGs induced secretion of nitric oxide and expression of cytokines/chemokines 
more effectively than other classes of CpG in both alveolar (MH-S) and blood 
monocyte/macrophage (J774) cell-lines. In addition, MH-S macrophages were 
shown to secrete more nitric oxide but less IL-6 and TNF-a than J774 
macrophages after CpG stimulation. In an in vitro model of infection with VACV, 
pre-treatment of macrophages with CpG-B and CpG-sC significantly restricted 
viral replication independently of nitric oxide production. These antiviral 
properties led to the investigation of CpG-sC 10109 as a prophylactic against 
VACV in vivo where it conferred complete protection.
Collectively, these results suggest CpGs are highly immuno stimulatory and can 
confer full protection against VACV when given pre-exposure. This protection 
correlates with the induction of a strong, local immune response prior to VACV 
challenge, without which, the host fails to control infection effectively.
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IMV Intracellular Mature Virus
IP-10 IFN-y inducible Protein 10
IRAK IL-1 Receptor-Associated Kinase
IRF Interferon Regulatory Factor
ISG IFN-Stimulated Genes
ISRE Interferon Stimulatory Response Element
IV Immature Virus
IkB Inhibitor of NF-kB
JAK Janus Kinase
kb Kilobase
KSHV Kaposi’s Sarcoma-associated Herpesvirus
L-NMMA NG-Methyl’L-arginine Acetate salt
LPS Lipopolysaccharaide
LRR Leucine Rich Repeats
LSM Lymphocyte Separation Medium
LVS Francisella tularensis Live Vaccine Strain
Pg Microgram
Pi Microlitres
pM Micromolar
MAP Mitogen-Activated Protein
MCMV Mouse Cytomegalovirus
MCP Membrane Cofactor Protein
MCV Molluscum Contagiosum Virus
MDA Melanoma-Differentiation-Associated
MGB Minor Groove Binder
MHC Major Histocompatability Complex
MIP Macrophage Inhibitory Protein
MKK MAP Kinase Kinase
MLD Mean Lethal Dose
MMTV Mouse Mammary Tumour Virus
mRNA messenger Ribose Nucleic Acid
MVA Modified Vaccinia Ankara,
MyD88 Myeloid Differentiation Factor 88
NED N-1 -napthylethylenediamine dihydrochloride
NFQ Non-Fluorescent Quencher
NF-kB Nuclear Factor Kappa B
NIH National Institute of Health
NK cell Natural Killer Cell
NLR Nod-Like Receptor
nm Nanometres
nM Nanomolar
N 02‘ Nitrite
NOD Nucleotide-binding Oligomerisation domain
OAS Oligoadenylate Synthetase
ODE-CDV Octadecycloxyethyl-Cidofovir
ODN Oligodeoxynucleotide
OMP Orotidine Monophosphate
PAMPs Pathogen Associated Molecular Patterns
PBMC Peripheral Blood Mononuclear Cell
PBS Phosphate Buffered Saline
pDC Plasmacytoid Dendritic Cell
PE Phycoerythrin
PKR Protein Kinase R
PO Phosphodiester
Poly I:C Polyinosinic Polycytidylic
PRR Pattern Recognition Receptor
PS Phosphorothioate
RANTES Regulated upon Activation, Normal T-cell Expressed, and
Secreted.
RBC Red Blood Cell
RIG Retinoic acid Inducible Gene
RK13 Rabbit Kidney 13
RLH RIG-Like Helicase
RNA Ribose Nucleic Acid
rpm revolutions per minute
RPMI Roswell Park Memorial Institute
RSV Respiratory Syncytial Virus
RT Reverse Transcription
RT-PCR Reverse Transcription Polymerase Chain Reaction
SAH S-Adenosylhomo-cysteine Hydrolase
SAM S-Adenosylmethionine
SARS Severe Acute Respiratory Syndrome
SDS Sequence Detection System
SPGF Smallpox Growth factor
SPI Serine Protease Inhibitor
ss Single Stranded
STAT Signal Transducers and Activators of Transcription
TAB TGFP-Activated kinase Binding protein
TAK TGFp-Activated Kinase
TCAV Tacaribe Arenavirus
TGFp Transforming Growth Factor Beta
Th T-helper cell
TIR Toll-Interleukin-1 Receptor
TLR Toll-Like Receptor
TMB T etramethyl-Benzidine
TNF Tumour-Necrosis Factor
TNFR Tumour-Necrosis Factor Receptor
TRAF Tumour-necrosis factor Receptor Associated Factor
TREM Triggering Receptors Expressed on Myeloid cells
TRIF Toll/IL-1 Receptor domain-containing adaptor inducing IFN-beta
U Units
UMP Uracil Monophosphate
UNG Uracil-N-glycosylase
VACV Vaccinia Virus
XXX
vCKBPs Viral Chemokine-Binding Proteins
vCKRs Viral Chemokine-Receptor homologues
VCP VACV Complement control Protein
vEGF Viral Epidermal Growth Factor
VESPR Virus-Encoded Semaphoring Protein Receptor
v-GAAP Viral Golgi Anti-Apoptotic Protein
VGF VACV-induced Growth Factor
vSEMA Viral Semaphorin Homologue
VSV Vesicular Stomatitis Virus
vTNFR Virus TNF Receptor
vVEGF Viral Vascular Endothelial Growth Factor
WR Western Reserve
XMP Xanthine 5’-Monophospahte
Chapter 1: General Introduction
1.1. The innate immune response
The innate immune system of multicellular organisms has evolved into a powerful 
system for the detection and elimination of infectious organisms. Innate immunity 
serves as the rapid, front-line of host defence that can be characterised by the 
initiation of effector mechanisms that interact immediately and directly with invading 
pathogenic organisms. This response is coupled with the ability to respond unchanged 
and equally to subsequent infections. This primitive response is a highly conserved 
ancient system that occurs in a vast range of species from higher order mammals, 
such as humans, down the phylogenetic tree to insects, metazoans and plants.
The mammalian immune system possesses a two tiered mechanism of protecting the 
host from infection. The innate system is characterised by the activation and 
recruitment of phagocytic cells such as macrophages and neutrophils along with the 
release of immunostimulatory cytokines, chemokines, and polyreactive IgM 
antibodies which can activate the complement system. In the vast majority of cases, 
the innate immune response proves too powerful for any invading organism and 
infection resolves without the development of symptomatic illness. Pathogens that are 
able to overcome the innate response however are faced by an adaptive immune 
response that is initiated by cells of the innate response. Innate immune cells such as 
dendritic cells and macrophages, present antigen and release effector molecules that 
activate the two key components of the adaptive response, B and T-lymphocytes. This 
typically leads to production of high affinity IgG antibodies and the generation of 
cytotoxic T-Lymphocytes (CTLs) through a process of clonal expansion. Ultimately,
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the adaptive immune response enables the generation of immunological memory and 
long lasting protection.
1.1.1. Pattern recognition
Research over recent years has afforded greater insight into the host ability to 
discriminate between self and non-self. Studies have shown that protection of the host 
by the innate immune system during the early stages of an infectious challenge in part 
relies upon its ability to recognise a highly conserved set of molecular motifs 
expressed by micro-organisms. These patterns have been defined as ‘pathogen- 
associated molecular patterns’ (PAMPs) and host organisms have developed a 
repertoire of germline-encoded receptors throughout evolution known as pattern 
recognition receptors (PRRs) that are capable of recognising these particular motifs 
(Medzhitov & Janeway, 1997). PRRs are expressed constitutively by the host and 
diversity within these PRRs has resulted from the evolution of a number of different 
families of pattern recognition receptors that fall broadly into one of two categories, 
namely, those located either on the cell surface or intracellularly (endosomal and 
cytosolic). The most studied family of receptors are the family of Toll-like receptors 
(TLRs).
1.1.2. Toll and the Toll-like receptors
TLRs have been widely shown to play a crucial role in initiating the immune response 
and as such are fundamental to the host’s ability to cope successfully with infection. 
Toll was first identified and characterised through studies using Drosophila 
melanogaster. These studies initially characterised Toll as an essential feature of 
Drosophila’s embryonic development but it was later shown to be crucial in its
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antifungal response (via activation of the antifungal peptide drosomycin) to 
Aspergillus fumigatus (Lemaitre et al., 1996). Soon after this discovery, a 
homologous family of receptors was identified in humans and to date 13 TLRs have 
been described in mammals with each receptor possessing specificity for particular 
PAMPs. TLRs are predominantly associated with cells that are most likely to be 
amongst the first to encounter invading organisms such as monocytes/macrophages, 
neutrophils, dendritic cells and epithelial cells (Table 1.1) (Akira, Uematsu & 
Takeuchi, 2006; Homung et al., 2002). Notably, TLR expression is also exhibited by 
a variety of other non-immune cell-types that are susceptible to infection including 
adipocytes, vascular endothelial cells and intestinal epithelial cells. This wide degree 
of cellular expression ensures the innate immune response is able to detect infection 
rapidly and mount an appropriate and immediate immune response. To fine-tune this 
innate response further, TLR family members are expressed differentially among 
immune cells with certain TLRs only being expressed by specific cell types and 
receptors being positioned either on the cell-surface (TLRs 1, 2, 4, 5, 6 and 11) or 
intracellularly within endosomal compartments (TLRs 3, 7, 8, and 9). Variation in the 
location of these receptors allows the host immune system to recognise a range of 
both intracellular and extracellular pathogens. For instance, TLR4 is expressed at the 
cell surface and recognises the lipopolysaccharide (LPS) component of extracellular 
Gram negative bacteria (Beutler, 2000). Conversely, the endosomally located TLR9 
has been widely shown to recognise unmethylated cytosine-phosphate-guanosine 
(CpG) dinucleotides, which are common in the genomes of most bacteria and DNA 
viruses but not in vertebrate genomes (Bauer et a l , 2001). This allows the TLRs to 
recognise PAMPs from a variety of micro-organisms such as bacteria, viruses, 
mycobacterium, spirochetes and yeasts.
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TLR Ligands Distribution Cellular
location
TLR1 Triacyl peptides (bacteria and mycobacteria) 
♦associates with and regulates TLR2 response
B-cells*** 
Monocytes*** 
NK cells** 
Neutrophils***
Cell surface
TLR2 Peptidoglycan (Gram+ bacteria) 
Lipoproteins (bacteria and mycoplasma) 
Atypical LPS (bacteria)
Porins (Neisseria)
Haemagluttinin protein (measles virus)
♦ associates with either TLR1 or TLR6
Monocytes* * * * * 
NK cells** 
B-cells** 
Neutrophils***
Cell surface
TLR3 dsRNA (Viruses) 
synthetic Poly (I:C)
NK cells**
T-cells**
DCs***
Intracellular
TLR4 LPS (Gram' bacteria)
Mannam (C.albicans)
Viral envelope proteins (RSV, MMTV) 
Glycoinositolphospholipids (Trypanosoma) 
HSP 60,70, Fibrinogen (Host)
Monocytes ****
B-cells*
Neutrophils*
Cell surface, 
CD14-MD2 
dependent 
response
TLR5 Flagellin (bacteria) Monocytes*** 
NK cells* 
Neutrophils*
Cell surface
TLR6 Microbial lipoproteins (bacterial)
♦ associates and regulates TLR2 response
Monocytes*** 
NK cells* 
Neutrophils*
Cell surface
TLR7 Synthetic Imidazoquinoline-like molecules 
ssRNA (virus)
pDC**
B-cells**
Monocytes*
Neutrophils*
Intracellular
TLR8 Synthetic Imidazoquinoline-like molecules 
ssRNA (virus)
Monocytes**
Neutrophils*
Intracellular
TLR9 CpG DNA (bacteria, virus, protozoa) pDC***
B-cells**
Neutrophils*
Intracellular
TLR10 Unknown B-cells*
pDC*
Neutrophils*
Cell surface
Mouse
TLR11
Uropathogenic bacteria
Profilin-like molecule {Toxoplasma gondii)
Kidney / Bladder 
epithelia*** 
Liver Epithelia*
Cell surface
Table 1.1. The mammalian TLR family: Ligand recognition and cellular 
distribution of TLRs 1-10 in humans and TLR11 in mice.
* Denotes relative expression o f  TLR on cellular source
Review reference (Akira, Uematsu & Takeuchi, 2006; Homung et al, 2002)
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Structurally, the Toll-like receptors possess characteristic external regions that consist 
of multiple leucine-rich repeats (LRR) that are responsible for ligand-binding and an 
intracellular, cytoplasmic portion that closely resembles the cytoplasmic portion of 
the IL-1 receptor family (Medzhitov et a l , 1997). Stimulation of TLRs results in the 
activation of nuclear transcription factors such as NF-kB (Figure 1.1). The nuclear 
factor-KB (NF-kB)/REL family of transcription factors has been shown to play a 
central role in coordinating the expression of a wide variety of inflammatory genes 
(Li & Verma, 2002). Whether located at the cell surface or intracellularly, each TLR 
possesses a highly conserved intracellular region known as the Toll/IL-IR (TIR) 
domain that is homologous to both Toll and the IL-1 receptor cytoplasmic regions. 
The TIR component of the receptor interacts with one of five cytoplasmic adaptor 
proteins that also contain TIR domains and this interaction has proven crucial for 
signal transduction following ligand binding (O’Neill & Bowie, 2007). The 
predominant adaptor protein utilised by the cell is the myeloid differentiation primary 
response gene 88 (MyD88) (Schnare et a l , 2000). With the exception of TLR3, all 
TLR binding can initiate a common and well characterised signaling cascade that is 
dependant upon the recruitment of MyD88. This molecule is recruited to the TIR 
domain, and upon binding, signals through its N-terminal ‘death domain’ resulting in 
the immediate recruitment of IL-1 receptor-associated kinases (IRAKs) 1, 2 and 4, 
depending on the TLR stimulated (Wesche et a l , 1997; Keating et al, 2007). 
Following the phosphorylation of IRAK-2 by IRAK-4, another critically important 
molecule, the tumour-necrosis factor receptor (TNFR)-associated factor 6 (TRAF6) 
(Cao et a l, 1996), becomes activated by IRAK-2 through ubiquitination (Keating et 
al, 2007). This crucial step then permits TRAF6 to complex with TAK-1 (TGFp- 
activated kinase 1) and TAB (TAK 1 binding proteins) 1 and 2. Together they activate
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Figure 1.1. TLR pathway and activation.
Binding of ligand to TLRs results in adaptor protein recruitment 
(MyD88/TRIF/TRAM/MAL) that binds to the cytoplasmic TIR domain of the TLR. 
CpG-DNA binds to intracellular TLR9 and initiates signal transduction through a 
MyD88 dependent pathway. Here, signal transduction occurs through IRAK4, IRAK- 
1/IRAK2, TRAF-6, and the TAB1/TAB2/TAK1 complex. NF-kB activation results 
from activation of IKK complex (IKKa/IKKp/NEMO) and freeing of NF-kB from its 
inhibitor (IkB) for nuclear translocation. The binding of ligands to TLRs can also 
result in activation of additional transcription factors such as AP-1 via JNK, p38, Erk 
pathways and interferon genes through IRF-5. IRF-3 activation can occur through a 
MyD88 independent pathway via TRIF through TLRs 3 or 4 and IRF-7 can initiate 
IFN signalling in a pathway specific to pDC and TLR7/9 signaling.
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the inhibitor of NF-kB kinase complex (IKK) via tyrosine phosphorylation. The 
phosphorylation of IkB (inhibitor of NF-kB) results in the release of NF-kB allowing 
it to freely translocate into the nucleus of the cell. Import of NF-kB into the nucleus 
permits the transcription of hundreds of genes that encode mediators of inflammatory 
responses (reviewed in; Li & Verma, 2002). These include the synthesis of pro- 
inflammatory cytokines such as IL-ip, IL-6, IL-18, IL-12 and TNF-a and also the 
production of anti-inflammatory cytokines and mediators such as IL-10 and IL-1 
receptor antagonsist (IL-1RA) to help regulate the inflammatory response. Secretion 
of chemokines such as IL-8, CCL2, MIP-la/p, as well as inflammatory 
prostaglandins, leukotrienes and oxidants are also all under the control of NF-kB. 
Additional transcription factors are also activated through TLR signaling. For 
instance, TAK-1 is also able to simultaneously activate two members of the mitogen- 
activated protein (MAP) kinase kinase family MKK3 and MKK6, which are able to 
activate c-Jun N-terminal kinases and p38 to activate ATF2-cJun and AP-1 (Sato et 
a l , 2005;Hartmann & Krieg, 2000). IRF-5 is able to translocate into the nucleus of 
the cell and bind interferon stimulatory response element (ISRE) motifs present in the 
promoter regions of cytokine genes (Takaoka et al., 2005). A comprehensive review 
of the signaling pathways specific for individual TLRs is beyond the scope of this 
thesis but can be found in the following review article (Kawai & Akira, 2007).
1.1.3. Non-TLRPRRs
In addition to the TLR pathway, a number of additional transmembrane receptor 
families have been shown to possess PRR properties. One such group are the C-type 
lectin receptors (CLRs), a family with up to 17 subgroups, several of which can bind 
to PAMPs and also directly to micro-organisms themselves through CLR sugar
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moieties (Robinson et a l, 2006). CLRs are found on myeloid antigen presenting cells 
such as dendritic cells, macrophages and B-cells and are postulated to play a number 
of roles within the response to pathogenic organisms in addition to ensuring immune 
homeostasis. Well studied receptors within this family include DC-SIGN (dendritic 
cell-specific intercellular adhesion molecule 3-grabbing non-integrin) that can 
mediate the phagocytosis of mycobacteria (Neyrolles et a l, 2006). Other families 
include the TREM (triggering receptors expressed on myeloid cells) family of 
receptors (Klesney-Tait et a l, 2006), the siglec molecules (Crocker, 2005), collectins 
and also the mannose receptors that recognise mannosylated lipoarabinomannans.
Within the last few years our understanding of the molecular mechanism of pathogen 
recognition has been boosted even further by the discovery of two additional families 
of intracellular pattern recognition receptors. These comprise the NOD (nucleotide- 
binding oligomerisation domain)-like receptors (NLRs) and the RIG (retinoic acid 
inducible gene)-like helicases (RLHs). The NLRs are comprised of two predominant 
sub-classes, the NODs (NOD 1-5) and NALPs (NALP1-14) and recognise unique 
bacterial components such as peptidoglycan intracellularly (Meylan, Tschopp & 
Karin, 2006). The RLH receptors are key to the successful initiation of the type I 
interferon pathways in a TLR independent fashion and are covered in the following 
section.
1.1.4. Viral defence and PRRs
The structural components of viruses, including viral DNA, single and double 
stranded RNA and surface glycoproteins, are able to activate the innate immune 
system. Responses against viral pathogens are dependant upon recognition of viral
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PAMPs by pattern recognition receptors and subsequent induction of IFN-stimulated 
genes (ISGs) and production of antiviral cytokines such as the type I, II and III 
interferons (e.g. IFN-a/(3, IFN-y and IFN-A, respectively). Type I IFNs, (IFN-a and 
IFN-P in particular) are the first interferons synthesised following viral detection and 
can be produced by most cell types once virally infected where they act to confer an 
antiviral state in uninfected cells (reviewed in; Platanias, 2005). Amplification of 
these early type I IFNs and subsequent binding to the type IIFN receptor activates the 
Janus kinase and signal transducers and activators of transcription (JAK-STAT) 
pathway. Here, STAT1 and STAT2 combine with the IFN regulatory factor 9 to form 
the IFN-stimulated gene factor 3 complex, which translocates into the nucleus to bind 
IFN-stimulated response elements (ISRE) present in a variety of genes required for 
antiviral immunity (Takaoka & Yanai, 2006). This includes the induction of many 
pro-inflammatory cytokines including the type II interferon, IFN-y. IFN-y is 
specifically produced by activated NK cells and T-cells to perform numerous roles 
including macrophage activation and promoting the development of CD4+ Th-1 cells 
and cytotoxic CD8+ cells (Katze et al., 2002; Haller et al., 2006). The type III IFNs 
are less well defined and their roles in antiviral immunity are gradually being 
established although research has revealed a potent in vivo role for these interferons in 
a poxvirus infection model (Kotenko et al., 2003; Bartlett et al., 2005). Collectively, 
the interferon response is vital to the successful defence against viral pathogens, 
incorporating both arms of the host immune response. This has been shown 
repeatedly in virally-infected mice with a dysfunctional interferon response, rapidly 
leading to overwhelming infection and death (Muller et al., 1994).
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Control of type I IFN genes is tightly regulated by a number of transcription factors 
including NF-kB, ATF2-c-Jun, but predominantly by members of the interferon 
regulatory factor (IRF) family of transcription factors (Honda & Taniguchi, 2006). 
The intracellular recognition of viral PAMPs has recently been shown to occur via a 
newly identified set of cytosolic PRRs collectively known as the RLHs. These RNA 
helicases act as sentinels for the detection of viral RNA and consist of 2 family 
members, these being melanoma-differentiation-associated gene 5 (MDA5) 
(Andrejeva et al., 2004) and Retinoic-acid-inducible gene-1 (RIG-I) (Yoneyama et 
al., 2004). RIG-I and MDA-5 are ubiquitously expressed in most tissues and exhibit 
specificity for distinct sets of RNA viruses (Kato et al, 2006). Both RLHs have been 
shown to recognise dsRNA, which is generated as an intermediate of viral 
transcription and recently, the exact ligand for RIG-I has been reported to be 5’- 
triphosphate groups on RNA (Homung et al., 2006). The sensing of viral RNA in 
most cell types typically leads to the serine/threonine phosphorylation of IRF-3 which 
enables it to homodimerise and translocate into the nucleus where it promotes the 
initiation of IFN-P mRNA synthesis and activation of other ISGs. Activation of IRF-7 
follows shortly after to synergise with IRF-3 in the production of a variety of different 
IFN-a subtypes (Haller et a l, 2006). Additionally, dsRNA is recognised by dsRNA- 
dependant protein kinase (PKR), which in response to stimulation, inhibits host 
translation through phosphorylation of the a-subunit of eukaryotic protein synthesis 
initiation factor 2 (eIF-2a). This inhibition of translation thwarts the virus’ ability to 
utilise host machinery to synthesise proteins critical to its survival (Saunders & 
Barber, 2003). It is perhaps very likely that additional PRRs exist that recognise 
dsDNA as type I IFN responses have been demonstrated to occur in response to 
cytosolic dsDNA that are independent of TLR or RIG-I activation (Ishii et al, 2006).
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A potential candidate for this has recently been identified as the DNA-dependent 
activator of IRFs (DAI) (Takaoka et al, 2007).
1.1.5. TLR recognition of viral PAMPs
Recognition of viral PAMPs by members of the TLR family has also been widely 
documented with TLRs 2, 3, 4, 7, 8 and 9 being able to recognise viral ligands 
(Gorden et al., 2006). Deficiencies in the TLR pathway have been shown to result in 
exacerbated viral infection, as seen in the susceptibility of MyD88 deficient mice to 
respiratory syncytial virus (RSV) infection (Rudd et al., 2007).
1.1.5.1. TLR2
TLR2 recognises the haemagluttinin protein of wild type measles viruses, and a virion 
protein of human cytomegalovirus (CMV) (Bieback et al., 2002; Compton et al., 
2003). More recently, the secretion of pro-inflammatory cytokines in response to 
vaccinia virus (VACV) has been suggested to rely on TLR2 activation on dendritic 
cells (Zhu et al., 2007). In this paper, signaling was thought to initiate via TLR2 
interaction with core or envelope proteins given UV-inactivated VACV generated 
similar levels of cytokine responses. This makes it unlikely that newly-synthesised 
VACV virions stimulated responses through TLR2 (Zhu et al, 2007).
1.1.5.2. TLR3
TLR3 was the first TLR to be identified with antiviral properties having been widely 
shown to recognise dsRNA as a by-product of viral replication (Alexopoulou et a l, 
2001). TLR3 is endosomally located and its activation recruits the adaptor protein 
TRIF, not MyD88 as typically utilised by all other TLRs. This subsequently results in
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activation of NF-kB, the IFN response pathway via IRF-3 and the initiation of 
apoptosis (Figure 1.1) (Schroder & Bowie, 2005). The cellular distribution of TLR3 
on NK cells and, in particular, myeloid DCs may also promote cross-priming and 
generation of virus specific CD8+ T-cells (Datta et a l , 2003). Interestingly, TLR3 has 
recently been suggested to be detrimental following VACV infection (Hutchens et al, 
2008). Here, mice deficient in TLR3 had increased survival and reduced disease 
morbidity, virus dissemination and lung inflammation compared to wildtype mice 
(Hutchens et al, 2008). This implies that TLR3 interactions with dsRNA from VACV 
may contribute to the pathogenesis of severe and fatal cases of poxvirus infection.
1.1.53. TLR4
TLR4, which is predominantly recognised as the receptor for bacterial LPS, is also 
able to recognise viral components and initiate a pro-inflammatory response. This has 
been demonstrated through TLR4 specific recognition of RSV fusion protein F as 
well as the envelope protein of mouse mammary tumour virus (MMTV) (Rassa et a l , 
2002; Kurt-Jones et a l, 2000). Like TLR3, TLR4 activation can also be mediated via 
the adaptor protein TRIF in a MyD88 independent pathway resulting in the activation 
of IRF-3 (Wietek et a l, 2003).
I.I.5.4. TLRs 7 and 8
One cell type in particular that has proven crucial to the initiation of the interferon 
response is the plasmacytoid dendritic cell (pDC) (Asselin-Paturel et a l, 2001). 
Activation of pDCs via the intracellular TLRs 7, 8 or 9 leads to the recruitment of 
MyD88, TRAF-6 and IRF-5/7 which in turn leads to the synthesis of multiple type I 
IFN-a genes and copious release of IFN-a (Kawai et a l, 2004; Takaoka et al, 2005).
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pDCs are unique in that they constitutively express IRF-7 whereas in other cell types, 
IRF-7 is generally undetectable in the cells’ quiescent or resting state prior to IRF-3 
activation. Mouse TLR7 has been found to recognise and respond to ssRNA from 
numerous viruses including human immunodeficiency virus (HIV), influenza and 
vesicular stomatitis virus (VSV) whilst TLR8 has also been shown to recognise HIV 
in humans (Heil et al., 2004; Diebold et al., 2004).
1.1.5.5. TLR9
TLR9 on pDCs can also be activated by the presence of CpG motifs present in the 
genomes of DNA viruses such as herpes-simplex virus-1 and 2 (HSV-1 and HSV-2) 
(Krug et al., 2004; Lund et al., 2003) and present in synthetic CpG 
oligodeoxynucleotides (CpGs). Numerous studies have shown that TLR9 deficiency 
in mice results in extreme susceptibility to viral infection and an inability to induce 
necessary antiviral responses (Tabeta et al., 2004). In contrast, mice lacking TLR9 
have been shown to mount normal IFN-a responses in response to highly attenuated 
strains of VACV questioning the importance of TLR9 in iniating responses to VACV 
infection (Waibeler et al, 2007). The finding that CpG motifs from prokaryotic DNA 
can stimulate the immune system and the subsequent development of CpGs has 
stimulated extensive research into the potential therapeutic uses of these synthetic 
compounds. Over the last decade they have been used as vaccine adjuvants, in cancer 
and allergy treatments and as protective agents in their own right.
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1.2. Immunostimulatory properties of CpG motifs
1.2.1. The identification of CpG motifs
Evidence for bacterial preparations being able to confer a therapeutic effect to cancer 
patients was reported as far back as 1893 by Coley (Coley, 1893) following successful 
treatment of sarcomas. However, the effects of bacterial DNA specifically were 
questioned and generally considered to be immunologically inert. The concept of 
DNA acting purely as a genetic code was first questioned in studies dating back to 
1963 where DNA from viruses was reported to induce the production of interferon 
(Rotem et a l, 1963). It was not until 1984, when bacterial DNA was first reported to 
confer a therapeutic effect against tumours (Tokunaga et a l , 1984), that the field of 
CpG research began to take shape.
In a series of pioneering studies where the anti-tumour effect of DNA from 
Mycobacterium bovis bacille Calmette-Guerin (BCG) was analysed, it was shown that 
a purified fraction of BCG DNA (designated MY-1), was able to activate natural 
killer cells (NK cells) and B-cells and to initiate the production of type I and type II 
interferons (Yamamoto et a l, 1992b; Messina et a l, 1991). Significantly, these 
results could not be reproduced using vertebrate DNA and were abolished by pre­
treatment of the MY-1 fraction with DNase. Yamamoto et al showed that it was 
possible to recreate the stimulatory effects of bacterial DNA using synthetic 
oligodeoxynucleotides (ODN) containing unique self-complementary palindromic 
sequences (Yamamoto et a l, 1992a). Closer examination of these hexameric 
stimulatory palindromes revealed one common feature, namely the presence of a 
central cytosine and guanosine dinucleotide motif and two flanking base pairs. 
Analysis of bacterial and vertebrate DNA revealed that bacterial DNA seemed to
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feature far more of these active palindromes than vertebrate DNA did, although at the 
time the flanking sequences of the CpG motif were not thought to be so critical. 
Methylation of CpGs was also not originally thought to have a deleterious effect on 
the stimulatory ability of DNA (Kuramoto et al., 1992). This was contradicted by 
results published by Pisetsky and colleagues who demonstrated that methylation of 
poly-(dC,dG) was sufficient to abolish its stimulatory effects (Messina et al., 1993).
A number of these concepts were later revised in a seminal paper by Krieg and 
colleagues in experiments where massive stimulation of B-cells using particular 
ODNs was demonstrated (Krieg et al., 1995). It was shown that the stimulatory effect 
of CpG ODNs could be eliminated if the cytosine base of the CpG motif was 
substituted for a 5-methyl cytosine. Conversely, methylation of any other cytosine 
bases, not part of the CpG dinucleotide, was shown to have no effect on the 
immunostimulatory capacity. This work also highlighted that the stimulatory strength 
of ODNs featuring the CpG motif lay primarily in the context of bases immediately 
adjacent to the CpG dinucleotide and did not require the motif to be in a palindromic 
sequence. Altering the positions of the CpG motif could also be shown to reduce the 
degree of immune stimulation. This allowed the identification of a sequence motif 
that afforded optimal stimulation and helped define the characteristics of 
oligonucleotides that would prove most stimulatory. In a mouse model, it was 
recognised that oligonucleotides with a CpG dinucleotide flanked by two 5’ purines 
and two 3’ pyrimidines (5,-Pu-Pu-CpG-Pyr-Pyr-3’) proved most stimulatory (Balias 
et al., 1996). Ideally, these motifs were preceded on the 5' side by an ApA, GpA, or 
GpT and followed with a TpT. Soon after came the discovery that CpG dinucleotides 
sandwiched between cytosine and guanosine bases in the sequence CCGG were
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practically inert (Krieg et a l , 1998). These CCGG motifs were identified as being 
able to specifically neutralise the immunostimulatory effects of stimulatory CpG 
motifs and were coined CpG-N motifs. The significance of these findings helped 
shape the idea that the mammalian immune system might be able to use differences 
between bacterial and its own DNA to initiate a response to infection.
1.2.2. Differences between bacterial and vertebrate DNA
There are a number of key differences between bacterial DNA and vertebrate DNA 
(Stacey et al., 2003). Firstly, CpG dinucleotide motifs in bacterial DNA are present at 
the level expected given random base utilisation (estimated as 1 per 16 bases). In 
contrast, vertebrate DNA features only a quarter of this CpG content, suggesting a 
high degree of CpG suppression (Bird, 1987). Secondly, cytosine methylation in 
vertebrate CpG motifs (approximately 70%) differs substantially from bacterial DNA, 
where the vast majority of CpG motifs are unmethylated (Razin & Friedman, 1981). 
Thirdly, CpG dinucleotide motifs in vertebrate DNA are typically flanked by the 
immune-neutralising sequences described by Krieg (Krieg et al., 1998). Genomic 
sequence analysis of the human genome also revealed the suppression of those CpG 
motifs that have proven to be most stimulatory (e.g GACGTT). Finally, mammalian 
DNA is capped with specialised DNA-protein structures called telomeres that are rich 
in hexameric TTAGGG motifs. These motifs are rare in bacteria, and have proven to 
be highly immunosuppressive through down-regulation of IL-12 and IFN-y 
production (Gursel et al., 2003; Shirota et al., 2004). These TTAGGG motifs have 
emerged as potential therapeutic agents in their own right (Klinman et al., 2005).
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The combination of these factors has led to the hypothesis that the presence of 
bacterial DNA or mimicking synthetic ODNs can be detected by cells of the innate 
immune system and can initiate a rapid immune response. Recent years have seen a 
prolific advance in our understanding of how CpG motifs are recognised by cells of 
the immune system and the signaling cascade that results in immune cell activation. 
Advances in our understanding of ODN chemistry have facilitated the development of 
a variety of structurally different CpG ODNs that can differentially activate particular 
cells of the immune system.
1.2.3. Species differentiation and other organisms
Bacterial DNA itself has been shown to vary in its stimulatory capacity, with DNA 
from different species of bacteria resulting in differing levels of immune activation. 
DNA from Escherischia coli is highly effective at stimulating immune cell activity, 
whilst DNA from Clostridium perfringens induces a weak immune response (Neujahr 
et a l , 1999). This variation may be due to differences in the quantity and quality of 
internal stimulatory CpG motifs, along with the presence of immune neutralising 
motifs.
Although the vast majority of work related to CpG stimulation originates from the 
immunostimulatory properties of bacterial DNA, it is of note that other organisms 
possess DNA that also proves to be stimulatory. Much work has focused on the 
genomes of viruses and the notable degree of variation in their CpG content (Karlin et 
al., 1994). It is has been demonstrated that nearly all pathogenic vertebrate viruses 
exhibit a high degree of CpG suppression. This is believed to be part of an 
evolutionary defence mechanism to limit the host’s response to infection. Viruses that
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exhibit the smallest degree of CpG content are most able to establish long-lasting 
infections such as HIV, where only one fifth of the expected numbers of CpG motifs 
are present (Karlin et a l , 1994). In addition, both adenovirus type 2 and 5 have about 
5-fold higher concentration of CpG-N motifs to help further suppress the host 
response and limit inflammation (Krieg et a l , 1998).
Drosophila extracts have been shown to have stimulatory properties along with DNA 
from nematodes and this is a result of the high degree of unmethylated CpG motifs 
present in the genome (Sun et al., 1996; Sun et a l, 1997). Studies have demonstrated 
that the optimal CpG motif in human responses is the hexameric GTCGTT motif 
(Hartmann & Krieg, 2000) and a wide variety of other vertebrate species has also 
been investigated for their responsiveness to CpGs. Cows, sheep, goats, pigs, as well 
as cats and dogs have all been shown to respond to the GTCGTT motif that optimally 
stimulates human immune cells, suggesting a high degree of evolutionary 
conservation (Rankin et a l, 2001). However, not all vertebrates share this preference 
for the GTCGTT motif as the study by Rankin et al, 2001, revealed that inbred 
strains of mice and rabbits responded best to the motif GACGTT. Studies have 
revealed that the amino acid sequence for the human TLR9 receptor differs by 24% 
from the mouse TLR9 amino acid sequence, and this may explain the difference in 
CpG motif preference between the two species (Hemmi et a l, 2000).
It is known that the cells of the immune system that express TLR9 differ between 
different species as well. In humans, it has been suggested that B-cells and pDCs are 
the only cell types to express TLR9 (Homung et a l, 2002) (Figure 1.2) although other 
research has recently suggested TLR9 expression may also be functional in human
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Figure 1.2. Human CpG activation and immunity.
CpG-ODN or bacterial DNA is recognised by endosomally located TLR9 on pDCs or 
B-cells (A). Activation of B-cells results in cytokine release and B-cell proliferation 
and differentiation into antibody secreting plasma cells (B). Binding of CpG to 
plasmacytoid dendritic cells (pDCs) results in pro-inflammatory cytokine release (C) 
prompting dendritic cell activation and maturation (D). This is coupled with the 
activation of additional immune cell types including NK cells, macrophages, 
neutrophils and T-cells and subsequent release of cytokines and pro-inflammatory 
mediators (E).
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neutrophils (Hayashi et a l, 2003) and pulmonary epithelial cells (Platz et al., 2004). 
Despite the uncertainty surrounding the exact cell types responding to CpGs directly 
through TLR9 activation in humans, it is clear that pDCs and B-cells are also key 
TLR9 expressing cells in mice. Here, immune cells of the myeloid lineage such as 
monocytes, macrophages and myeloid dendritic cells have also been shown to 
respond directly to stimulation with CpGs (Iwasaki & Medzhitov, 2004). It is also 
clear that in order to stimulate TLR9, DNA needs to enter the cell and associate with 
TLR9 in endosomal compartments. This occurs once TLR9 relocates from the 
endoplasmic reticulum to lysosomes containing CpG-DNA where the signaling 
cascade is initiated following TLR9 receptor dimerisation (Latz et a l, 2004; Latz et 
a l, 2007). This signaling cascade is dependent upon MyD88 and results in the 
activation of transcription factors such as NF-kB and AP-1 and subsequent induction 
of inflammatory gene mRNA synthesis (Kumagai, Takeuchi & Akira, 2008). This 
process can be inhibited by the addition of lysosomal inhibitors such as chloroquine 
and bafilomycin, which prevent endosomal maturation and subsequent CpG-TLR9 
binding and signal transduction (Hacker et a l, 1998). More recently, a TLR9 
independent cytosolic pathway of DNA recognition has also been suggested by 
Nagata and colleagues (Okabe et a l, 2005) in which binding of DNA that has escaped 
lysosomal degradation is reported to induce activation of the innate immune system.
1.2.4. The significance of backbone chemistry
Studies have shown that the backbone of synthetic DNA can alter its stimulatory 
abilities (Sester et a l, 2000). CpG constructs created using a modified nuclease- 
resistant backbone, such as a phosphorothioate (PS) backbone, confer far greater 
resistance against degradation and protection from cell nucleases than non-modified
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phosphodiester (PO) backbones (Zhao et a l, 1993; Stein et al., 1988). The PS 
backbone also enhances the ability of ODNs to bind to cell membranes and 
consequently results in more successful cellular uptake. The effect of these backbone 
modifications varies depending on the cell type taking up the oligonucleotides in 
question. CpGs constructed with a PS backbone are far more potent at activating B- 
cells than the same sequence CpG motif constructed with a PO backbone (Krieg et al.,
1996). In contrast, ODNs on a pure PS backbone are not as potent at activating 
macrophages and NK cells as ODNs with mixed PS and PO content (Boggs et al.,
1997). The chemical composition of CpGs has helped in the development of a variety 
of different classes of CpGs that preferentially activate particular cells of the immune 
system.
1.2.5. Different classes of CpGs
There are currently three main classes of synthetic CpG typically varying between 8- 
30 bases in length. Many factors have contributed to the development of these 
different CpG classes. These include the number and spacing of CpG motifs (2-4 
motifs being optimal), the sequence specificity and the presence of either poly G 
regions or other stimulatory sequences at the terminal ends of the oligonucleotide. In 
addition, another important aspect is the oligonucleotide backbone chemistry. Native 
DNA possesses a phosphodiester backbone and CpGs are often totally or partially 
modified to a nuclease-resistant phosphorothioate backbone which serves to prolong 
the in vivo half-life and immunostimulatory power of the ODN. These classes result in 
different patterns of immune activation.
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1.2.5.1. CpG-A / D-type
CpG-A ODNs (sometimes referred to as “D-type” CpGs), are constructed using a 
mixed phosphodiester and phosphorothioate backbone and are potent induces of IFN- 
a production from plasmacytoid dendritic cells (Krug et a l, 2001). This activation 
also directly induces pDC maturation and strongly activates NK cells indirectly 
(Balias et al., 1996). These A-class CpGs are able to induce a far more potent IFN-a 
response than that resulting from actual bacterial DNA and are comparable to 
bacterial DNA in their NK stimulatory capacity. However, although able to bind 
TLR9 on B-cells, they promote a poor response as measured by the degree of 
proliferation and maturation (Verthelyi et al., 2001).
CpG-A typically contain either a single hexameric purine-pyrimidine-CG-purine- 
pyrimidine motif (Verthelyi et al., 2001) or multiple CpG motifs that are flanked by 
self-complementary bases that are palindromic (Krug et al., 2001). These self- 
complementary bases have the potential to form a stem-loop structure and two- 
dimensional computer analysis suggests that this may expose the CpG at the apex. 
The central CpG motifs and vast majority of the A-class ODN is built with a PO 
backbone; however, the ends of the ODN are modified to feature 5’ and 3’ PS ends. 
The modified PS ends are also typically complemented with poly-G motifs that are 
able to interact with those on adjacent ODNs to form G-tetrads (Kerkmann et al., 
2005). It has been suggested that these motifs act to improve cellular uptake, NK cell 
activation and IFN-a production by pDCs.
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Example type: CpG 2336 (Coley, Ca)
G*G*G GACGACGTCGTGG*G*G*G*G*G
* denotes phosphorothioate bonds, all others bonds are phosphodiester.
I.2.5.2. CpG-B/K-type
CpG-B ODNs differ in many ways from their CpG-A relatives. The most basic of 
these differences stems from the fact that CpG-B ODNs are constructed using only a 
PS backbone, making them incredibly resistant to degradation. CpG-B motifs encode 
multiple CpG motifs that are optimal when flanked by a thymidine immediately 5’ 
and either a TpA or TpT on the 3’ side. From an immunological perspective, these 
factors combine to promote an extremely potent stimulation of B-cells, as determined 
by enhanced cellular proliferation, increased expression of co-stimulation markers and 
IgM antibody and IL-6 cytokine production (Verthelyi et a l, 2001; Yi et al., 1996a). 
However, in contrast to CpG-A, CpG-B are only able to induce a limited stimulatory 
effect on pDCs and NK cells, resulting in limited production of IFN-a and IFN-y 
(Verthelyi et al., 2001). Finally, B-class ODNs do not feature the self-complementary 
CpG-flanking regions that are typical of CpG-A ODNs and as such do not typically 
form higher-ordered structures. Reports have shown that forcing B-class motifs into a 
higher ordered structure on microparticles and other such delivery systems will 
promote a more typical A-class response as determined by enhanced IFN-a 
production (Kerkmann et al., 2005).
Example type: CpG-B 7909 (Coley, Ca) (Commercial No: PF-3512676) 
TCGTCGTTTTGTCGTTTTGTCGTT
23
1.2.5.3. CpG-C / C-type
The C-class of CpGs are a mixture of the A and B classes and are designed to have 
immunostimulatory properties of both these types of CpG (Hartmann et al., 2003). 
They are constructed using only a phosphorothioate backbone (like CpG-B) and also 
commonly feature multiple CpG motifs. In addition, whilst internal CpG motifs may 
be similar to those often seen in CpG-B class ODNs (e.g. TCG dimer at the 5’ end), 
they are also sometimes peripheral to a central CpG motif embedded within a 
palindromic sequence characteristically seen in CpG-A ODNs (e.g. GTCGTT) 
(Hartmann et al., 2003). They are also constructed without poly-G motifs, which are 
typical of A-class CpG ODNs, but do possess palindromic 3’ends which promote the 
formation of duplexes that are essential for IFN-a production (Vollmer et al., 2004). 
These factors combine to create a class of CpGs that are capable of strongly 
stimulating B-cells to secrete IL-6 and to express co-stimulatory molecules, whilst 
also activating pDCs and NK cells resulting in IFN-a and IFN-y release (Marshall et 
al., 2003).
Example type: CpG 2395 (Coley, Ca)
5’- TCGTCGTTTTCGGCGCGCGCCG -  3’
3 ’ -GCCGCGCGCGGGTTTTGCTGCT-5 ’
1.2.5.4. CpG-sC / Semi-soft C-type
Recently, a modified C-type CpG has been designed. This CpG bares close 
resemblance to the characteristics of the C-type oligonucleotide described above 
(section 1.2.5.3), but differs primarily in the chemical composition of its 
oligonucleotide backbone. Here, the PS backbone present in the C-type CpGs has
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been part replaced with phosphodiester bonds between the CG dinucleotide motifs to 
form a mixed PS-PO backbone. This modification increases the ODN’s susceptibility 
to nuclease degradation and consequently, this new type of CpG is currently being 
referred to as a softer version of the C-class ODN or a semi-soft C-class. Recently, the 
use of CpG-sC 10109 as an adjuvant in anthrax studies has been investigated and 
reported to significantly boost the immunogenicity of the BioThrax® vaccine (Gu et 
al, 2007). No reports of the stimulatory effects of CpG-sC on individual cell-types 
have currently been published.
Example type: CpG 10109 (Coley, Ca)
TCGTC*G TTTTAC*GGCGCC*GTG CCG
* denotes phosphodiester bonds, all others bonds are phosphorothioate.
1.2.6. Immune consequences of CpG-TLR9 recognition
Stimulation of TLR9 by CpGs results in two separate types of immune response, these 
being a rapid activation of innate cells and a subsequent enhancement of the antigen- 
specific immune response (reviewed in; Krieg, 2002). Direct stimulation of cells 
expressing TLR9 results in rapid release of pro-inflammatory cytokines such as IFN- 
a, IL-12, IL-18, IL-6 and TNF-a, along with secretion of chemokines such as IL-8, 
IFN-y inducible protein 10 (IP-10) and CCL2 (Krieg et al., 1995; Yi et al., 1996b; 
Krug et al., 2001; Klinman et al., 1996). This is accompanied by an increase in 
expression of both MHC and co-stimulatory molecules such as CD40, CD80 and 
CD86 on antigen presenting cells, as well as cellular maturation to boost the host’s 
ability to present antigen to T-cells (Krieg et a l , 1995). This is aided by the up- 
regulation of the chemokine receptor CCR7 on these cell types, which directs cellular
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traffic to the T-cell zones of the lymph nodes. The direct stimulation of TLR9 on both 
naive and memory B-cells functions synergistically with the B-cell receptor to 
facilitate their rapid proliferation and differentiation into antibody secreting plasma 
cells (Jung et a l, 2002). Additionally, Fey receptors can be upregulated on B-cells 
and polymorphonuclear leukocytes such as neutrophils, to enhance levels of antibody 
dependent cellular cytotoxicity (ADCC) (Krieg, 2002). The direct, or indirect, 
activation of neutrophils (Weighardt et a l, 2000) and macrophages by CpGs also 
increases cellular migration along chemotactic gradients, and enhances phagocytosis 
and respiratory burst defences (Gao et a l, 2002). NK cells are also rapidly activated 
following CpG stimulation, demonstrating enhanced responsiveness to IL-12 (Sivori 
et a l, 2006) and pDC derived IFN-a and TNF-a resulting in IFN-y release and 
increased cytotoxicity (Marshall et a l, 2006). Together, these cell types promote the 
formation of a highly skewed Th-1 cytokine milieu, which consequently affects the 
development of Th-0 CD4+ cells and drives them to adopt a Th-1 phenotype (Klinman 
et a l, 1996). CpGs can also augment the function of antigen-specific CD8+ T-cells 
and enhance their survival (Beloeil et a l , 2003).
1.2.7. Therapeutic applications of CpGs
I.2.7.I. Use of CpGs in allergy, cancer and as vaccine adjuvants
The immunostimulatory properties of CpGs have led to their use in a variety of 
different therapeutic applications. Over the last decade, they have been investigated as 
adjuvants to pre-existing or newly developing vaccines, as cancer and allergy 
treatments and as therapeutic agents against disease (reviewed in; Krieg, 2006). Most 
of these studies have occurred in mice, although currently six CpGs are in human 
clinical trials. These human trials are examining the therapeutic effect of CpGs as
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vaccine adjuvants for influenza (Cooper et a l, 2004), anthrax (Klinman, 2006) and 
hepatitis B (Halperin et a l, 2003), as cancer therapies for non-Hodgkins lymphoma 
(Link et a l, 2006) and metastatic melanoma (Speiser et a l, 2005) and as direct 
treatment against hepatitis C (McHutchison et a l, 2006) and asthma (Racila & Kline, 
2005).
The potent adjuvant effects of CpGs are presumed to be a result of the Th-1 cytokine 
phenotype that they promote and as such they are currently surpassing any other 
commonly used adjuvant system such as alhydrogel/alum salts, which typically 
generate a Th-2 milieu. The induction of a Th-1 cytokine environment by CpG greatly 
enhances the function of APCs, T-cells and B-cells, as well as inducing IgG class 
switching (He et a l, 2004; Sparwasser et a l, 2000; Jegerlehner et a l, 2007). 
Ultimately the CpG adjuvant effect could permit the reduction in number of 
vaccinations required and therefore the amount of antigen and costs required to reach 
vaccine efficacy. In addition, they may also improve the vaccine’s long-term 
protective activity by encouraging sustained antibody levels (Krieg, 2006). The 
success of CpGs against allergic responses is likely to stem from the Th-1 type 
cytokine patterns produced following CpG administration. This Th-1 induction 
counteracts the negative effects of Th-2 dominated allergic responses (Lin et a l, 
2004; Kline et a l, 1998; Kitagaki et a l, 2002). The mode of action for this effect may 
however be more complicated than a simple switch in cytokine production and has 
been suggested to also induce T-regulatory cells (Jain et a l, 2002). As a cancer 
therapy, CpGs have been well documented to have anti-tumour activity (Krieg, 2007). 
Within this field, use of CpGs as a monotherapy have yielded some success against 
small tumours, but CpGs have needed to be combined with other effective anti­
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tumour approaches to be effective against larger tumours. Here, it is suggested that T- 
cells play an important role in tumour rejection, having been primed by TLR9 
activated pDCs to develop into tumour-specific effector CD8+ cells instead of 
maintaining tolerance (Krieg, 2006). The use of CpGs in this capacity is leading the 
way to becoming the first fully licensed therapeutic CpG.
I.2.7.2. The use of CpGs against infectious disease
Studies have shown that administration of CpGs can offer protection against a wide 
variety of bacterial, viral and parasitic infections (Krieg, 2006). In total, these 
experiments have all shown a variety of direct and indirect CpG mediated effects that 
have typically included the release of Th-1 associated cytokines such as IL-12, IL-6 
and IFN-y as well as the activation of numerous cell-types including macrophages, 
dendritic cells and NK cells, as well as B and T-lymphocytes. The exact protective 
effects of CpG treatment are likely to vary between different micro-organisms (with 
certain infections responding better to different classes of CpG), according to the 
nature of the infection and activation of those cell types most crucial to fighting it. 
With this in mind, in order for any CpG to be utilised as an effective and licensed 
therapeutic, it is fundamental that the relationship between the CpG and organism is 
well understood. This thesis will address whether CpGs could be used in a protective 
capacity against smallpox, the disease caused by infection with variola virus, using its 
close relative VACV as a model for infection. The next section will introduce the 
disease process of smallpox and provide an introduction to VACV as the laboratory 
virus model used throughout this project.
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1.3. Smallpox and pathogenesis
Following a worldwide vaccination campaign, the late 1970s provided the world’s 
first success at defeating a global disease when smallpox was eradicated. The 
etiological agent of smallpox, variola virus, proved the most formidable pathogen of 
the modem age killing more people throughout recorded history than all other 
infectious diseases combined (Fenner et a l , 1998). The vast majority of these deaths 
resulted from infection with a particularly pathogenic strain of variola known as 
variola major, which proved fatal in between 5-40% of those infected. A second, less 
vimlent strain, known as variola minor, also presented but resulted in mortality in 
fewer than 1% of patients. Both strains of vims exhibited an extremely narrow host 
range with humans being the only known host for infection and person to person 
spread being a well-documented phenomenon. Clinically, infection with variola 
typically occurred via the aerosol route, allowing the vims to infect the mucosal tissue 
of the airways and migrate into the lymphatic system and local lymph nodes (Stanford 
et a l , 2007). After a period of multiplication in the lymph nodes, the host typically 
developed an asymptomatic primary vireamia by the fourth day that allowed the vims 
to spread to other parts of the body and induce a secondary vireamia typically around 
four days later. This asymptomatic phase was known to last up to 17 days prior to the 
onset of clinical symptoms such as fever and malaise and the explosion of the 
characteristic macropapular rash on the mucosa of the mouth, pharynx and face. This 
rash then continued to spread systemically and often managed to quilt the entire body 
of the infected patient 10 days after symptom onset, at which point the rash became 
pustular. Death of the patient was often attributed to the toxaemia associated with the 
infection and massive inflammatory responses but could also result from 
haemorrhagic and malignant forms of variola infection. (Fenner et al, 1998). The
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vaccination campaign centred on the use of VACV, a close relative of variola, as a 
live vaccine. Today, complications with the smallpox vaccine, that are unacceptable 
by modem standards, and fears over the deliberate release of variola on a new 
generation of unvaccinated individuals have led to an increased effort to design an 
effective new approach to combating infection. Given the exquisite host specificity of 
variola for humans, research into the pathogenesis of disease using variola vims has 
not been possible. Consequently, research has focused on animal models using highly 
related orthopoxviruses to expand on the limited amount currently known of the 
disease processes associated with smallpox.
1.3.1. Animal models
A variety of animal models have been well established to study orthopoxvirus 
infection. These include studies using poxviruses such as ectromelia and VACV in 
mice, monkeypox in primates and myxoma vims in rabbits (Smith & Kotwal, 2002). 
The use of these vimses in animal models is somewhat limited by the specificity of 
these vimses for certain hosts. For instance, ectromelia is a natural mouse pathogen 
that can not infect primates whereas VACV can infect a broad range of species 
(Stanford et al., 2007). In mouse models, both ectromelia and VACV have proven 
excellent animal models in a vast array of studies (Smith & Kotwal, 2002). 
Ectromelia infection in mice typically follows inoculation of the vims into the footpad 
of the mouse resulting in an acute infection (mousepox) that mimics variola infection 
in humans (Chaudhri et al., 2006). However, the specificity of ectromelia for mice 
makes studies investigating the efficacy of dmg treatments impossible to transfer into 
higher order animals such as primates. This limits the use of ectromelia vims as a 
model for othropoxvims infection. In contrast, intranasal infection of mice with
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VACV also results in an acute infection that can be compared with existing 
information from human infections (Xu et al, 2004). This makes the use of VACV 
the most useful orthopoxvirus in studies looking to assess the efficacy of particular 
antiviral treatments and the virus of choice to use in studies throughout this thesis.
1.3.2. Vaccinia virus
Vaccinia virus, like variola, is an orthopoxvirus and member of the family poxviridae, 
a complex family of large brick-shaped DNA viruses that replicate in the cytoplasm 
of host cells. VACV possesses a large linear double-stranded genome of 
approximately 200kb and a variety of different strains of vaccinia have been 
characterised to date including Copenhagen (Goebel et a l, 1990), modified vaccinia 
Ankara (MVA) (Antoine et a l, 1998), western reserve (WR), lister (Garcel et a l, 
2007) and International health department (IHD). These strains all have a highly 
conserved central region of approximately lOOkb that contains the majority of the 
essential genes needed for replication. Within this region, 90 genes are conserved 
amongst all poxviruses (Upton et a l, 2003), which helps explain the morphological 
and functional similarities amongst family members. Away from this central region 
non-essential genes, or those not critical for ensuring competent replication, are 
found. These genes encode various proteins responsible for virus virulence and host 
range tropism and are not as conserved as the central region. Instead, this section 
contains a number of deletions, mutations and transpositions and these differences 
contribute to the unique characteristics of each poxvirus in terms of host range, 
pathogenesis and immunomodulatory capacity. Unlike other poxviruses that are 
restricted in their host range (e.g. camelpox, variola), vaccinia is able to infect a wide
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range of hosts, including humans and its large number of genes enables it to replicate 
in the majority of mammalian cells.
I.3.2.I. Vaccinia virus life cycle
Replication of VACV takes place in the cytoplasm of the host cell and occurs almost 
entirely independently of the cell nucleus (Figure 1.3). The infection process begins 
with the attachment of VACV virions to the surface of the targeted cell. Both the 
attachment and entry processes of VACV into the cell are poorly understood and both 
processes are complicated as a result of two infectious forms of VACV virion being 
produced. These virions take the form of the intracellular mature virus (IMV) and the 
extracellular enveloped virus (EEV) and are structurally and antigenically different 
from one another (Boulter & Appleyard, 1973). Currently, evidence suggests that 
IMV particles possess a single lipid bilayer that is embedded with non-glycosylated 
viral proteins, although a two-membrane model has also been proposed (Moss, 2006). 
Regardless of whether IMVs possess one or two membranes, EEV particles are 
known to possess one extra. Consequently the entry processes of IMV and EEV 
virions into the cell are thought to differ as well. A number of virion proteins have 
been suggested to help facilitate attachment of VACV to the cell, since no specific 
cellular receptor for vaccinia has been clearly identified to date. This research is 
further advanced for IMV with virion proteins H3L (Lin et al., 2000), A27L (Chung 
et al., 1998) and D8L (Hsiao et al., 1999) all presumed to play a part. EEV virions 
possess at least five virus-encoded surface proteins in their outer membrane including 
A33R, A34R, A56R, B5R and F13L but evidence for a direct role of any of these 
proteins in cellular attachment has not being convincingly presented. The IMV 
receptors are all thought to interact with cell glycosaminoglycans such as heparan or
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Figure 1.3. Vaccinia virus life-cycle.
Intracellular mature virus (IMV) or Extracellular enveloped virus (EEV) particles 
enter the cell via an ill-defined process (most likely fusion) that may involve 
glycosaminoglycans (A). Once inside, the virus core uncoats to release viral DNA 
(B). This is then followed by the transcription and translation of early viral genes (C), 
viral DNA replication (D) and finally intermediate (E) and late (F) gene processing. 
New particles begin to form in crescent shapes (G) before morphing into a non- 
infectious immature virus (IV) (H) and then intracellular mature virus particles 
(IMV). IMVs then acquire additional membranes via the golgi apparatus or early 
endosomes (I) to become intracellular enveloped virus particles (IEV). IEV fuses to 
the cell surface to become cell-associated virus (CEV) (J) or gets released from the 
cell as a free EEV particle (K).
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chondroitin sulphates or components of the extracellular matrix. The ubiquitous 
presence of glycosaminoglycans on most cells would help to explain the ability of 
VACV to invade so many different cell types.
Once attached, IMV and EEV are thought to adopt similar strategies for entering the 
cell although different strategies have been proposed (Vanderplasschen et a l, 1998). 
IMV entry is thought to occur via one of three mechanisms. The most accepted 
mechanism is that VACV IMV fuses with the plasma membrane of the cell and gains 
entry (Armstrong et a l, 1973) whilst another suggests that the virus actually uncoats 
outside of the cell without fusion and then somehow crosses the external membrane 
(Locker et a l, 2000). Thirdly, bound IMV may be endocytosed and then may fuse 
with the vesicular membrane of the endosome to free the core virus particle into the 
cytoplasm (Moss, 2006). It is possible that both endosomal and plasma membrane 
entry paths are used depending on the strain of virus and type of cell being infected. 
Either way, there appears to be at least one virion protein that is conserved (VACV- 
A28) and is likely to be involved throughout the fusion/entry process (Senkevich et 
a l, 2004). Entry of EEV is no more clear-cut as suggestions for cell entry include 
fusion with the plasma membrane or entry via endocytosis and acidified envelope 
degradation (Ichihashi, 1996). Current reviews suggest that the fusion process is 
mediated by a group of viral proteins associated with the IMV membrane that are 
conserved across all poxviruses (Moss, 2006).
Having entered the cell and lost all outer membranes, the virus core moves through 
the cytosol towards the centre of the cell along microtubules (Carter et a l, 2003) 
(Figure 1.3). Within twenty minutes, VACV begins to synthesise viral mRNA using
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its own endogenous DNA-dependent RNA polymerase and encapsulated transcription 
factors to transcribe and translate early genes required for replication and survival. 
Approximately half of the entire genome is transcribed here and a number of these 
early proteins prompt the dissolution of the virus core to release genomic DNA into 
the cytoplasm allowing it to act as a template for DNA replication. DNA synthesis 
begins one to two hours post-infection next to the site of the uncoated core and viral 
factories then begin to develop. This process also mediates the transcription of the 
intermediate class of genes that, unlike the early genes, are thought to require 
assistance from the host’s own transcription factors to synthesise proteins (Rosales et 
al., 1994). The intermediate genes encode a number of proteins, some of which are 
necessary for late gene transcription to occur and tend to reach their peak synthesis at 
approximately two hours. Throughout the translation of early and intermediate VACV 
genes, host cellular mRNA translation begins to be inhibited selectively by small non­
translated poly-A mRNAs (Bablanian et al., 1991). This contributes to a reduction in 
host cellular mRNAs and a rise in VACV mRNAs, resulting in a marked shift towards 
the preferential synthesis of VACV polypeptides. As late gene transcription occurs, 
the synthesis of many of the proteins required for assembling new virus particles is 
seen. These late genes also encode enzymes that are packaged within newly formed 
virions to instigate the next cycle of infection.
As late genes are continuously synthesised, the assembly of new virus particles occurs 
in cytoplasmic factories that have been shown to be free of any cellular organelles 
(Ichihashi et al., 1971). The first morphologically distinct structures produced within 
these factories are crescent-shaped, which soon grow to form ovals and incorporate a 
variety of host-derived lipids and virus proteins. These initial structures are known as
35
immature virus particles (IV) and are non-infectious. These soon grow to form new 
infectious IMV particles by acquiring a number of external membranes (Figure 1.3). 
These IMV particles accumulate to great numbers, becoming the predominant 
infectious progeny virus within each infected cell. A number of IMVs leave the virus 
factories along microtubules, utilising the A27L membrane protein (Sanderson et al.,
2000) and may acquire a double outer membrane from either the trans-golgi network 
(Schmelz et al., 1994), early endosomes (Tooze et al., 1993; van Eijl et al., 2002) or 
perhaps membranes from both sources (Husain & Moss, 2003; Moss, 2006) to form 
intracellular enveloped virus (IEV). The IEV continues along microtubules serving as 
an intermediary virus particle until it reaches, and then fuses with, the plasma 
membrane, losing one of its external membranes in the process. Once fused, the virion 
is exocytosed and becomes the cell-associated enveloped virus (CEV) if it remains 
attached to the cell wall or extracellular enveloped virus (EEV) if it is released from 
the cell completely. Whether an IEV remains cell-associated or is released is 
dependent on the strain of virus as well as the infected host cell itself. For instance, 
VACV IHD strain has been shown to release approximately 50-fold more EEV than 
the WR strain. This may be due to a point mutation within the A34R gene locus that 
encodes a lectin-like protein (McIntosh and Smith, 1996). By this stage, host protein 
synthesis is usually completely shut off and host DNA replication may also have been 
inhibited, possibly as a result of VACV encoded endonucleases (Dales, 1990; Buller 
& Palumbo, 1991).
To continue the spread of infection, CEVs are propelled towards neighbouring cells 
via actin polymerisation (Cudmore et a l , 1995; Stokes, 1976) and are predominantly 
thought to mediate the local cell-cell spread of infection. EEVs, in contrast, are free to
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initiate long range spread of infection systemically if they can avoid neutralisation by 
the host immune response. The third and most dominant way for infection to progress 
is the non-specific release of streams of IMV particles after the death of the infected 
cell and subsequent cell lysis. This only occurs following the completion of the 
infectious virus cycle and, as such, is too slow to promote the rapid spread of virus but 
is key in promoting the local dissemination of infectious virus progeny.
1.3.3. Poxvirus immunomodulation
In order to survive and prosper within the host, viruses have evolved ways to avoid or 
manipulate the host antiviral immune response so that they are able to establish their 
habitat, complete their replication cycle and find additional viable cells to infect. 
Viruses are able to modulate host response mechanisms like apoptosis, complement, 
antibodies, pro-inflammatory cytokines and chemokines as well as lymphocyte 
function and signaling. Large DNA viruses, such as herpesviruses and poxviruses are 
particularly able to encode multiple classes of immunomodulatory proteins capable of 
fighting these host defence systems because of their large genomes and array of non- 
essential genes. VACV has been shown to possess an arsenal of immunomodulatory 
proteins that serve to promote its continued survival within the host. The defensive 
strategies utilised by poxviruses can be grouped into three broad main categories: 
virokines, viroreceptors and viral proteins that interfere with signaling and effector 
pathways (Figure 1.4).
I.3.3.I. Virokines
Virokines are virally encoded proteins that are synthesised during replication and 
secreted from the infected host cell into the extracellular environment. The vast
37
mm
POXVIRUS{ Nucleus
(3
Oo o o n  o
□□IZI
15
16
17
18
Figure 1.4. Examples of three types of poxvirus immunomodulatory strategy.
Virokines Viroreceptors Signal transd
1. wEGF* 8. Cowpox crmE 19. SPI-1*
2. vvSEMA* 9. Pox crmB/C/D/E* 20. SPI-2*
3. OrfIL-10 10. crmE/TNF-R* 21. K3L*
4. Orf vVEGF 11.IL-1PR* 22. E3L*
5. Orf GIF 12. IFN-yR* 23. A46R*
6. Myxoma SERP 13. Swinepox CXCR1 24. A52R*
7. VCP* 14. Capripox CCR-1 25. NIL*
15. IFN-a/p BP* 26. K1L*
16. IL-18BP*
17. vCKBPl (M-T7)
18. vCKBP2 (35KDa) *
27. M2L*
*VACV encoded
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majority are mimics of host cytokines or chemokines and are thought to have been 
acquired by the virus throughout evolution following capture of host genes. Many of 
these mimicking proteins share a high percentage of the structural and functional 
characteristics of the host protein that they mimic. Several poxviruses have been 
shown to secrete virokines including the parapoxvirus orf, which produces a viral IL- 
10 homologue (Imlach et a l, 2002), an inhibitor of granulocyte-macrophage colony- 
stimulating factor (GM-CSF) and Interleukin-2 (IL-2) collectively known as GIF 
(Deane et al., 2000) and vascular endothelial growth factor (VEGF) (Wise et a l, 
1999). VACV has been shown to release a homologue of epidermal growth factor 
referred to as vEGF, which enhances cell proliferation (Brown et a l, 1985), 
presumably to increase the number of cells available for infection.
Another identified virokine produced by VACV is vSEMA (viral semaphorin 
homologue). Semaphorins serve a dual role as both chemoattractants and 
chemorepellants in the host system and are involved in directing axons during the 
development of the nervous system (Spriggs, 1999). The VACV vSEMA protein 
(encoded by A39R in WR) binds the semaphorin receptor VESPR (virus-encoded 
semaphoring protein receptor) in macrophages and, in doing so, is thought to prompt 
the synthesis and expression of cytokines and adhesion molecules (Gardner et a l,
2001). vSEMA has also been shown to bind the plexin Cl receptor in dendritic cells 
where it induces actin cytoskeleton rearrangement and also prevents integrin- 
mediated adhesion and chemokine-induced migration. (Walzer et a l, 2005).
Other non-poxvirus virokines identified to date include homologues for a number of 
other cytokines and chemokines including IL-6 and macrophage inflammatory protein
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2 (vMIP2) produced by Karposi’s sarcoma-associated herpesvirus (KSHV), and IL-10 
homologues secreted by both Epstein-Barr virus (EBV) and human cytomegalovirus 
(HCMV). These cytokines serve a variety of pro- and anti-inflammatory functions in 
the host and viral homologues are likely to manipulate these functions to suit their 
own purpose. The release of key viral chemokine homologues may serve to promote 
virus dissemination and growth or assist in re-directing the host response to avoid 
detection and neutralisation. This has been seen with the release of the vCXCl protein 
encoded by HCMV which induces neutrophil chemotaxis to either assist in the 
dissemination of virus or recruitment of fresh cells for infection (Penfold et al., 1999)
I.3.3.2. Viroreceptors
Viroreceptors have been shown to play a fundamental role in the survival of viruses 
during infection. They act as viral mimics of chemokine and cytokine receptors and 
can be either released extracellularly or retained intracellularly/on the cell surface to 
block or bind host cytokines and chemokines. Closer examination of the virus genes 
that encode these receptors show that they possess sequence similarity to the 
extracellular binding domains of the host cytokine receptors but do not share any 
homology with the transmembrane or signaling domains. Consequently, viroreceptors 
act as decoy receptors, competing for and ‘mopping up’ free cytokines and 
chemokines in the local environment to prevent the binding of the intended host 
messenger molecules to true receptors. So far, a wide variety of these receptors have 
been identified in a range of pox and herpesviruses.
Myxoma virus has been shown to encode a soluble vTNFR (virus TNF receptor), 
encoded by the T2 gene, that prevents the dimerisation of the TNF receptor which is
40
required for signal transduction. This enables the virus to neutralise the activity of 
TNF and act as a potent virulence factor (Schreiber et al., 1996). A variety of other 
poxviruses (including cowpox, vaccinia, variola and ectromelia) have also been 
shown to encode different TNF receptor homologues from the one encoded by 
myxoma. These sets of TNF-like receptors have been grouped into a family of 
receptors and are commonly known as cytokine-response modifiers (Crm). To date 
CrmB, CrmC, CrmD and CrmE have been identified, with each virus encoding either 
one or a subset of these receptors (Loparev et al., 1998; Reading et al., 2002). The 
majority of these TNF-receptors are secreted from the infected cell but, as Reading 
and colleagues have shown, there is also evidence for membrane bound TNF-binding 
activity via CrmE in cells infected with certain strains of VACV including Lister, 
USSR and Evans (Reading, Khanna & Smith, 2002).
Soluble cytokine receptors also exist for IL-ip (vIL-lpR) and IFN-y (vIFN-yR), both 
of which are secreted and produced by VACV. IL-lp is a pyrogenic cytokine and the 
decoy IL-lp receptor encoded by the B15R gene of VACV (WR) is able to efficiently 
block the febrile response (Alcami & Smith, 1992). Likewise, the B8R gene of VACV 
WR encodes for a vIFN-yR and binds IFN-y from various species (Alcami & Smith, 
1995). Recently, the IFN-y binding protein (IFN-y bp) of ectromelia virus has been 
shown to play a pivotal role in reducing the strength of the host inflammatory 
response (Sakala et al., 2007).
In addition to cytokine receptors, homologues of key cytokine binding proteins have 
also been discovered that are produced by ectromelia virus, cowpox, VACV, variola 
and molluscum contagiosum virus. These include homologues of the IFN-a/p binding
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protein encoded by the B18R gene in VACV (WR) (Colamonici et al., 1995). The 
VACV IFN-a/p receptors have been shown to bind to the host cell surface to prevent 
IFN binding to genuine IFN receptors (Alcami et al., 2000). In addition, numerous IL- 
18 binding proteins (IL-18bp) have been reported in the literature. IL-18 is a key 
cytokine involved in driving the interferon response during the onset of infection, 
through the activation of NK cells (Tomura et al., 1998). The viral IL-18 binding 
proteins have been shown to possess very little homology to the mammalian IL-18 
receptors and instead mimic the shape of mammalian IL-18 binding proteins (IL- 
18bp) that are thought to help regulate IL-18 activity (Smith et al., 2000). In VACV, 
deletion mutants lacking the IL-18bp (encoded by VACV (WR) gene C12L) have 
been shown to be markedly attenuated in vivo and enable a more vigorous IFN-y and 
cytotoxic T-cell response to develop (Reading & Smith, 2003a).
Viral chemokine-receptor homologues (vCKRs) are best described for herpesviruses 
such as KSHV, HCMV and mouse cytomegalovirus (MCMV) and are not well 
characterised in the genomes of poxviruses. However, several genes encoding vCKRs 
have been identified in poxvirus genomes based purely on their sequence similarity 
with host receptors. These include the CXCR1 homologue of swinepox (Massung et 
al., 1993) and the CC-chemokine receptor homologue of capripoxvirus (Cao et al., 
1995), but no specific function has been assigned to these proteins. Unlike the vast 
majority of cytokine-receptor homologues, these vCKRs are not secreted but are 
membrane bound and possess the characteristic seven-transmembrane structure of 
host chemokine receptors. Herpesvirus vCKRs have been shown to sequester 
chemokines from the extracellular milieu of infected cells and influence cellular 
proliferation and signal transduction (Arvanitakis et al., 1997). It is possible that the
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vCKR homologues encoded by poxviruses may also perform similar functions during 
infection although this has yet to be conclusively reported.
Two families of soluble chemokine-binding proteins (vCKBPs) have been described 
that use distinct methods of combating host chemokines. The first family (type I) is 
comprised of a solitary member known as chemokine binding protein 1 (vCKBPl), 
encoded by the M-T7 gene from myxoma virus. This protein was originally identified 
as a soluble IFN-y receptor (Mossman et al., 1995), and is secreted from the infected 
cell to bind a wide variety of CC, CXC and C-chemokines with relatively low affinity 
(Lalani et al., 1997). The second family, comprising of vCKBP2 produced by both 
myxoma and VACV, has been shown to exhibit greater specificity than vCKBPl for 
binding CC-chemokines such as RANTES (regulated upon activation, normal T-cell 
expressed and secreted) (Graham et a l , 1997; Bums et a l , 2002). The low-affinity 
binding of vCKBPl is thought to interfere with the positioning and presentation of 
chemokines to cell surface GAG proteins whereas the stronger affiliation between 
vCKBP2 proteins actually inhibits the interaction of the chemokines with their 
intended targets.
Finally, the complement system has also been shown to be a target for vims 
immunomodulatory proteins. The best studied of these belongs to VACV and is the 
complement control protein (VCP). This protein resembles human complement 4b 
binding protein (C4b-BP) (Kotwal & Moss, 1988) and mimics the biological 
functionality of a number of complement control proteins including factor H, 
membrane cofactor protein (MCP) and decay-accelerating factor (DAF) (Sahu et a l , 
1998). VCP is known to thwart both the classical and alternative complement
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pathways by binding to C3 and C4 and encouraging the destruction of the C3 
convertase (Kotwal et al., 1990). This ensures the complement system is blocked at 
multiple sites to prevent the formation of the final membrane attack complex and 
release of additional pro-inflammatory mediators such as C3a/C4a/C5a. This results 
in reduced cellular influx and inflammation (Isaacs et a l, 1992). By hindering the 
complement system, VCP serves as a key virulence factor and enables VACV to 
escape a key arm of the innate immune response to promote its own survival within 
the host.
1.3.3.3. Viral inhibition of signal transduction
Poxviruses possess a variety of mechanisms to interfere with key signaling pathways 
in the host cell to promote their survival within the cell. One key strategy utilised by a 
variety of poxviruses is blocking cellular apoptosis. Apoptosis has long been 
established as an effective way of protecting the host from viral infection because 
early induction of cell death can prevent pathogen replication by rendering host 
macro-molecular machinery inactive (Zimmermann et al., 2001). In addition, 
apoptotic cells can be phagocytosed rapidly by other cells of the immune system 
before the inflammatory intracellular contents of the cell are released. A number of 
proteins in the cell’s apoptotic pathway are targeted by viral proteins to prolong the 
life of the infected cell so that the virus is able to replicate to higher titres (Benedict et 
al., 2002). In VACV a number of proteins have been identified that may prevent 
apoptosis. Most recently, a protein encoded by both VACV and camelpox has been 
identified by Gubser and colleagues and has been termed viral golgi anti-apoptotic 
protein (v-GAAP) (Gubser et al., 2007). This protein was found to be highly 
homologous to the human GAAP, a transmembrane protein of the Golgi apparatus,
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which prevents apoptosis. Over-expression of v-GAAP was shown to prevent 
apoptosis in vitro, whilst deletion of v-GAAP from VACV was shown to effect 
virulence in vivo (Gubser et al., 2007). Other anti-apoptotic proteins encoded by 
VACV include a serine protease inhibitor (serpin/SPI) known as SPI-2 (encoded by 
VACV WR B13R), which blocks apoptosis triggered by binding of both TNF-a to the 
TNF receptor 1 and Fas ligand to CD95 Fas receptor (Dobbelstein & Shenk, 1996; 
Kettle et al., 1995). VACV SPI-2 is a potent inhibitor of cysteine aspartate protease-1 
(caspase-1), an enzyme previously known as ICE (IL-ip converting enzyme). 
Caspase-1 is the functional form of pro-caspase, an enzyme that naturally exists in the 
cell in an inactive state. In its active state, caspase-1 plays an important role in 
apoptosis by initiating the proteloytic caspase cascade (Concha & Abdel-Meguid,
2002). VACV SPI-2 has been shown to inhibit this process by blocking the cleavage 
event necessary to convert the inactive pro-caspase into active caspase-1 and thus 
prevent the initiation of apoptosis. It has been suggested that apoptosis involves many 
other caspases such as caspase-8, and these may also be potential targets for other 
poxvirus serpins, such as cytokine response modifier A (CrmA), encoded by cowpox, 
that may inhibit apoptosis (Zhou et al., 1997). An additional serpin encoded by 
VACV known as SPI-1 (encoded by VACV (WR) B22R gene) may synergise with 
SPI-2 to induce complete inhibition of apoptosis (Macen et al., 1996).
The inhibition of caspase-1 by VACV SPI-2 also has a profound anti-inflammatory 
effect. Active caspase-1 is directly responsible for the cleavage of both pro-IL-lp and 
pro-IL-18 into their functional forms (Giamila & Charles, 1999). Pro-caspase-1 has 
been shown to be at the heart of the variety of multi-protein assembly units known as 
inflammasomes (Martinon et al., 2002). Along with pro-caspase-1, inflammasomes
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typically consist of a NOD-like receptor, other cellular caspases and adaptor 
molecules specific for each inflammasome (Mariathasan & Monack, 2007). Upon 
inflammasome activation, pro-caspase-1 is cleaved into its functional form. Therefore, 
by inhibiting caspase-1, VACV SPI-2, along with related serpins from other 
poxviruses, blocks the conversion of the non-functional form of cytokines to the 
functional form and thus prevents the synthesis of key cytokines that have a multi­
faceted role in inflammation. Some groups looking at the virulence of poxviruses 
lacking SPI-1 and SPI-2, using deletion studies, have reported an increase in virulence 
(Tscharke et a l, 2002), although other groups have contradicted this finding (Kettle, 
et al, 1995). Thus, it remains unclear how much VACV SPI-2 contributes to 
virulence in an in vivo system.
In addition to inhibiting the extracellular compounds of the IFN response, VACV also 
targets intracellular components of the IFN signaling cascade. Upon binding to 
cellular receptors, IFN induces the expression of a number of pathways (section 1.1.4) 
and enzymes. Two of these enzymes, IFN-induced dsRNA-dependent protein kinase 
(PKR) and 2’-5’-oligoadenylate synthetase (2’-5’ OAS), are activated by the copious 
amounts of dsRNA produced during viral replication (Honda & Taniguchi, 2006). 
PKR, a ubiquitously expressed serine/threonine kinase, phosphorylates itself to 
become activated and then phosphorylates the eukaryotic translation factor 2a (elF- 
2a) to inactivate it. This inactivation stops the translation of essential proteins and 
thus results in apoptosis. The VACV gene product encoded by K3L produces an elF- 
2a mimic, which prevents PKR phosphorylation of eIF-2a and thus prevents the 
inactivation of eIF-2a. This, in turn, prevents translational arrest and allows the cell to 
continue synthesising its necessary proteins (Davies et a l, 1992). 2’5’-OAS functions
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to activate a latent cellular RNase known as RNase L. RNAse L prevents protein 
synthesis by cleaving RNA molecules and thus preventing their translation into 
protein. VACV also targets this process by binding dsRNA with a protein encoded by 
the gene E3L, and prevents the activation of RNase L and subsequent RNA 
degradation (Langland et a l, 2006; Chang et al., 1992). This, in turn, also acts as an 
additional method of viral inhibition of apoptosis as deletion of E3L in virus mutants 
accelerates the rate of cellular apoptosis (Kibler et a l, 1997).
Another significant method of interfering with the cellular regulation of key 
molecules is through targeting of the TLR pathway. The significance of TLRs as 
pattern recognition receptors of invading organisms was discussed in section 1.1.2. 
Viruses have evolved to target numerous elements in the signaling pathway to disrupt 
the transduction of pro-inflammatory signals. Several proteins in particular have been 
shown to play significant, yet different, roles in virally-induced TLR 
immunomodulation. VACV protein A46R has been shown to target the intracellular 
TIR domains of both the IL-1 and toll-like receptors (Bowie et a l, 2000; Stack et a l, 
2005). Binding of A46R to the TIR domain may prevents the co-localisation of 
important adaptor molecules such as MyD88, TRAM, TRIF and Mai. Other VACV 
proteins target the signaling pathway further downstream. A52R has been shown to 
associate with both IRAK2 and TRAF6 and prevent their respective associations with 
other key cellular components, or disrupt signaling complexes, thus preventing further 
signal transduction (Harte et a l, 2003) The intracellular NIL protein of VACV has 
been reported to associate with several proteins of the IKK complex, one suggested 
target being TBK1, and its deletion has been shown to cause marked attenuation in 
vivo (DiPema et a l, 2004; Bartlett et a l,  2002). VACV K1L has been shown to
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inhibit the degradation of IicBa by interacting with the IKK complex and thus prevent 
the activation of NF-kB (Shisler & Jin, 2004). Additionally, the VACV M2L protein 
has been shown to interfere with the ERK2 pathway and prevent NF-kB activation 
(Gedey et al., 2006). Most recently, a new protein referred to as K7 from VACV has 
been shown to inhibit both NF-kB activation and the initiation of antiviral immune 
pathways (Lucas et al., 2007). This protein was initially identified as having 
sequence similarity to VACV A52R, although the specifics of where in the immune 
signaling pathway it acts have yet to be elucidated.
1.3.4. Vaccination complications
The smallpox vaccine led to the worldwide eradication of smallpox disease in the late 
1970’s. Whilst it was successful, the vaccination campaign was also plagued with 
complications due to a higher incidence of side-effects than any other current or past 
vaccine (Fulginiti et a l , 2003). The majority of these side effects resulted from 
uncontrolled VACV replication, either at the site of inoculation or at distant sites, 
following accidental infection or internal dissemination. Such complications were 
most common in those vaccinees suffering from an underlying condition such as 
eczema/atopic dermatitis or an immune system deficiency (Lane et al., 1970). Despite 
these issues, the smallpox vaccine remains the primary countermeasure against 
exposure to smallpox infection as no clinically approved antiviral treatments for 
smallpox, or any other orthopoxvirus infection, have been licensed. The current threat 
of variola virus being released deliberately as a biowarfare agent has further prompted 
demands for other vaccination approaches, such as a third generation MVA vaccine, 
or new antivirals against Orthopoxvirus infection (Parrino et al., 2007). Research
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activity has focused on developing antiviral drugs as well as immunomodulatory 
compounds that can modulate the host response to infection.
I.3.4.I. Targeting viral enzymes and proteins
The targeting of essential viral enzymes has proven to be very successful in a variety 
of viral infections, resulting in approximately 20 licensed antiviral drugs for HIV 
alone (Greene, 2004). Examples of this approach are listed in Table 1.2 and include 
azidothymidine (AZT), which inhibits HIV reverse transcriptase (Nakashima et al., 
1986) and acyclovir, a compound that inhibits the DNA polymerase of HSV (Freeman 
& Gardiner, 1996). Both of these compounds are licensed and have proven useful in 
the treatment of infected individuals. Nucleoside phosphonate analogues of cellular 
deoxyribonucleotides are another class of drug that have proven to have broad 
spectrum antiviral activity against DNA viruses (De Clercq, 2007). Within this class, 
the drug cidofovir (((S)-l(3-hydroxy-2-phosphonylmethoxypropyl)) cytosine or 
HPMPC or CDV) has been shown to be a potent inhibitor of viral DNA polymerases 
and activity has been demonstrated against adeno-, polyoma-, herpes- and poxviruses, 
including lethal doses of VACV (Smee et a l , 2001a), variola, cowpox, monkeypox 
and molluscum contagiosum virus (MCV) (De Clercq, 2002). Cidofovir has been 
shown to work by incorporating itself into the extending viral DNA chain. This is 
only possible following several intracellular phosphorylation steps, converting CDV 
into the diphosphate form where it can then cause chain termination (Magee et al., 
2005). Currently, CDV is unlicensed for use against poxviruses and has only obtained 
approval for clinical use in the treatment of CMV retinitis (Lalezari, 1997), a 
complication that frequently results from HIV infection. Clinical trials have also 
established the in vivo efficacy of topical CDV in humans against MCV in AIDS
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Target Enzyme Involved in: Example
HIV reverse transcriptase Converts viral RNA into 
cDNA copy
AZT (Azidothymidine) 
Tenofovir
HSV DNA polymerase Viral DNA synthesis Acyclovir
Viral DNA polymerases of 
a wide variety of viruses 
including:
adeno-, polyoma-, herpes- 
and poxviruses.
Viral DNA synthesis Cidofovir (CDV) and 
derivatives of including 
HDP-CDHV and ODE- 
CDV
HBV DNA polymerase Viral DNA synthesis Adefovir
HIV protease Protein cleavage Saquinavir, Ritonavir, 
Indinavir, Nelfinavir
Picomavirus protease Protein cleavage AG6084
Herpesvirus assemblin Viral capsid assembly Flavin, CL13933
Target Protein Involved in: Example
37 kDa palmitylated 
peripheral membrane 
protein (e.g VACV F13L)
Othopoxvirus egress 
(Envelope wrapping of 
IMV)
ST-246
F13L Orthopoxvirus egress Compound 14
Virus envelope proteins / 
glycolipids
HIV entry Enfuvirtide
Table 1.2. Virus specific enzyme or protein targets.
Table lists examples of antiviral compounds that target virus specific proteins or 
enzymes.
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patients and also efficacy against orf virus. (Meadows et a l, 1997). Whilst promising 
and recommended by the Centre for Disease Control (CDC) for use against 
complications arising from smallpox vaccination (Wharton et al., 2003), its use may 
be hindered by the requirement for intravenous delivery and high levels of 
nephrotoxicity (Cundy, 1999). Extensive studies have been conducted recently in 
vitro and in animal models and currently oral derivatives based on lipid conjugates 
such as hexadecyloxypropyl-cidofovir (HDP-CDV) and octadecycloxyethyl-cidofovir 
(ODE-CDV) are being formulated to boost uptake from the small intestine and reduce 
levels of nephrotoxicity (Keith et a l, 2004; Quenelle et a l, 2004). These derivatives 
are currently exhibiting over 100 times greater activity against VACV and cowpox 
replication than unmodified CDV (Kern et a l, 2002). This may be due to an increased 
uptake (Aldem et a l, 2003) and ability to reach target tissues (Ciesla et a l, 2003) 
Other acyclic nucleoside analogues such as adefovir and tenofovir have been licensed 
and have proven successful in the treatment of hepatitis B virus (HBV) (Hadziyannis 
et a l, 2005) and HIV (Robbins et a l, 1998) respectively.
Other key viral enzymes targeted by antiviral compounds include viral proteases and 
neuraminadases (Table 1.2). Inhibiting viral proteases has achieved success in the 
treatment of HIV (e.g. saquiniavir, ritonavir, indinavir and nelfinavir), and is an 
approach that is being investigated to combat picomaviruses (AG6084), the capsid 
assembly protein assemblin in herpeseviruses (flavin, CL13933) and the hepatitis C 
virus (HCV) protease (Patick & Potts, 1998). Viral neuraminadases are potential 
targets in the treatment of influenza virus types A and B, owing to their fundamental 
role in permitting virus escape from the cell following replication. This has led to the 
design of drugs to inhibit this process (von Itzstein et a l, 1993; Smee et a l, 2001b).
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This resulted in the manufacture of oseltamivir (Nicholson et a l, 2000) and zanamivir 
(Hayden et al., 1997), both of which exhibit potent anti-neuraminidase activity. 
Antiviral compounds that target the cysteine proteinase (encoded by I7L) in VACV 
have been identified and reported to block viral maturation (Byrd et al., 2004). This 
study investigated the role of this viral proteinase and demonstrated that it was 
responsible for essential cleavage events during maturation that lead to the formation 
of infectious IMV particles. Inhibition of these cleavage events was reported to 
restrict viral titers in in vitro systems (Byrd & Hruby, 2005).
The targeting of viral proteins is an additional strategy that has yielded success 
therapeutically (Table 1.2). The drug ST-246 has proven to be very effective against a 
wide range of orthopoxviruses such as VACV, monkeypox, camelpox, ectromelia and 
variola viruses (Yang et al., 2005a). This drug works by targeting a 37-kDa 
palmitylated peripheral membrane protein (F13L in VACV), preventing the 
enveloping of IMV particles and thus inhibiting the formation of EEV particles. 
Studies show that this approach protects against orthopoxvirus-induced disease and, 
unlike CDV, can be delivered orally with much lower toxicity. Screening assays to 
identify new antiviral compounds have recently reported an additional compound that 
targets F13L and this has also proven effective at preventing viral egress and disease 
in initial studies (Bailey et a l, 2007). Other antivirals target virus envelope proteins or 
glycolipids used during the entry of the virus into the host cell e.g. enfuvirtide. This is 
currently an approach being investigated in the fight against HIV infection (Este & 
Telenti, 2007).
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I.3.4.2. Targeting host enzymes
An alternative antiviral approach is to interfere with host cell processes and 
machinery that viruses require to ensure competent replication and survival within the 
intracellular environment. A number of studies have shown efficacy against a range of 
viruses including poxviruses (Table 1.3).
The targeting of cellular enzymes, such as inosine 5’-monophosphate (IMP) 
dehydrogenase, has received much attention. This enzyme converts IMP to xanthine 
5’-monophospahte (XMP), which is required for the de novo biosynthesis of the 
purine mononucleotides such as guanosine 5’monophosphate (GMP) / diphosphate 
(GDP) / triphosphate (GTP). By inhibiting this enzyme, the availability of these 
guanosine mononucleotides is greatly reduced and this in turn inhibits both viral RNA 
and DNA synthesis (Robins et al., 1985). This is the basis of the antiviral drug 
ribavirin, which inhibits VACV replication in vivo through its 5’-monophosphate 
metabolite (Sidwell et a l, 1973).
S-adenosylhomo-cysteine (SAH) hydrolase is another key target enzyme of antiviral 
compounds. This enzyme is responsible for hydrolysing SAH, a compound that 
inhibits S-adenosylmethionine (SAM)-dependent methyltransferase reactions. SAM 
acts as a methyl donor for 5’-cap formation during RNA synthesis and the inhibition 
of SAH hydrolase results in the accumulation of SAH and interference of key 
methylation steps that effect RNA stability. Inhibition of SAH hydrolase has been 
shown to preferentially affect viruses, such as VACV, in their replication cycle by 
disrupting the stability of VACV mRNA (Borchardt et a l, 1984). Many adenosine 
analogues, such as neplanocins A and C and carbocyclic 3-deazaadenosine have been
53
Target Enzyme Involved in: Examples
IMP dehydrogenase Converts IMP to XMP Ribavirin
SAH hydrolase SAH hydrolysis Neplanocins A and C 
Carbocyclic 3- 
deazaadenosine
OMP decarboxylase Converts OMP to UMP Pyrazofurin
CTP synthetase Converts UTP to CTP Cyclopentyl cytosine
Thymidylate synthetase Converts dUMP to dTMP 5-amino-dUrd
Table 1.3. Host cellular enzyme targets.
Table lists examples of antiviral compounds that exert their effects by targeting host 
cellular enzyme targets
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described as inhibitors of SAH hydrolase with broad spectrum activity against 
poxviruses, negative strand RNA viruses and a host of others (De Clercq et al., 1984; 
De Clercq & Montgomery, 1983).
Additional enzymes useful as antiviral targets include orotidine 5’-monophosphate 
(OMP) decarboxylase, cytosine 5’-triphosphate (CTP) synthetase and thymilidate 
synthetase. OMP decarboxylase inhibitors prevent the conversion of OMP to uracil 
5’monophosphate (UMP), which blocks the accumulation of UTP and CTP pools. 
CTP pools are also depleted by CTP synthetase inhibitors, which block the conversion 
of UTP into CTP. Both of these inhibitors ultimately promote depletion of either UTP 
or CTP reservoirs and this results in the suppression of RNA synthesis. Key examples 
of these compounds in action come from the effect of the OMP decarboxylase 
inhibitor pyrazofurin and its derivatives on the replication of a variety of viruses 
(Chen et al., 1993) along with CTP synthetase inhibitors such as cyclopentenyl 
cytosine (Ce-Cyd) (De Clercq et al., 1991). Thymidylate synthetase inhibitors target 
the thymidylate synthetase enzyme, which prevents conversion of dUMP into dTMP 
(deoxy thymidine monophosphate). This inhibition leads to a lack of deoxy thymidine 
triphosphate (dTTP) and consequently results in defective DNA synthesis. Derivatives 
of diphosphohexose deoxyuridine (dUrd), such as 5-amino-dUrd, have demonstrated 
a potent activity against VACV (De Clercq, 1980).
I.3.4.3. Targeting host systems
More recently, a variety of studies have been published that have targeted poxvirus 
replication by targeting host cellular signaling pathways (Table 1.4). These include 
the drug Cl-1033, which interferes with the cellular ErbB-1 signal transduction
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Target Pathway Involved in: Examples
ErbB-1 Physiological growth 
factor signalling by EGF
CI-1033
ABl-family tyrosine kinase Actin motility STI-571 (Gleevac)
Interferon Antiviral state formation, 
cell signalling
(Pegylated) IFN-a 
Poly IC
Table 1.4. Host signalling targets.
Table lists examples of antiviral compounds that exert their effects by targeting host 
pathways
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pathway (Yang et al., 2005b). This pathway is activated by orthopoxvirus growth 
factors such as VGF in VACV/SPGF in variola (Tzahar et al., 1998), and inhibition 
via CI-1033 was shown to improve protection against a lethal VACV infection (Yang 
et al., 2005b). Additionally, targeting of the Abl-family of tyrosine kinases has also 
proved to be a valid approach with studies revealing a substantial drop in VACV 
spread following inhibition with STI-571 (Gleevac) and increased survival of infected 
mice (Reeves et al., 2005). Alternatively, interferon is a known antiviral and methods 
of inducing this pathway via administration of poly IC have been shown to induce a 
protective effect against VACV in rabbits (Levy & Lvovsky, 1978). Many other 
systems, some virus specific, are also viable targets for antiviral therapies that aim to 
interfere with virus attachment through specific cellular receptors, cell entry, virus 
motility and replication. Many of these are also able to demonstrate potential use as 
antiviral strategies such as the fusion inhibitor T-20 that is approved for the treatment 
of HIV (Kilby et al., 1998).
1.4. Aims of this research
The aims of this research are to establish the effectiveness of using CpGs as an 
antiviral against orthopoxvirus infection. The prophylactic or therapeutic efficacy of 
CpGs will be assessed in both pre-exposure and post-exposure model systems. This 
work will also attempt to establish the key immune parameters behind the success or 
failure of CpGs in protecting against orthopoxvirus infection so that the future use of 
CpGs as an antiviral strategy can be determined.
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Chapter 2: Materials and Methods
2.1. Cell culture
Macrophage cell lines were obtained from ECACC (HPA, UK) and were maintained 
in vitro at 37°C under atmospheric conditions of 5% carbon dioxide (CO2) and 95% 
humidity in vented tissue culture flasks (Coming®). MH-S cells were grown in 
endotoxin-free RPMI 1640 medium (Gibco® Invitrogen) and J774 cells were 
maintained in endotoxin-free Dulbecco’s modified Eagle’s medium (DMEM) (Gibco® 
Invitrogen). Both media were supplemented with 10% foetal calf semm (FCS) 
(Gibco® Invitrogen) and 2 mM L-glutamine (Sigma, UK). Rabbit kidney epithelial 
cells (RK-13) were obtained from ECACC (HPA, UK) and maintained in DMEM 
supplemented with 10% FCS, 2% HEPES-buffer, 1% tylosin, 100 U/ml penicillin, 
and 100 pg/ml streptomycin plus 2 mM L-glutamine (PSG), all from Sigma, UK.
2.1.1. CpG stimulation
Cells, were incubated in 6, 24 or 96-well plates at a concentration of 1 x 106/ml 
overnight at 37°C to allow cells to adhere. Cell supernatants were then removed and 
replaced with an equivalent volume of CpG (Table 2.1) made up to the desired 
concentration in appropriate media. CpGs 2336, 7909, 10103, 10101, 10109, 2137 
and 2243 were all obtained from Coley Pharmaceutical group (Ottawa, Canada). 
Plates were then re-incubated at 37°C and supernatants removed at individual time- 
points for subsequent analysis. Extraction of total RNA from macrophages for 
cytokine analysis is detailed in section 2.3.2.
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CpG Sequence Class Supplier
2336 G* G* GGACG ACGTCGTGG* G* G* G* G* G 
Mixed PS-PO backbone
A Coley Pharmaceuticals, 
Canada
10103 TCGTCGTTTTTCGGTCGTTTT 
PS backbone
B Coley Pharmaceuticals, 
Canada
7909 TCGTCGTTTTGTCGTTTTGTCGTT 
PS backbone
B Coley Pharmaceuticals, 
Canada
10101 Not available 
PS backbone
C Coley Pharmaceuticals, 
Canada
10109 TCGTC*GTTTTAC*GGCGCC*GTGCCG 
Mixed PS-PO backbone
Semi- 
soft C
Coley Pharmaceuticals, 
Canada
2243 G* G* GGGAGC ATGCTGG* G* G* G* G* G 
Mixed PS-PO backbone
A
(control)
Coley Pharmaceuticals, 
Canada
2137 TGCTGCTTTTGTGCTTTTGTGCTT 
PS backbone
B
(control)
Coley Pharmaceuticals, 
Canada
Table 2.1. CpG sequences used throughout
* Denotes phosphorothioate (PS) bonds in an otherwise phosphodiester (PO) 
backbone
* Denotes phosphodiester (PO) bonds in an otherwise phosphorothioate (PS) 
backbone
— Denotes palindromic sequence within ODN
2.1.2. Nitric oxide measurements
Production of nitric oxide (NO) was measured using the Griess reagent system 
(Promega, UK) as detailed in Figure 2.1. Briefly, 50 pi sample supernatants were 
carefully removed from individual wells following stimulation with CpG, and 
incubated with 50 pi sulphanilamide solution (1% sulphanilamide in 5% phosphoric 
acid) and 50 pi N-1 -napthylethylenediamine dihydrochloride (NED) solution (0.1% 
NED in water), as detailed in manufacturer’s instructions (Promega, UK). Levels of 
nitrite (NO2'), the stable end product of NO breakdown, were measured using a 
Thermolab multiscan plate reader at 540 nm using Ascent software 2.4.2 (Thermolab 
systems, UK). Standard curves were run on each plate (100 pM-0 pM) using a 0.1 M 
sodium nitrite standard to allow accurate calculation of nitrite concentration and 
determination of nitric oxide production in each sample.
2.1.3. Nitric oxide inhibition
Inhibition of nitric oxide synthesis was achieved using the generic inhibitor of nitric 
oxide synthase (NOS) NG-methyl-L-arginine acetate salt (L-NMMA) (Sigma, UK). 
Working solutions of L-NMMA were prepared daily in fresh medium and either 
added alone or in combination with CpG as replacement medium for macrophages 
that had been incubated overnight at a concentration of 1 x 106/ml. Cells were then 
incubated at 37°C for a period of 24 hours and supernatant removed prior to further 
analysis or viral infection.
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Sulphanilamide
H2NO2S- -NH2
n h 2 
h 2n o 2s - -N24
NED
— N-
NH2
-► H2N 0 2S ■N=N
Figure 2.1. The Griess reaction.
Levels of NO are determined by measurement of nitrite (NO2'), a stable end product 
of NO breakdown. Addition of sulphanilamide and N-1 -napthylethylenediamine 
dihydrochloride (NED) under acidic conditions creates a colorimetric change that is 
measurable at an absorbance of 540 nm.
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2.2. Viral titrations
2.2.1. Cell culture infected macrophages
Macrophages at a concentration of lx l0 6/ml were left to adhere overnight at 37°C in 
24-well plates in 1 ml volumes. The following day, suspensions of VACV (strain 
IHD) were prepared in cell-line specific medium at a concentration of 5 x 106 plaque- 
forming units per ml (pfu/ml) and used to infect macrophages in triplicate. Briefly, 
400 pi of medium were removed from each well and 100 pi viral suspension added 
and incubated for 1 hour at 37°C. After 1 hour, 500 pi of cell supernatant were 
removed from each well and cells washed twice with 500 pi PBS. Following the 
second wash, 1 ml of fresh medium was added to each well and plates re-incubated at 
37°C with this point serving as time 0 hours in the infection timeline. At specific time 
points, plates were removed from the incubator and placed immediately into a -20 °C 
freezer to stop the infection process.
2.2.2. Viral titre calculation
Plates were removed from the freezer, thawed and then cells scraped from the bottom 
of wells using a pipette tip. Triplicate wells were then merged into a 3 ml Dounce 
homogeniser. Wells were then washed with 100 pi PBS to ensure maximum recovery 
of virus and cellular debris. Cells were then homogenised with between 20-30 strokes 
to release the viral progeny. Homogenates were then poured into 15 ml falcon tubes 
and centrifuged for 10 minutes at 2000 revolutions per minute (rpm) to pellet the cell 
debris. Once pelleted, 2 pi aliquots of viral supernatants were added to one column of 
a 96-well plate containing 200pl of DMEM with 2% FCS. Remaining viral 
supernatant was stored at -20°C in fresh tubes for further analysis. A 1:10 dilution 
series of the clarified suspension was prepared across a 96-well plate using DMEM
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with 2% FCS as the diluent; each dilution occupied a column of 8 wells. Once 
complete, 100 pi were transferred from each well and used to infect 5 x 104 RK13 
cells/well in DMEM 2% FCS in 96-well plates. Assay plates were incubated at 37°C 
for 48 hours before being fixed with formal saline for a minimum of 4 hours. Finally, 
formal saline was then removed and cells stained with 1.5% filtered crystal violet to 
determine viral titres using the Reed-Miiench method (Reed & Muench, 1938).
2.3. Reverse transcription polymerase chain reaction (RT-PCR)
2.3.1. RNA isolation from macrophage cell-lines and primary macrophages
Total RNA from macrophage cell-lines and primary alveolar macrophages was 
isolated using Ambions RNAqueous® phenol-free isolation kits. MH-S and J774 cell 
macrophages were grown in 96-well plates and assayed in triplicate. Preparation of 
cell lysates was achieved through removal of culture supernatants and addition of 250 
pi of RNAqueous® lysis solution containing guanidinium isothiocyanate 
(Chomczynski & Sacchi, 1987) to each well. Adherent cells were scraped from the 
bottom of wells using a pipette tip. Triplicate wells were then merged to provide a 700 
pi sample of cell lysate and mixed with 64% ethanol as described in manufacturer’s 
instructions. Samples were then centrifuged for 15 seconds through a filter cartridge 
into a collection tube at 12000 rpm to bind RNA to the glass fibres in the filter as 
described by Boom and colleagues and Marko (Boom et a l , 1990; Marko et a l, 
1982). Sample flow through was discarded and any remaining sample passed through 
the same filter cartridge to bind residual RNA. Bound RNA was then washed three 
times with 2 wash solutions, the first containing guanidinium isothiocyanate to 
denature residual RNAses and the second an 80% ethanol based solution to further
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remove contaminants. After washing, RNA was finally eluted in 2 x 50 pi low ionic 
strength elution buffer pre-heated to 75°C.
2.3.2. DNA-free treatment
Extracted RNA samples were all treated using Ambion’s TURBO DNA-free™ kit to 
remove traces of contaminating DNA. This involved addition of a one tenth sample 
volume of 10X TURBO DNase buffer to the RNA along with 2 pi (4 units) TURBO 
DNase, followed by a 30 minute incubation step at 37°C. Inactivation of TURBO 
DNase and removal of divalent cations was achieved through mixture of sample with 
0.1 x volume of DNase inactivation reagent for 2 minutes at room temperature. 
Samples were then centrifuged at 12,000rpm for 1 minute and the DNA-free RNA 
supernatant transferred to a fresh tube.
2.3.3. RNA purification
RNA samples were subjected to an additional purification step to purify and 
concentrate RNA using the RNeasy® MinElute™ cleanup kit (Qiagen, UK). Briefly, 
samples were mixed with a guanidine salt buffer containing 0.01 x volume of P- 
mercapto-ethanol (P-ME) and 100% ethanol, and then passed through a centrifuge 
column containing a silica-gel membrane at 12,000 rpm for adsorption of RNA. 
Contaminants were washed away using 2 separate ethanol wash solutions in 30 
second 12,000 rpm centrifuge steps prior to a 5 minute spin to dry the column and 
subsequent elution of RNA in 20 pi of RNA-free water. Sample purification was 
validated using 1 pi of pre and post-treated RNA on the Agilent 2100 Bioanalyzer 
using the Agilent RNA 6000 Nano-assay kit (Figure 2.2) and also on the NanoDrop® 
ND-1000 spectrophotometer (NanoDrop,UK).
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Figure 2.2. Typical bioanalyser analysis of RNA samples.
Figure shows RNA before (a), and after (b), purification with Qiagen MinElute kit. 
Peaks and bands represent 28s and 18s components of RNA. A typical overlap of 
RNA peaks pre- and post-purification is also represented (c).
_  Before purification 
_  After purification
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2.3.4. Reverse transcription
Purified RNA was reverse transcribed into complementary DNA (cDNA) using the 
Qiagen Omniscript® reverse transcription (RT) kit. Template RNA was combined 
with lOx buffer RT, 5 mM of 2’deoxy-nucleotide-5’-triphosphates (dNTPs), 4 U 
Omniscript® reverse transcriptase and RNase-free water (all Qiagen, UK 
components), along with 40 U RNase inhibitor (Ambion, UK) and 20 pg random 
primers (Promega,UK). The reaction mixture was incubated at 37°C for 60 minutes 
and cDNA stored at -20°C or processed immediately.
2.3.5. Relative quantitation of gene expression
All gene expression assays were acquired from Applied Biosystems (ABI) ‘Assays- 
on-Demand’ service and all samples were assayed in triplicate on the Taqman® 7000 
machine using the protocol shown in Figure 2.3. Each gene expression assay 
consisted of a FAM™ dye labelled Taqman® minor groove binder (MGB) probe 
formulated at a final concentration of 250 nM, and two unlabelled PCR primers 
formulated at 900 nM concentration in a single 20x assay tube. The specifics of RT- 
PCR are detailed below in Figure 2.4. 18s eukaryotic RNA was used throughout as an 
endogenous control and relative quantitation of gene expression was calculated using 
the delta delta cycle threshold method (2'AAct) as described by Livak (Livak & 
Schmittgen, 2001). All samples were run in a final reaction volume of 25 pi 
comprising of 1.25 pi Taqman® gene expression assay (20x), 12.5 pi Taqman® 
universal PCR master mix, no AmpErase uracil-N-glycosylase (UNG), 9.25 pi of RT- 
PCR grade water and 2.0 pi cDNA sample, and all analyses were performed using 
ABI Prism 7000 sequence detection system (SDS) software (Figure 2.5).
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Figure 2.3. Universal thermocycler PCR reaction programme: (Applied 
Biosystems 9600 Emulation).
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Figure 2.4. Real-time PCR and fluorescence resonance energy transfer 
(FRET) technology.
Following reverse transcription, double stranded cDNA is denatured (A) and acts as a 
template in the initial steps of the RT-PCR reaction. Forward and reverse primers at a 
final concentration of 900nM bind to the cDNA (B), along with an ABI 
AmpliTaqGold® (TAQ) DNA polymerase (C) and assay specific Taqman® minor 
groove binder (MGB) probe (D) featuring a 5’ reporter (R) dye (such as 6-FAM) and 
non-fluorescent quencher dye (NFQ) at the 3’ end. The 5’ nuclease activity of TAQ 
allows cleavage of the Taqman® MGB probe (E) resulting in dissociation of the 
reporter dye from the quencher and subsequent increase of reporter fluorescence (F). 
Signal increases exponentially throughout the reaction as PCR products accumulate.
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Figure 2.5. Detection of reporter signal by ABI Prism 7000 SDS software.
Relative quantitation of gene expression requires setting of a threshold level (A) 
during the exponential phase of the PCR reaction. A baseline level is set (B) to ignore 
non-specific detection of signal prior to specific gene amplification. An endogenous 
control gene such as 18sRNA (C) is included in each reaction and expression of target 
genes (D/E) are calculated relative to its cycle threshold (ct) value, obtained from the 
point at which its fluorescence crosses the threshold level. Sample wells with water 
and no cDNA template (F) are run as negative controls.
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2.4. Cytokine analysis via protein detection
2.4.1. BD™ cytometric bead array (CBA)
Protein levels of specific cytokines were measured using BD™ cytometric bead array 
(CBA) technology on a BD™ FACScan flow cytometer. All samples were analysed 
using the BD™ mouse inflammation kit. Equal volumes of mouse inflammation 
capture beads (10 pl/test) specific for the inflammatory cytokines IL-12p70, IL-6, IL- 
10, CCL2, TNF-a and IFN-y were pooled and a 50 pi cocktail combined with 50 pi of 
sample supernatant and 50 pi PE detection reagent in single 12x75 mm polypropylene 
tubes or 96-well plates. Samples were incubated for 2 hours at room temperature in 
the dark and were then washed in 300pi BD™ wash buffer, centrifuged for 5 minutes 
at 200g and resuspended in 300 pi BD™ wash buffer with 4% paraformaldehyde 
prior to analysis. Standard curves were run as a reference in each experiment ranging 
from 0-5000 pg/ml using 1 vial of reconstituted mouse inflammation standards 
(Figure 2.6). Relative concentrations of sample cytokine concentrations were 
determined using the BD CBA software.
2.4.2. IFN-a sandwich enzyme linked immunosorbent assay (ELISA)
Protein levels of mouse IFN-a were measured using a sandwich immunoassay using a 
mouse specific IFN-a kit obtained from PBL Biomedical Laboratories (USA). Mouse 
sera or tissue supernatants were obtained from whole blood or homogenised animal 
tissue following centrifugation at 10,000 rpm for 10 minutes. Samples were either 
frozen at -20°C or processed immediately. Microtitre plates (96-wells), pre-coated 
with IFN-a capture monoclonal antibody were supplied ready for use. Experimental 
samples were added in duplicate in 100 pi quantities alongside a reference standard 
curve (0-500 pg/ml) constructed using the National Institute of Health’s (NIH)
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Figure 2.6. Cytokine quantification through CBA protein detection.
(a) Supernatant samples are run through a flow cytometer and cytokine specific 
capture beads identified using FSC:SSC. (b) Data is filtered using FCAP software and 
quantification determined using standards run from Opg/ml (c) to 5000pg/ml (d). 
Example specimen positive for IL-6, CCL2 and TNF-a (e).
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international reference standard for mouse IFN-a (Pestka, 1986) and dilution buffer 
containing 0.1 g/L thiomersal to act as a preservative. Plates were then sealed with a 
plastic cover and incubated at room temperature for 1 hour in a sealed container. 
Secondary antibody concentrate was then diluted 1:20 with dilution buffer as 
recommended by the manufacturer’s instructions (50 pi into 950 pi) making a 
secondary antibody stock solution. This stock solution was used at a ratio of 12.5 pi 
stock solution per 1 ml dilution buffer as required (e.g. 25 pi antibody stock solution 
to 2 ml dilution buffer) to make a secondary antibody working solution. After 1 hour 
incubation, plates were washed once with wash solution, tapped dry onto absorbent 
lint-free paper and then incubated for 24 hours with 100 pi mouse IFN-a secondary 
antibody solution per well at room temperature in a sealed container. Plates were then 
washed three times with wash solution, tapped dry and each well incubated with 100 
pi horseradish peroxidise (HRP) enzyme conjugate solution for 1 hour at room 
temperature and then washed four times with wash solution. Once dry, plates were 
incubated with 100 pi of tetramethyl-benzidine (TMB) as a substrate for 15 minutes at 
room temperature in the dark. This reaction was stopped by addition of 100 pi stop 
solution and read immediately on a Thermolab multiscan plate reader using Ascent 
software 2.4.2 (Thermolab systems, UK) at a wavelength of 450 nm. Concentration of 
mouse IFN-a in the samples was determined via extrapolation from the reference 
curve specific for each plate.
2.5. Flow cytometry
Cells obtained from mouse lung and tissue samples were analysed on either BD 
FACScan™ or BD FACSCanto™ II flow cytometers, using CellQuest Pro software 
or FACSDiva respectively. Organs were homogenised using a sterile sieve and
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plunger with 1 ml of PBS into one well of a 6-well plate. Homogenised samples were 
then centrifuged at 4,000 rpm for 5 minutes to pellet cells. Supernatants were frozen 
at -20°C for analysis via ELISA or CBA. Pelleted cells were then resuspended in 5 ml 
flow buffer (PBS with 2% FCS), carefully layered over 3 ml of lymphocyte separation 
medium (LSM®, ICN/Cappel), then centrifuged at 800g for 30 minutes to separate red 
blood cells, mononuclear cells and plasma. Following centrifugation, the central 
lymphocyte layer was removed and made up to 10 ml with flow buffer. Samples were 
then centrifuged at 200g for 10 minutes to pellet cells then resuspended in flow 
buffer.
2.5.1. Antibody staining
Antibody specific for CD32/CD16 (BD Biosciences, UK) was added to each sample 
at a ratio of 2 pi per 106 cells to prevent non-specific binding of antibody to the 
common antibody chain receptors present on immune cells (BD fragment 
crystallisable (Fc) block™). After mixing, samples were incubated at 4°C for 5 
minutes, then 100 pi sample was incubated for 30 minutes in 12x75 mm 
polypropylene tubes or 96-well plates at room temperature with appropriate antibody 
cocktails specific for cell identification and activation markers. After staining, cells 
were washed in 1 ml of flow buffer, centrifuged at 4000 rpm for 5 minutes, and 
resuspended in either flow buffer with 4% paraformaldehyde or BD fixation solution 
(containing 3% paraformaldehyde) to preserve antibody conjugations. Prior to 
analysis, cells were incubated overnight at 4°C. Isotype controls specific to each 
antibody isotype were run alongside each experiment along with unstained and single 
stained control samples. 50 pi of flow-count fluorospheres (Beckman Coulter, UK)
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were added to each sample immediately before reading to allow determination of 
absolute cell counts whenever possible.
2.5.2. Apoptosis measurement
Macrophage cell-lines were assessed for apoptosis using a BD Pharmingen™ 
Annexin-V apoptosis kit. Briefly, macrophages were grown overnight in 6-well plates 
at a concentration of lx l0 6/ml overnight at 37°C to allow cells to adhere. Cell 
supernatants were then removed and either replaced with fresh medium or stimulated 
with CpG at the desired concentration for 24 hours at 37°C. Cells were then washed 
twice in cold PBS and resuspended in calcium binding buffer ( as per instructions) at 
a concentration of lx l0 6/ml. A 100 pi aliquot (1x10s macrophages) was then 
incubated with 5 pi of Annexin-V antibody conjugated to PE and 5 pi of 7-Amino- 
Actinomycin D antibody conjugated to APC. Cells were incubated for 15 minutes at 
room temperature in the dark and then washed with 1 ml of PBS. Cells were 
resuspended in 400 pi of calcium binding buffer and read via flow cytometry 
immediately.
2.6. Animals and infection
2.6.1. Sources of animals
All animal experiments were conducted in accordance with the Scientific Procedures 
Act 1986, under both personal and project licences issued by the Home Office. Adult 
female Balb/C mice (6-8 weeks old) were obtained from Charles River laboratories 
(Kent, UK) and genetic B-cell knock-out mice on a Balb/C background were obtained 
from Taconic (USA), model number 001487-MM.
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2.6.2. Infection with VACV strain IHD
Mice were infected with VACV strain IHD in 10 pi volume via the intranasal route 
according to experimental design. Previous studies in house had established the MLD 
of VACV to be 5xl04 pfu/ml. Mice were monitored daily at regular intervals 
throughout infection periods and clinical signs of infection recorded thoroughly. 
Humane endpoints were enforced throughout all experiments, as governed by a 30% 
decrease in body weight, blindness or severe respiratory distress as has been 
previously described (Pulford et ah, 2004).
2.6.3. CpG and PBS dosing
Mice were dosed with varying concentrations of CpG, made up in 50 pi volumes of 
PBS, via intramuscular, intranasal, sub-cutaneous or intra-peritoneal routes, according 
to experimental design. Control mice were given an equal volume of PBS via the 
same route.
2.6.4. Bronchoalveolar lavage collection and staining
Lung lavage samples were obtained from Balb/C as described by Maxeiner and 
colleagues (Maxeiner et al., 2007). Five volumes of PBS (0.2 mis) were injected 
through mouse tracheal tubes using a syringe, recovered and placed in a glass vial and 
stored temporarily at 4°C. Macrophage purity of lavage samples was determined 
through immunohistological staining. Briefly, 0.5 ml of pooled lavage sample was 
centrifuged onto a microscope slide using a Shandon cytospin (Thermo Scientific, 
UK) for 10 minutes at 1800 rpm. Once dry, slides were placed into a mechanical rack 
and stained using the Hema ‘Gurr’ rapid staining set for haematology as detailed in
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Table 2.2. Slides were then air-dried and analysed beneath a light microscope at either 
x 400 or x 1000 magnification.
2.6.5. Alveolar macrophage purification
Pooled lavage samples were centrifuged at 400g for 5 minutes and resuspended in 
lml of endotoxin-free RPMI 1640 medium with 2mM L-glutamine containing 10% 
FCS, 100 U/ml penicillin, and 100 pg/ml streptomycin. Cells were then placed into 
wells of a 96-well plate to allow cells to adhere overnight. The following morning, 
supernatants were removed and wells washed to remove any non-adherent cell types. 
Adherent cells were then stimulated with CpG or lysed using the method detailed in 
section 2.3.1 for isolation of total RNA.
2.6.6. Neutrophil ablation
Neutrophil ablation was achieved using the monoclonal antibody RB6-8C5 (RB6) 
(Chemicon Europe) that binds specifically to Gr-1. Prior to use, stock concentration of 
antibody was diluted to 1 mg/ml and 500 pg administered intraperitonealy one day 
prior to VACV infection. An IgG2b isotype control monoclonal antibody (Mac-5) 
was used alongside RB6 in the neutrophil ablation study as a non-specific control.
2.6.7. Technical assistance
All animal handling, infections and dissections throughout this thesis were conducted 
by trained colleagues and not in any part by me. As such, their invaluable assistance 
and help throughout, needs to be acknowledged.
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Step Solution Task
1 Fixing solution (Buffered methanol) 5 x Is dunk
2 Staining solution 1 (Buffered Eosin) 3 x Is dunk
3 Staining solution 2 (Buffered Methylene Blue) 6 x Is dunk
4 Buffer solution 7.2 45s
Table 2.2. The Hema Gurr rapid staining procedure. Samples fixed upon 
microscope slides were stained for haematological analysis.
* s -  second(s)
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2.7. Statistical Methods
Two statistical packages were used to analyse data obtained throughout this thesis. 
Two-way analysis of variants (ANOVAs) with Bonferroni’s post-test corrections, and 
Kaplan-Meier log rank survival analyses were performed using GraphPad Prism® 4 
software (GraphPad, USA). All other statistical tests employing three or four 
parameter general linear analysis, with Bonferroni’s post-tests, were conducted using 
Minitab® Release 14. All mean values quoted or depicted graphically represent the 
geometric mean of samples unless otherwise stated.
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Chapter 3: The prophylactic use of CpG-B 7909 against VACV
3.1. Introduction
The immunostimulatory properties of CpGs have led to their use in a variety of 
different therapeutic applications (section 1.2.7). An extensive number of studies have 
investigated CpGs against a range of different infectious diseases caused by bacterial, 
parasitic and viral pathogens. The results of these studies against infectious diseases 
have varied greatly with the type of CpG used, the route of administration, and also 
the timing of CpG delivery.
3.1.1. CpG prophylaxis and bacterial infection
CpG treatment against bacterial pathogens has achieved protection in a number of 
murine models resulting in the alleviation of clinical signs of disease and reduction in 
bacterial loads. For instance, intraperitoneal CpG treatment of mice prior to infection 
with Francisella tularensis live vaccine strain (LVS) and Listeria monocytogenes has 
been shown to confer complete protection against infection (Elkins et al., 1999b). 
Here, mice treated with a single dose of CpG or bacterial DNA between 3 and 7 days 
prior to infection with lethal doses of bacteria all survived infection. Additionally, 
pre-treatment of mice with CpG 10 days and 14 days prior to infection with 
Francisella tularensis (LVS strain) was still able to confer 80% and 40% levels of 
protection respectively (Elkins et a l , 1999b). Following on, studies by Klinman and 
colleagues demonstrated that this level of protection could be maintained indefinitely 
against both Francisella and Listeria with repeated CpG dosing at regular 2-weekly 
intervals (Klinman et a l, 1999). Protection against Burkholderia pseudomallei has 
also been demonstrated using CpGs (Wongratanacheewin et a l, 2004). In these
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studies, high levels of protection (90-100%) were observed when mice were pre­
treated with CpG between 10 and 2 days prior to infection. These high levels of 
protection were associated with attenuated levels of the pro-inflammatory cytokine 
IFN-y as well as significant reductions in bacterial burdens. Mice were still protected 
to a lesser extent (57%) when pre-treated 15 days beforehand with CpG. Interestingly, 
these results were obtained using an intramuscular dose of CpG against an 
intraperitoneal infection. Studies have also demonstrated protection against 
Burkholderia mallei, a close relative of Burkholderia pseudomallei (Waag et a l , 
2006). This study investigated the effect of two different classes of CpGs (CpG-A and 
CpG-B) and demonstrated a clear difference in their protective capacity against 
aerosol infection with Burkholderia mallei. Intraperitoneal CpG administration with 
the B-class CpG-B 7909 two days prior to infection was shown to confer complete 
protection against lethality and restricted bacterial growth in both the lungs and 
spleens of infected mice. This level of protection dropped slightly to 90% when mice 
were treated on the day of infection but plummeted to 10% when treated 24 hours 
post-infection. The A-class CpG 2216 did not confer any protection against 
Burkholderia mallei (Waag et al., 2006). Intratracheal CpG treatment of mice infected 
with Klebsiella pneumoniae has also proven effective with 80% of infected mice 
surviving lethal infection when pre-treated two days before bacterial infection (Deng 
et al., 2004). This study reported rapid increases in neutrophil, NK cell and T- 
lymphocyte numbers in the lung and increases in a variety of type-1  cytokines 
including TNF-a, IL-12 and IFN-y. Once again, administration of CpG resulted in 
significant reductions of bacterial burdens in key organs such as the lung and also 
reduced bacteraemia in the blood. Systemic administration of CpG has also been 
shown to have therapeutic value in pulmonary tuberculosis, reducing lung
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inflammation and mycobacterial growth potentially via an IFN-y dependent 
mechanism (Juffermans et al., 2002).
3.1.2. CpG prophylaxis and parasitic infection
Protective responses have also been reported against parasitic infections. Treatment of 
mice with CpG-B 1826 up to 48 hours prior to challenge with Plasmodium yoelii 
sporozoites, a causative agent of murine malaria, conferred sterile protection against 
infection (Gramzinski et a l, 2001). These studies associated this sterility with early 
and rapid increases in levels of IFN-y and IL-12. CpG administration 7 days prior to 
challenge was also able to prevent infection in 60% of cases whereas CpG treatment 
on the day of challenge failed to prevent infection. In contrast, treatment with CpG 2 
hours prior and 10 hours after challenge with Leishmania major afforded long-term 
protection (up to 22 weeks) against disease (Zimmermann et a l , 1998b). CpG- 
mediated protection against parasitic infection may be due to the prevention of the 
Th-2 mediated disease profile associated with many parasitic infections. In this way, 
therapy possibly echoes that seen in the treatment of allergic responses which also 
benefit from the skewing of the immune response to a Th-1 profile.
3.1.3. CpG prophylaxis and viral infection
CpGs have also been assessed for their prophylactic or therapeutic value against a 
number of viral pathogens both in vitro and in a number of animal models. Many 
studies have utilised the adjuvant effects of CpGs in the treatment of viruses such as 
HBV (Halperin et al., 2003), VACV (Belyakov et a l, 2006), lymphocytic 
choriomeningitis virus (LCMV) (Vabulas et a l, 2000) and influenza (Cooper et a l,
2004). CpGs have also been studied for their direct antiviral properties. Recent in
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vitro studies have suggested CpGs may be effective against severe acute respiratory 
syndrome (SARS) (Bao et al., 2006). In these studies, supernatants from human 
PBMCs stimulated with CpG were shown to significantly protect epithelial cells from 
SARS-CoV infection. Other in vitro studies have suggested that co-culture of PBMCs 
with CpGs can inhibit hepatitis B virus replication (Li et al., 2006). In animal models, 
many studies using CpGs as a monotherapy have been able to demonstrate increased 
levels of protection. Studies in C57BL/6 mice have shown that intravaginal delivery 
of CpG prior to infection with HSV-2 can confer complete protection against lethality 
when given 24 hours prior to infection (Sajic et al., 2003; Ashkar et al., 2003) and 
confer 90% protection when given 48 hours before infection (Harandi et al., 2003). 
These studies were all able to demonstrate significant reductions in viral titres and 
minimal vaginal pathology in pre-treated animals. Interestingly, altering the route of 
CpG delivery in these studies also resulted in a loss of protection, suggesting that the 
local delivery of CpG could be important against viral infection. In neonatal mice, 
studies have shown CpG administered on the day of infection was able to protect 
against a lethal challenge with the neurotrophic tacaribe arenavirus (TCAV) (Pedras- 
Vasconcelos et al., 2006). Here, CpG-treated neonates were shown to have reduced 
viral titres in the brain following systemic administration of CpG. However, once 
again the level of protection afforded varied according to the route of CpG and virus 
delivery. This was evident from results showing that intraperitoneal CpG delivery 
conferred 52% protection against intraperitoneal virus infection, whereas intranasal 
dosing of CpG failed to confer any protection against intraperitoneal infection. 
Indeed, local delivery of the B-class CpG-B 7909 has been shown to protect against 
intranasal VACV infection in a Balb/C mouse model of infection (Rees et al., 2005). 
Results from this study suggested that CpG-B 7909 administered up to 7 days prior to
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infection could provide complete protection against lethality. This study also reported 
a reduction in viral titres in the brain, spleen and lungs of infected mice and an 
increase in the levels of chemokines such as RANTES and MIP-lp. In addition, this 
study also examined the use of CpG-A 1585 as a prophylactic against VACV and 
found that complete protection was also achieved if given by the intranasal route. This 
protection relied upon substanially higher doses of CpG and failed to reduce disease 
morbidity (measured by weight loss) as effectively as CpG-B (Rees et al, 2005).
3.2. Aims of this chapter
The pre-treatment of mice prior to challenge with infectious pathogens has achieved 
success in a variety of bacterial, parasitic and viral infections. These include the use of 
both CpG-A 1585 and CpG-B 7909 against VACV. In these preliminarly studies with 
VACV, CpG-B 7909 proved most effective in conferring protection (Rees et al,
2005). In addition, the early release of chemokines like RANTES and MIP-ip 
following CpG-B 7909 administraion suggest that components of the innate immune 
system play a key role in CpG mediated protection against VACV infection (Rees et 
a l , 2005). More detailed studies are therefore required to understand the roles and 
function of cells of the innate system during CpG-B mediated protection against 
VACV infection. In this chapter, an immunological analysis of the kinetics of the 
innate immune response, after local delivery of CpG is investigated.
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3.3. Results
3.3.1. Experimental outline
The in vivo responses of animals pre-treated with the B-class CpG-B 7909 were 
compared against those given a control PBS dose. Two groups of six-eight week old 
female Balb/C mice were pre-treated with 75 pg CpG-B 7909 intranasally or PBS 
three days prior to intranasal infection with 10 MLD VACV. Groups of mice (n=4) 
from both treatment groups were humanely culled prior to infection on day 0 , and 
thereafter on days +1, +3, +5, +7 and +9 post-infection, for comparative immune 
analyses. Cytokine analyses of lung, spleen and serum preparations for the pro- 
inflammatory cytokines TNF-a, IL-6 , IFN-a and IFN-y, along with the chemokine 
CCL2 and anti-inflammatory cytokine IL-10 were determined throughout the course 
of the experiment. The expression of key activation markers on macrophages, 
neutrophils, DCs, NK cells, B-cells and T-cells in the lungs and spleens of mice were 
enumerated by flow cytometry.
3.3.2. Cytokine responses in the lung
The levels of the pro-inflammatory cytokines and chemokines measured in the lungs 
of mice pre-treated with CpG-B 7909, all differed significantly from PBS control 
mice throughout the early stages of infection. Over the first 3 days of infection, levels 
of TNF-a (Figure 3.1a), IL- 6  (Figure 3.1b), and IFN-a (Figure 3.1c) were all 
expressed in significantly higher quantities in the lungs of CpG-B 7909 treated mice 
(p<0.001). Levels of IFN-y (Figure 3.Id) and CCL2 (Figure 3.1e) were also 
significantly greater in CpG-treated animals on days 0 and +1 (p<0.001) and day +3 
(IFN-y p<0.01; CCL2 p<0.05). By day +5, only pro-inflammatory TNF-a (p<0.05) 
and IFN-a (p<0.05) levels were significantly higher than those measured in the PBS
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Figure 3.1. Measurement of lung cytokine levels in Balb/C mice pre-treated 
with either CpG-B 7909 or PBS throughout infection with VACV. Protein levels 
determined via CBA analysis or IFN-a elisa. Bars represent the geometric mean of 
four mice (Logio pg/ml) and error bars indicate 95% confidence intervals for 
cytokines (a) TNF-a; (b) IL-6; (c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests. 
Significant findings between treatment groups are represented as * (p<0.05), ** 
(p<0.01) and *** (p<0.001).
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control group. Beyond this, no significant differences between treatment groups were 
found in any of the cytokines or chemokines measured. The anti-inflammatory 
cytokine IL-10 was also elevated in the lungs of CpG-B 7909 pre-treated mice during 
the early stages of infection (Figure 3.If). In contrast to the pro-inflammatory 
cytokines, levels of IL-10 only differed significantly from control levels on day +1 of 
infection (p<0.05).
3.3.3. Cellular responses in the lung
3.3.3.I. Lung macrophage responses
Antibody specific to the mouse macrophage cell marker F4/80 was used to label 
macrophages from lung cell suspensions. The activation status of macrophages at 
each time point was determined via the expression of CD54 and MHC class II 
molecules (IA/IE) on the surface of F4/80 positive cells.
Figure 3.2a shows the total number of F4/80+ cells in the lungs of mice pre-treated 
with CpG-B 7909 and those pre-treated with PBS. Total macrophage numbers were 
significantly higher in CpG-treated individuals than in PBS treated mice throughout 
infection (p<0 .0 0 1 ), but followed the same trend over time regardless of treatment 
group. The most significant difference in the level of macrophage numbers was seen 
24 hours post infection (p<0.001). Increases in total macrophage cell numbers were 
accompanied by an increase in the number of activated cells as indicated by the 
number of macrophages expressing CD54 (Figure 3.2b) and macrophages expressing 
IA/IE (Figure 3.2c).
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Figure 3.2. Lung macrophage numbers during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Mice were pre-treated with CpG on day -3 and
exposed to VACV on day 0. The numbers of F4/80+ macrophages in the lungs of 
infected mice were examined over days 0-9 using flow cytometry. Figure shows (a) 
total number of F4/80+ macrophages; (b) macrophages expressing CD54; (c) 
macrophages expressing IA/IE. Graph represents geometric mean of four mice. 
Results shown include ± SEM. Statistical significance was determined using a two- 
way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as *** (p<0 .0 0 1 ).
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An initial increase in the percentage of CD54+ macrophages was observed in both 
treatment groups during the first 24 hours of infection (Figure 3.3a). This level of 
expression was maintained by macrophages from CpG-treated animals out to day +3, 
but not in PBS control mice, where expression levels fell significantly below those in 
the CpG-treated group (p<0.05). In CpG-treated mice, the percentage of macrophages 
expressing MHC II was significantly lower than that observed in the PBS treated 
group on the first day of infection (p<0.01). By day +3, the percentage of MHC II+ 
macrophages was comparable between treatment groups and remained so throughout 
the duration of infection.
3.3.3.2. Lung neutrophil responses
Lung neutrophils were characterised by gating on granulocytic cells using forward 
scatter/side scatter dot plots and using a monoclonal antibody to Ly6 G as a cell 
marker. Activation of neutrophils was determined by monitoring expression of the 
activation makers CD54 and CD1 lb on Ly6 G positive cells.
Figure 3.4a illustrates the total number of lung neutrophils over the course of 
infection. On days 0 and +1, a significantly higher number of total lung neutrophils 
was observed in CpG-treated mice than in those treated with PBS (p<0.001). The 
numbers of activated cells were also significantly higher over this early stage, with 
higher numbers of CpG-treated neutrophils expressing CD54 (Figure 3.4b) on day 0 
(pO.OOl) and CpG activated neutrophils expressing C D llb  (Figure 3.4c) on both 
days 0 and +1 (p<0.001). From day +3 onwards, the total numbers of neutrophils as 
well as the number of activated neutrophils were identical in both treatment groups.
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Figure 3.3. Activation of lung macrophages during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Lung macrophage activation was monitored by 
expression of activation marker CD54 (Figure 3.3a) and co-stimulation marker IA/IE 
(Figure 3.3b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05) and ** (p<0.01).
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Figure 3.4. Lung neutrophil numbers during VACV infection in CpG-B 7909 
and PBS pre-treated groups. Numbers of Ly6 G+ neutrophils in the lungs of infected 
mice were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over 
a nine day period using flow cytometry. Figure shows (a) total number of Ly6 G+ 
neutrophils; (b) neutrophils expressing CD54; (c) neutrophils expressing CD llb. 
Graph represents geometric mean of four mice. Results shown include ± SEM. 
Statistical significance was determined using a two-way ANOVA and Bonferroni’s 
post-tests. Significant findings between treatment groups are represented as ***
(p<0 .0 0 1 ).
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The percentage of neutrophils expressing CD54 fluctuated over the course of 
infection in both treatment groups as seen in Figure 3.5a. On day 0, the percentage of 
cells expressing CD54 was comparable between PBS and CpG pre-treated groups. On 
day +1 of VACV infection, the percentage of neutrophils expressing CD54 in CpG- 
treated mice was significantly lower than that observed in PBS treated mice (pO.Ol). 
Beyond day +1, the percentage levels of CD54+ neutrophils were comparable between 
treatment groups. The percentage of C D llb+ neutrophils in CpG-treated mice was 
significantly higher than that in PBS mice on days 0 (pO.OOl) and +1 (pO.Ol) (Figure 
3.5b). C D llb  expression levels remained significantly higher than PBS C D llb  levels 
on day +3 (p<0.05) and day +9 (p<0.05).
3 3 3 3 .  Lung dendritic cell responses
Dendritic cell responses were characterised using the cell differentiation marker 
C D llc to identify lung DCs. The activation status of these cells was monitored via 
expression of MHC II (IA/IE) and the co-stimulation marker CD80.
The total numbers of dendritic cells in the lung increased significantly above pre­
infection levels (pO.OOl) after VACV infection in both CpG-B 7909 and PBS treated 
animals (Figure 3.6a). Dendritic cell numbers reached a peak on day +7 and total 
numbers only differed between treatment groups on day +9 where the lungs of PBS 
treated mice had significantly fewer DCs than in those treated with CpG-B 7909 
(p<0.01). Whilst the total numbers of DCs were similar between treatment groups, 
mice pre-treated with CpG-B 7909 had significantly higher numbers of MHC II+ DCs 
on day 0 (pO.OOl) and day +1 (pO.05) than mice pre-treated with PBS (Figure 
3.6b). This same trend was also observed in DCs positive for the co-stimulation
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Figure 3.5. Activation of lung neutrophils during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Lung neutrophil activation was monitored by 
expression of activation marker CD54 (Figure 3.5a) and diapedesis marker C D llb  
(Figure 3.5b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05), ** (p<0.01) and *** 
(pO.OOl).
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Figure 3.6. Lung dendritic cell numbers during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Numbers of CD1 lc+ DCs in the lungs of infected 
mice were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over 
a nine day period using flow cytometry. Figure shows (a) total number of C D llc+ 
DCs; (b) DCs expressing IA/IE; (c) DCs expressing CD80. Graph represents 
geometric mean of four mice. Results shown include ± SEM. Statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05), ** (p<0.01) and *** 
(pO.OOl).
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marker CD80 (Figure 3.6c). Here, CpG-treated mice had significantly higher numbers 
of CD80+ DCs on day 0 (p<0.01), day +1 (p<0.01) and day +3 (p<0.05) of infection 
than mice pre-treated with PBS.
The percentage of DCs expressing MHC II in CpG-treated mice was significantly 
higher than those in PBS mice on days + 1  (p<0.01) and +3 (p<0.01) (Figure 3.7a). In 
both treatment groups the percentage of MHC II+ cells dropped from baseline levels 
post-infection. The percentage of CD80+ DCs in CpG-treated mice was significantly 
higher than those in PBS mice on days 0 (p<0.001) and +1 (p<0.001) of infection but 
interestingly, were significantly below those in PBS mice by day +9 of infection 
(p<0.001) (Figure 3.7b).
3.3.3.4. Lung natural killer cell responses
The NK cell marker CD49b was used to distinguish NK cells in lung preparations. 
Activation of NK cells was determined using antibodies to CD54 and CD69.
NK cell numbers in CpG-treated mice remained constant throughout infection, but 
differed significantly from PBS NK cell numbers on days +1 and +9 (pO.OOl) 
(Figure 3.8a). On each of these days, CpG-B 7909 treated mice had greater numbers 
of NK cells in their lungs. NK CD54+ cells (Figure 3.8b) were only significantly 
elevated from PBS mice on day +9 of infection (p<0.01). In contrast, the number of 
NK cells expressing CD69 (Figure 3.8c) was significantly higher in CpG-B 7909 
treated mice than in PBS during the early stages of infection on days 0 (p<0.05), and 
day +1 (pO.OOl). As seen with NK CD54+ cell numbers, CpG-treated NK CD69+ cell 
numbers were significantly higher than PBS mice on day +9 of infection (p<0.05).
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Figure 3.7. Activation of lung dendritic cells during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Lung DC activation was monitored by expression 
of co-stimulation markers IA/IE (Figure 3.7a) and CD80 (Figure 3.7b) over the course 
of infection using flow cytometry. Graph represents geometric mean of four mice. 
Error bars represent ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as ** (p<0.01) and *** (pO.OOl).
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Figure 3.8. Lung natural killer cell numbers during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Numbers of CD49b+ NK cells in the lungs of 
infected mice were examined in both PBS and CpG-B 7909 animals pre-treated on 
day -3 over a nine day period using flow cytometry. Figure shows (a) total number of 
CD49b+ NK cells; (b) NK cells expressing CD54; (c) NK cells expressing CD69. 
Graph represents geometric mean of four mice. Results shown include ± SEM. 
Statistical significance was determined using a two-way ANOVA and Bonferroni’s 
post-tests. Significant findings between treatment groups are represented as * 
(p<0.05), ** (p<0.01) and *** (pO.OOl).
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The percentage of activated NK cells followed the same trend in both treatment 
groups. Percentages of NK cells in both PBS and CpG-B 7909 treated mice 
expressing CD54 (Figure 3.9a) and CD69 (Figure 3.9b) dropped significantly over 
time (pO.OOl) from their day 0 baseline levels. The percentage of CD54+ NK cells in 
PBS mice was significantly higher than in CpG-treated mice on day 0 (p<0.05) but no 
other differences in percentage levels were seen between groups post infection.
3.3.3.5. Lung B-cell responses
Antibody specific to CD 19 was used to label B-cells from cell suspensions. The 
activation status of B-cells at each time point was determined by staining of co­
stimulatory molecules CD80 and CD8 6 .
Total B-cell numbers on days 0 and +1 (Figure 3.10a) were significantly higher in 
mice pre-treated with CpG-B 7909 than those from the PBS control group (p<0.05). 
This was also observed in the number of B-cells expressing CD8 6  (day 0 p<0.01; day 
+1 p<0.05) (Figure 3.10b) and the number of B-cells expressing CD80 (p<0.05 on 
days 0 and +1) (Figure 3.10c). After day one of infection, neither total B-cell numbers 
nor activation marker specific B-cell numbers differed significantly between 
treatment groups.
No significant differences in the percentage of activated B-cells were observed 
between treatment groups until day +9 of infection. The percentage of CD 19 CD8 6 + 
cells (Figure 3.11a) and CD 19 CD80+ cells (Figure 3.11b) were both significantly 
higher in PBS mice than in those from mice that had been treated with CpG-B 7909.
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Figure 3.9. Activation of lung natural killer cells during VACV infection in 
CpG-B 7909 and PBS pre-treated groups. Lung NK cell activation was monitored 
by expression of activation markers CD54 (Figure 3.9a) and CD69 (Figure 3.9b) over 
the course of infection using flow cytometry. Graph represents geometric mean of 
four mice. Error bars represent ± SEM. Statistical significance was determined using a 
two-way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as * (p<0.05).
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Figure 3.10. Lung B-cell numbers during VACV infection in CpG-B 7909 and 
PBS pre-treated groups. Numbers of CD19+ B-cells in the lungs of infected mice 
were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over a 
nine day period using flow cytometry. Figure shows (a) total number of CD19+ B- 
cells; (b) B-cells expressing CD8 6 ; (c) B-cells expressing CD80. Results shown 
include ± SEM. Statistical significance was determined using a two-way ANOVA and 
Bonferroni’s post-tests. Significant findings between treatment groups are represented 
as * (p<0.05) and ** (p<0.01).
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Figure 3.11. Activation of lung B-cells during VACV infection in CpG-B 7909 
and PBS pre-treated groups. Lung B-cell activation was monitored by expression of 
activation markers CD8 6  (Figure 3.11a) and CD80 (Figure 3.11b) over the course of 
infection using flow cytometry. Graph represents geometric mean of four mice. Error 
bars represent ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as * (p<0.05).
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3.3.3.6. Lung T-cell responses
Both CD4 and CD8  positive T-cells were monitored over the course of infection using 
CD3 as a pan T-cell marker. Lung CD4+ T-cell responses are represented in Figure 
3.12a. Throughout infection, the number of CD4+ T-cells was higher in mice pre­
treated with CpG-B 7909 than those given PBS, although only significantly so at the 
very start (day 0; p<0.01) and end (day +9; pO.OOl) of the experiment. Lung CD8 + 
T-cells followed the same pattern of influx and efflux regardless of treatment regimen 
and did not differ significantly throughout infection at any time-point (Figure 3.12b).
3.3.4. Cytokine responses in the spleen
Very few differences in the expression of cytokines and chemokines were identified 
between CpG-B 7909 and PBS control mice throughout infection. Protein levels of 
the pro-inflammatory cytokines TNF-a (Figure 3.13a), IL- 6  (Figure 3.13b), and IFN-a 
(Figure 3.13c) were all expressed at similar quantities in the spleens of CpG-B 7909 
treated mice and PBS control mice (p>0.05). Levels of IFN-y (Figure 3.13d) did differ 
statistically between treatment groups at particular stages of infection. Mice pre­
treated with CpG-B 7909 had significantly more IFN-y detectable in their spleens on 
day 0 (pO.OOl) and day +1 (pO.05) compared to untreated comtrols. By day +3 post 
infection, the level of IFN-y in PBS mice peaked at a level significantly above that 
seen in CpG-B 7909 mice (pO.OOl). The expression of CCL2 (Figure 3.13e) and IL- 
10 (Figure 3.131) did not differ between treatment groups throughout the course of 
infection at any time point (p>0.05). The levels of all cytokines measured were shown 
to vary significantly throughout infection (pO.05).
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Figure 3.12. Lung T-cell numbers during VACV infection in CpG-B 7909 and 
PBS pre-treated groups. Numbers of CD3+ T-cells in the lungs of infected mice 
were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over a 
nine day period using flow cytometry. Figure shows (a) total number of CD4+ T-cells; 
(b) total number of CD8+ T-cells. Graph represents geometric mean of four mice. 
Results shown include ± SEM. Statistical significance was determined using a two- 
way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as ** (p<0.01) and *** (pO.OOl).
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Figure 3.13. Measurement of spleen cytokine levels in Balb/C mice pre-treated 
with either CpG-B 7909 or PBS throughout infection with VACV. Protein levels 
determined via CBA analysis. Bars represent the geometric mean of four mice (Logi0 
pg/ml) and error bars indicate 95% confidence intervals for cytokines (a) TNF-a; (b) 
IL-6 ; (c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05) and *** (pO.OOl).
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3.3.5. Cellular responses in the spleen
3.3.5.1. Spleen macrophage responses
Over the first five days of infection, no differences were observed between the 
numbers of macrophages from CpG-treated mice and those from control PBS mice 
(p>0.05). By day +7, the total number of macrophages in CpG-treated mice were 
significantly higher than those recorded in PBS mice (p<0.01). The numbers of 
macrophages in CpG-treated mice were also significantly higher on day +9 (p<0.001). 
The numbers of activated macrophages expressing CD54 (Figure 3.14b) and 
macrophages expressing MHC II (Figure 3.14c) mirrored this finding. MHC II+ 
macrophages in CpG-treated mice were significantly higher on day +7 than those in 
control mice (p<0.05) and on day +9 both CD54+ (p<0.01) and MHC II+ (pO.OOl) 
macrophage numbers were also significantly higher in CpG-treated animals.
The percentage of activated splenic macrophages varied significantly from baseline 
levels over time (pO.05) but percentage levels of CD54+ (Figure 3.15a) and MHC II+ 
(Figure 3.15b) macrophages did not differ between treatment groups at any stage 
throughout infection (p>0.05).
3.3.5.2. Spleen neutrophil responses
The total numbers of neutrophils in both treatment groups fluctuated significantly 
over the course of infection (pO.OOl) reaching a peak on day +7 before returning 
towards baseline levels on day +9 (Figure 3.16a). On day +9, mice treated with CpG- 
B 7909 retained a small but significantly greater number of neutrophils in their 
spleens compared to mice pre-treated with PBS. This trend was mirrored when 
examining the number of activated neutrophils expressing CD l ib  (Figure 3.16c).
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Figure 3.14. Spleen macrophage numbers during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Numbers of F4/80+ macrophages in the spleens 
of infected mice were examined in both PBS and CpG-B 7909 animals pre-treated on 
day -3 over a nine day period using flow cytometry. Figure shows (a) total number of 
F4/80+ macrophages; (b) macrophages expressing CD54; (c) macrophages expressing 
IA/IE. Graph represents geometric mean of four mice. Results shown include ± SEM. 
Statistical significance was determined using a two-way ANOVA and Bonferroni’s 
post-tests. Significant findings between treatment groups are represented as * 
(p<0.05), ** (p<0.01) and *** (pO.OOl).
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Figure 3.15. Activation of spleen macrophages during VACV infection in CpG- 
B 7909 and PBS pre-treated groups. Spleen macrophage activation was monitored 
by expression of activation marker CD54 (Figure 3.15a) and co-stimulation marker 
IA/IE (Figure 3.15b) over the course of infection using flow cytometry. Graph 
represents geometric mean of four mice. Error bars represent ± SEM. No statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests.
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Figure 3.16. Spleen neutrophil numbers during VACV infection in CpG-B 7909 
and PBS pre-treated groups. Numbers of Ly6 G+ neutrophils in the spleens of 
infected mice were examined in both PBS and CpG-B 7909 animals pre-treated on 
day -3 over a nine day period using flow cytometry. Figure shows (a) total number of 
Ly6 G+ neutrophils; (b) neutrophils expressing CD54; (c) neutrophils expressing 
CD lib . Graph represents geometric mean of four mice. Results shown include ± 
SEM. Statistical significance was determined using a two-way ANOVA and 
Bonferroni’s post-tests. Significant findings between treatment groups are represented 
as * (p<0.05).
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Here, significant differences between treatment groups were only determined on day 
+9 of infection where higher numbers of C D llb+ neutrophils were found in CpG- 
treated mice (p<0.05). The number of neutrophils expressing CD54 (Figure 3.16b) did 
not vary between treatment groups at any stage throughout infection.
A very low percentage of neutrophils in the spleen were found to express CD54 and 
percentages values were seen to fluctuate significantly over time (pO.OOl 1) (Figure 
3.17a). Whilst no significant differences between treatment groups were identified at 
any particular time-point, the effect of CpG treatment was found to have a significant 
overall effect on the percentage of neutrophils expressing CD54 (p=0.0456). In 
contrast, on day 0 the percentage of neutrophils expressing CD l ib  in CpG-treated 
mice was significantly higher than that observed in PBS treated mice (pO.OOl) 
(Figure 3.17b). Beyond day 0, levels of C D llb  increased relative to baseline in both 
treatment groups and Ly6G C D llb+ percentage levels were not seen to differ 
significantly from each other at any further time-point.
3.3.5.3. Spleen dendritic cell responses
Time was seen to have a significant effect on the total numbers of DCs in the spleen 
(pO.OOl) with numbers increasing gradually over the early stages of infection in both 
treatment groups (Figure 3.18a). Numbers of DCs peaked on day +7 in both treatment 
groups. On day +9, the total numbers of splenic DCs were significantly higher in 
CpG-B 7909 treated mice (pO.Ol). This was also observed in the number of MHC II 
expressing DCs (Figure 3.18b) where numbers fluctuated in an almost identical 
fashion to that seen with total DC numbers. The numbers of CD1 lc CD80+ cells also
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Figure 3.17. Activation of spleen neutrophils during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Spleen neutrophil activation was monitored by 
expression of activation marker CD54 (Figure 3.17a) and diapedesis marker CD l ib  
(Figure 3.17b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as *** (pO.OOl).
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Figure 3.18. Spleen dendritic cell numbers during VACV infection in CpG-B 
7909 and PBS pre-treated groups. Numbers of C D llc+ DCs in the spleens of 
infected mice were examined in both PBS and CpG-B 7909 animals pre-treated on 
day -3 over a nine day period using flow cytometry. Figure shows (a) total number of 
C D llc+ DCs; (b) DCs expressing IA/IE; (c) DCs expressing CD80. Graph represents 
geometric mean of four mice. Results shown include ± SEM. Statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05) and ** (p<0.01).
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fluctuated over time (Figure 3.18c) but did not differ between treatment groups at any 
stage.
Almost all splenic DCs expressed MHC II constitutively (Figure 3.19a.). The high 
level of MHC II expression was seen in both treatment groups equally and percentage 
levels were only seen to dip significantly on day +7 (pO.OOl) before returning to 
baseline levels on day +9. In contrast, the percentage levels of DCs expressing CD80 
were very low in both treatment groups on day 0 (Figure 3.19b). Following infection, 
the percentage of DCs expressing CD80 increased significantly in both CpG-B 7909 
and PBS mice (pO.OOl). On day +3 of infection, percentage levels of CD1 lc CD80+ 
cells in CpG mice dropped significantly below those seen in PBS mice (pO.OOl). By 
day +5, percentage levels in both treatment groups returned towards baseline and 
thereafter remained comparable with each other until the end of the experiment.
3.3.5.4. Spleen natural killer cell responses
The total numbers of spleen NK cells did not differ significantly between treatment 
groups until day +9 of infection when mice that had received CpG-B 7909 prior to 
infection had significantly higher numbers of CD49b+ cells (Figure 3.20a). Numbers 
of NK cells positive for CD54 (Figure 3.20b) or CD69 expression (Figure 3.20c) 
varied significantly over the course of infection (p<0.001) but no significant 
differences were seen between treatment groups at any point of infection for either 
activation marker.
The percentage of NK cells expressing CD54 (Figure 3.21a) fluctuated significantly 
over the course of infection in both treatment groups (p<0.001). At each time-point,
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Figure 3.19. Activation of spleen dendritic cells during VACV infection in 
CpG-B 7909 and PBS pre-treated groups. Spleen DC activation was monitored by 
expression of co-stimulation markers IA/IE (Figure 3.19a) and CD80 (Figure 3.19b) 
over the course of infection using flow cytometry. Graph represents geometric mean 
of four mice. Error bars represent ± SEM. Statistical significance was determined 
using a two-way ANOVA and Bonferroni’s post-tests. Significant findings between 
treatment groups are represented as *** (pO.OOl).
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Figure 3.20. Spleen natural killer cell numbers during VACV infection in CpG- 
B 7909 and PBS pre-treated groups. Numbers of CD49b+ NK cells in the spleens of 
infected mice were examined in both PBS and CpG-B 7909 animals pre-treated on 
day -3 over a nine day period using flow cytometry. Figure shows (a) total number of 
CD49b+ NK cells; (b) NK cells expressing CD54; (c) NK cells expressing CD69. 
Graph represents geometric mean of four mice. Results shown include ± SEM. 
Statistical significance was determined using a two-way ANOVA and Bonferroni’s 
post-tests. Significant findings between treatment groups are represented as *** 
(pO.OOl).
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Figure 3.21. Activation of spleen natural killer cells during VACV infection in 
CpG-B 7909 and PBS pre-treated groups. Spleen NK cell activation was monitored 
by expression of activation markers CD54 (Figure 3.21a) and CD69 (Figure 3.21b) 
over the course of infection using flow cytometry. Graph represents geometric mean 
of four mice. Error bars represent ± SEM. No statistical significance was determined 
using a two-way ANOVA and Bonferroni’s post-tests.
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the percentage of NK cells expressing CD54 was lower in CpG-B 7909 pre-treated 
mice than that seen in control PBS mice. Although percentage levels at any one time- 
point did not differ significantly between treatment groups, pre-treatment with CpG-B 
7909 did have a significant effect overall (p=0.0004). The percentage levels of NK 
cells expressing CD69 (Figure 3.21b) also varied significantly over time (pO.OOl). 
Both treatment groups exhibited a similar trend throughout infection with percentage 
levels of CD49b+ CD69+ cells gradually falling over time. CpG-B 7909 pre-treatment 
did not significantly affect the percentage levels of NK cells expressing CD69, 
relative to control PBS levels, at any time-point individually during infection.
3.3.5.5. Spleen B-cell responses
Figure 3.22a shows the total number of B-cells present in the spleens of CpG-B 7909 
and PBS pre-treated mice. Total B-cell numbers were significantly elevated on day 0 
(pO.OOl) and day +9 (pO.OOl) in the spleens of CpG-treated mice compared to 
those given PBS. Levels of B-cell activation were comparable between treatment 
groups until day +9 of infection (Figures 3.22b and 3.22c) where activated B-cell 
numbers in control mice dropped significantly below those from CpG-treated mice 
(pO.OOl).
On day 0, the percentages of B-cells expressing CD86 (Figure 3.23a) and CD80 
(Figure 3.23b) were both significantly lower in the spleens of mice that had been pre­
treated with CpG-B 7909 compared to control PBS mice (pO.OOl). Upon infection, 
the percentage of B-cells expressing these co-stimulatory markers increased 
significantly (pO.OOl). This resulted in comparable levels of CD80 and CD86 
expression between treatment groups. Throughout the remainder of infection, the
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Figure 3.22. Spleen B-cell numbers during VACV infection in CpG-B 7909 and 
PBS pre-treated groups. Numbers of CD19+ B-cells in the spleens of infected mice 
were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over a 
nine day period using flow cytometry. Figure shows (a) total number of CD19+ B- 
cells; (b) B-cells expressing CD86; (c) B-cells expressing CD80. Results shown 
include ± SEM. Statistical significance was determined using a two-way ANOVA and 
Bonferroni’s post-tests. Significant findings between treatment groups are represented 
as *** (pO.OOl).
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Figure 3.23. Activation of spleen B-cells during VACV infection in CpG-B 7909 
and PBS pre-treated groups. Spleen B-cell activation was monitored by expression 
of activation markers CD86 (Figure 3.23a) and CD80 (Figure 3.23b) over the course 
of infection using flow cytometry. Graph represents geometric mean of four mice. 
Error bars represent ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as *** (p<0.001).
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percentage levels of B-cells expressing CD86 or CD80 in both treatment groups, 
fluctuated with no significant difference between treatment groups.
3.3.5.6. Spleen T-cell responses
Cell numbers for CD4+ (Figure 3.24a) and CD8+ (Figure 3.24b) T-cells both altered 
significantly over the course of infection (p<0.001). CD4+ T-cells increased more than 
CD8+ T-cells relative to baseline. In both cases, no significant differences were seen 
in the number of T-cells in either treatment group until the final day of infection. On 
day +9, the number of CD4+ and CD8+ T-cells were both significantly higher in the 
spleens of mice that had been pre-treated with CpG-B 7909 than those from the 
control PBS group (p<0.001).
3.3.6. Cytokine responses in the sera
Levels of all cytokines were detectable in the serum of both CpG pre-treated and PBS 
treated mice albeit at substantially lower levels than that detected in the lungs or 
spleens. No significant differences between treatment groups were detected in the 
measurement of the vast majority of samples. The levels of pro-inflammatory 
cytokines TNF-a (Figure 3.25a), IL-6 (Figure 3.25b), IFN-a (Figure 3.25c) and IFN-y 
(Figure 3.25d) were all detected at comparable levels in the sera of CpG-B 7909 
treated mice and PBS control mice (p>0.05). Levels of the chemokine CCL2 (Figure 
3.25e) did not differ significantly between treatment groups either. However, the anti­
inflammatory cytokine IL-10 was seen to be significantly higher on day +1 of 
infection in CpG pre-treated mice (p<0.001) but at no other time throughout infection. 
The levels of all cytokines measured in the serum samples, varied significantly
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Figure 3.24. Spleen T-Cell numbers during VACV infection in CpG-B 7909 and 
PBS pre-treated groups. Numbers of CD3+ T-cells in the spleens of infected mice 
were examined in both PBS and CpG-B 7909 animals pre-treated on day -3 over a 
nine day period using flow cytometry. Figure shows (a) total number of CD4+ T-cells; 
(b) total number of CD8+ T-cells. Graph represents geometric mean of four mice. 
Results shown include ± SEM. Statistical significance was determined using a two- 
way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as *** (p<0.001).
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Figure 3.25. Measurement of serum cytokine levels in Balb/C mice pre-treated 
with either CpG-B 7909 or PBS throughout infection with VACV. Protein levels 
determined via CBA analysis or IFN-a elisa. Bars represent the geometric mean of 
four mice (Logio pg/ml) and error bars indicate 95% confidence intervals for 
cytokines (a) TNF-a; (b) IL-6; (c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests. 
Significant findings between treatment groups are represented as *** (p<0.001).
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throughout infection (p<0.05), with the exception of TNF-a (Figure 3.25a) and IFN-a 
(Figure 3.25c) (p>0.05).
3.3.7. The role of B-cells in CpG mediated VACV protection
The results detailed above show a prominent pro-inflammatory response in mice pre­
treated with CpG-B 7909 compared to mice given PBS. The initiation of this response 
is likely to have been mediated through interaction of CpG and TLR9 expressing cells 
in the lung environment given the intranasal route of CpG delivery. B-class CpGs, 
such as CpG-B 7909, are known to exert their most potent stimulatory effects on B- 
cells (Krieg et al., 1995). This suggests that B-cells may be crucial to the initiation of 
the protective response against VACV following CpG stimulation. In addition, the 
data presented here supports a role for B-cells in CpG-mediated protection against 
VACV, as indicated by the increased numbers of activated B-cells in the lungs of 
CpG-treated mice (Figure 3.10). Therefore, the role of B-cells in protection against 
VACV following CpG treatment was investigated using B-cell knock-out (KO) mice 
on a Balb/C background. Groups of wild-type and B-cell KO mice (n=8) were pre­
treated with 75pg/ml CpG-B 7909 or PBS three days prior to challenge with 10 MLD 
VACV and monitored over a 14-day period. Results show that 75% of B-cell KO 
mice pre-treated with CpG survived infection (6/8) compared to 86% (6/7) of CpG- 
treated intact mice (Figure 3.26a). This figure also shows that 75% of PBS-treated 
immunocompetent mice survived infection compared to 38% (3/8) in B-cell KO that 
had been treated with PBS. A log-rank test on survival data failed to determine any 
significant difference between these treatment groups (p=0.1970). The severity of 
disease in treatment groups as determined by % weight loss, was found to differ 
significantly between treatment groups (p=0.0146). Here, intact mice receiving CpG-
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Figure 3.26. Effect of B-cell KO on CpG-mediated VACV protection. Groups of 
B-cell KO mice (n=8) were pre-treated with either 75pg CpG-B 7909 or PBS three 
days prior to challenge with 10 MLD VACV. Wild-type (Wt) mice were treated and 
challenged in parallel with 75pg CpG-B 7909 (n=7) or PBS (n=8). (a) Survival data: 
(b) Mean weight loss: Mice were weighed daily throughout the experiment, data 
points represent geometric mean weight per time-point ± SEM. Statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests.
* Wt CpG v Wt PBS (p<0.05); f  Wt CpGv B KO PBS (p<0.05); $ W t P B S v B K O  
CpG (p<0.05).
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B 7909 tolerated infection significantly better than intact PBS mice and B-cell KO 
PBS mice, particularly in the latter stages of infection (Figure 3.26b). Interestingly, B- 
cell KO mice treated with CpG-B 7909 also fared better than wild-type mice treated 
with PBS, with the average weight between treatment groups being significantly 
higher on day +9 of infection (Figure 3.26b). Treatment was also found to have a 
significant effect on the rate of the development of clinical signs of infection and 
recovery (p=0.0005) as measured by the kinetics of weight loss.
3.3.8. The role of neutrophils in CpG mediated VACV protection
Following intranasal delivery of CpG-B 7909 into the lung, the numbers of various 
pulmonary innate effector cells increased significantly compared to non-CpG-treated 
controls (Section 3.3.3). Amongst these, the numbers of activated neutrophils in CpG- 
treated mice were found to be significantly elevated compared to those pre-treated 
with PBS (Section 3.3.3.2). Neutrophils are potent phagocytic cells that are known to 
be amongst the first cell types recruited to the site of infection and have been shown 
to phagocytose VACV in vitro (West et al., 1987). Therefore, the role of neutrophils 
in response to CpG stimulation in VACV challenged mice was investigated. A 
neutralising antibody (RB6-8C5) to a prevalent neutrophil marker Gr-1 was used to 
ablate neutrophil responses from the initial stages of infection. Groups of mice (n=8) 
were treated with 75pg/ml CpG-B 7909 or PBS three days prior to challenge with 10 
MLD VACV. The day before challenge, mice were injected with 500pg of either the 
neutrophil ablating antibody RB-6 or a non-specific IgG2b isotype control antibody 
(Mac-5). Survival data for this experiment is represented in Figure 3.27a. Neutrophil 
depletion was found to have no significant protective effect on survival as determined 
by the Kaplan-Meier log-rank survival test (p=0.4205). However, disease severity was
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Figure 3.27. Effect of neutrophil depletion on CpG-mediated VACV protection.
Groups of Balb/C mice (n=8) were treated with a neutrophil depleting antibody (RB- 
6) or an isotype control antibody (Mac-5) and then pre-treated with either 75pg/ml 
CpG-B 7909 or PBS three days prior to challenge with 10 MLD VACV. (a) Survival 
data: (b) Mean weight loss; Mice were weighed daily throughout the experiment, data 
points represent geometric mean weight per time-point ± SEM. Statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests.
* Denotes statistical significance (p<0.05) between RB-6 PBS and Mac-5 CpG 
treatment groups.
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found to vary significantly between treatment groups (p=0.0238) (Figure 3.27b). In 
addition, CpG treatment also had a significant effect on the rate of weight loss 
between groups (p=0.0124). Here, mice depleted of neutrophils and treated with PBS 
lost weight significantly quicker over the early stages of infection than neutrophil 
depleted mice treated with CpG (p<0.0232). Towards the end of infection on days 
+11, +12 and +13, the mean weights recorded for neutrophil depleted mice treated 
with PBS (RB-6 PBS) and control antibody mice treated with CpG-B 7909 (Mac-5 
CpG) differed significantly (p<0.05) (Figure 3.27b).
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3.4. Discussion
The use of CpGs as an immunotherapy has demonstrated success in a wide variety of 
studies when administered prior to challenge with an infectious pathogen. These have 
included studies into the protective effects of different classes of CpGs against a 
variety of bacterial, parasitic and viral pathogens (Elkins et al., 1999b; Ashkar et a l , 
2003; Krieg, 2006). To date, the use of CpGs as a prophylactic against orthopoxvirus 
infection has not been fully studied. Studies by colleagues here at Dstl have 
previously established that CpG-B 7909 can provide full protection against an 
intranasal challenge with VACV (Rees et al., 2005). These studies established that 
CpG-B 7909 could be given up to seven days prior to challenge with VACV and still 
confer complete protection. Additionally, this preliminary work observed significant 
differences in the dissemination of VACV in CpG-treated and untreated groups and 
also noted an increase in the levels of the chemokines RANTES and MIP-ip in CpG- 
treated mice compared to un-treated control mice (Rees et al., 2005). However, this 
study did not provide a comprehensive immunological investigation into other 
cytokines or cell-types that may prove vital to the protective response against VACV 
afforded by intranasal CpG delivery. Therefore, this chapter has re-examined the use 
of CpG as a prophylactic against VACV and presents a comprehensive analysis of the 
immunological effects of CpG-B 7909 when administered prior to intranasal 
challenge with VACV.
The immunomodulatory nature of CpGs results from their direct interaction with cells 
that express the pattern recognition receptor TLR9 (Hemmi et al., 2000). In the lung, 
a range of different cell types express TLR9 and can respond directly to CpG 
stimulation. B-class CpGs such as CpG-B 7909 are predominantly recognised as
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potent stimulators of B-cells by direct binding and stimulation of TLR9. This has been 
shown to result in cellular proliferation and the up-regulation of co-stimulatory 
molecules such as CD80, CD86 and CD40 (Krieg et al, 1995). In the results 
presented in this chapter, flow cytometry analysis of lung samples identified 
significantly higher numbers of CD80+ and CD86+ B-cells in the lungs of CpG-treated 
mice on day 0 and +1 of infection compared to those from untreated animals. CD80 
and CD86 are required for effective antigen presentation to T-lymphocytes and their 
up-regulation is indicative of B-cell maturation and activation (Suvas et al., 2002). 
These increases in the numbers of activated B-cells in CpG-treated mice may have 
been a result of direct TLR9 stimulation. Other TLR9 expressing cells in the lung 
include myeloid and plasmacytoid dendritic cells and these cell-types can also be 
activated directly by CpG-B stimulation (Demedts et al., 2006; Sparwasser et al., 
2000). CpG stimulation of DCs results in DC maturation and increased antigen 
presenting capability. In this study, the numbers of C D llc+ DCs and percentages of 
activated dendritic cells (%CD80+, %MHC II+) were also significantly higher in the 
lungs of CpG-treated mice. Increases in the expression of CD80 and MHC II on DCs 
allow for more effective antigen presentation to T-lymphocytes and is a well 
documented response to CpG stimulation (Askew et al., 2000; Sparwasser et al, 
2000). In addition, levels of IFN-a were significantly higher in CpG-treated animals 
than in those receiving PBS. The predominant cellular source of IFN-a are pDCs and 
its prominent release from activated pDCs has been shown by a variety of groups 
following CpG stimulation (Krug et a l , 2001). These differences in PBS and CpG- 
treated mice may all have been a direct result of CpG stimulation.
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In addition to altering the phenotype of TLR9 expressing cells, direct stimulation of 
TLR9 results in the activation of transcription factors such as NF-kB and subsequent 
release of pro-inflammatory cytokines to promote a prominent Th-1 cytokine 
environment (Krieg et al., 1995; Yi et al., 1996b; Krug et al., 2001; Klinman et al., 
1996). Once secreted, these cytokines exert a wide range of effects including the 
stimulation of other cell types that do not express TLR9. Thus, CpGs influence the 
kinetics and activation of a variety of cell types through both direct and indirect TLR9 
stimulation. Collectively, these cytokines function to activate relevant cell types in the 
surrounding area and to recruit cells such as neutrophils and macrophages from the 
blood and surrounding tissues.
Expression of the type I and type II interferons, IFN-a and IFN-y, were significantly 
increased in the lungs of mice that received CpG treatment compared to untreated 
control mice. These cytokines may play a variety of roles in inflammation. The 
release of IFN-a often initiates a potent antiviral response in the host, resulting in the 
activation of many other interferon-related genes including IFN-y (Takaoka & Yanai, 
2006). The release of IFN-y following CpG stimulation has typically been observed 
from activated NK cells (Balias et al., 1996; Sivori et al., 2006; Marshall et a l, 2006). 
In this study, significantly elevated numbers of activated NK cells expressing the 
early activation marker CD69 were observed in the lung early in infection, correlating 
with the observed increases in pulmonary IFN-y levels. The antiviral properties of the 
interferons are well established. Together, interferons create an antiviral state that 
restricts the replication of viruses within host cells (Platanias, 2005; Katze, He, & 
Gale, 2002). Many other studies have examined the prophylactic effect of CpG 
treatment prior to viral challenge and these studies have reported reduced pathology
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and viral titres in CpG-treated animals compared to control groups (Ashkar et al, 
2003; Li et al, 2006; Harandi et al., 2003; Sajic et a l , 2003). In many cases, 
protection in these studies has relied upon strong IFN-y responses, as seen in the 
effective treatment of HSV-2 infection with another B-class CpG 1826 (Harandi, 
Eriksson, & Holmgren, 2003). Here, mice deficient in IFN-y, IL-12 or IL-18 failed to 
confer any significant protection against virus infection.
In addition to its direct antiviral properties, IFN-y has also been shown to stimulate 
macrophages to release TNF-a and promote the release of other pro-inflammatory 
cytokines such as IL-6 from B-cells (Yi et al, 1996a). It is of note that levels of both 
IL-6 and TNF-a were significantly elevated in the lungs of CpG-treated mice in this 
study. IL-6 is a potent pro-inflammatory cytokine with pyrogenic properties that is 
thought to play a role in the recruitment of monocytes to the site of infection and 
modulation of other cellular functions (Kaplanski et a l , 2003; Morales-Montor, 
2005). Importantly, IL-6 plays a fundamental role in the immune response against 
VACV as IL-6 knock-out (KO) mice fail to control virus replication efficiently (Kopf 
et a l , 1994). TNF-a is a pleiotropic pro-inflammatory cytokine with a variety of 
diverse immunological functions which can promote cellular proliferation and 
activation, apoptosis or contribute to the onset of septic shock if over-expressed 
(Rahman & McFadden, 2006). TNF-a has been shown to have powerful pro- 
inflammatory effects and many viruses, including VACV, encode TNF receptor 
homologues to combat its effects (Saraiva & Alcami, 2001; Rahman & McFadden, 
2006; Lidbury et a l , 1995). Other studies have also observed increases in IL-6 and 
TNF-a following intranasal CpG stimulation, with increased cytokine expression 
being detectable in the BAL of treated mice within 4 hours (Schwartz et a l , 1997).
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Levels of CCL2, a monocytic chemoattractant protein, were also significantly higher 
in the lungs of mice pre-treated with CpG-B 7909, as has been reported in previous 
studies involving CpGs (Edwards et a l , 2005). This chemokine acts as a 
chemoattractant to recruit monocytes and macrophages along a concentration gradient 
to the site of inflammation. Macrophages have been shown to respond to CpG 
stimulation both in vivo and in vitro with activation enhancing both phagocytic and 
anti-microbicidal activity in addition to pro-inflammatory cytokine and chemokine 
release (Utaisincharoen et al., 2002; Utaisincharoen et al., 2003; Huang et al., 2005). 
Macrophage numbers in this study were significantly elevated in the lungs of CpG- 
treated mice compared to control groups (Figure 3.2). In addition, macrophage 
expression of MHC II was found to be significantly lower in CpG-treated animals 
than in PBS mice (Figure 3.3b), a response that has also been documented in other 
studies (Chu et al., 1999). It is possible that the reduction of MHC II on macrophages 
enhances antigen presentation by other professional antigen presenting cells such as 
dendritic cells to promote a more effective specific immune response (Chu et al, 
1999). The expression of TLR9 on alveolar macrophages has been reported in a 
number of studies (Huang et al, 2005), although other studies have suggested that 
TLR9 on alveolar macrophages may be non-functional (Suzuki et a l , 2005). 
Therefore, the activation of macrophages in the lung may have been a result of 
cytokine stimulation (e.g. by IFN-y) or a direct consequence of TLR9 stimulation.
Neutrophil responses in the lung were also found to be significantly different between 
treatment groups. Neutrophils are key phagocytic cells that kill pathogens through 
release of lytic enzymes, reactive oxygen species or through release of extracellular
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chromatin nets (Nathan, 2006). Here, CpG-treated mice were found to have increased 
numbers of activated neutrophils compared to PBS mice over the first few days of 
infection. Neutrophils are not generally thought to express TLR9 although direct CpG 
stimulation of human neutrophils has been reported (Hayashi, Means, & Luster, 
2003). This makes the indirect stimulation of neutrophils more likely to account for 
the increases in neutrophil activation. Increases in CD l ib  expression are typically 
indicative of cellular egress and in this data, maybe a sign of recent recruitment of 
neutrophils to the site of stimulation. Interestingly, the percentage of CD54+ 
neutrophils was significantly lower on day +1 of infection in CpG-treated mice than 
in control mice. Expression of CD54, also known as intracellular adhesion molecule-1 
(ICAM-1), can be down-regulated by anti-inflammatory cytokines such as IL-10 and 
this down-regulation may prevent neutrophils leaving the site of infection (Tomioka 
et al., 2000).
Levels of the anti-inflammatory cytokine IL-10 were observed as being significantly 
higher on day +1 of infection in CpG-treated animals than untreated controls. Given 
the extent of cytokine stimulation in CpG-treated animals, increased levels of IL-10 
may act to help balance the immune response to prevent a detrimental immune 
response in the host. However, it has been suggested that IL-10 may serve a dual role 
in inflammation by enhancing NK activity (Lauw et a l , 2000). Therefore, it is 
possible that the increased activation of NK cells in CpG-treated animals may be 
linked to these increased levels of IL-10. This in turn may contribute to the high 
levels of IFN-y observed throughout the early stages of infection.
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Although thought to be transient in their expression, all cytokine levels were first 
determined three days after CpG delivery on the day of challenge (day 0) and 
remained significantly above control levels throughout the first three days of VACV 
infection. As a result it is unclear whether the levels of cytokines detected in the lungs 
of CpG-treated mice were at their peak levels, in a plateau phase or had reduced in the 
days following CpG delivery. It is likely that elevated levels of pro-inflammatory 
cytokines such as those described above, may have contributed significantly to the 
protective response against VACV through the presence of a fully activated and 
primed immune response at the time of infection.
The patterns of immune stimulation seen in the lungs of CpG stimulated mice were 
not mirrored in the spleens. However, other significant differences were observed 
between treatment groups suggesting that CpGs can result in significant immune 
effects at sites distal from their original point of delivery. Here, levels of pro- 
inflammatory cytokines such as IFN-a, TNF-a, and IL-6 in CpG-treated mice were 
comparable with control mice throughout the course of infection. Levels of IFN-y in 
the spleens of PBS treated mice on day +3 of infection were significantly higher than 
in those that received CpG-B 7909. In previous work, dissemination of VACV to the 
spleens of PBS mice also occurred on day +3 of infection (Rees et al, 2005). In 
contrast, mice pre-treated with CpG-B 7909 did not have peak titres of VACV in the 
spleen until day +4 of infection. Viral titres were not obtained throughout this study 
because lung and spleen cell suspensions were preserved for analysis by flow 
cytometry. However, it is of note that peak IFN-y levels in PBS treated mice in this 
study correlate with the arrival of VACV on day +3 in the Rees study. Likewise, peak 
IFN-y levels in CpG-treated mice in this study occurred on day +4 which matches the
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arrival of virus in the spleens of CpG-treated mice in the Rees study (Rees et al, 
2005). In addition, Rees and colleagues also observed significantly lower viral titres 
in the lungs of CpG-treated mice in the early stages of infection. It is possible that the 
release of high levels of IFN in the lung along with extensive cellular activation 
during the early stages of infection may have played a significant role in delaying 
dissemination of VACV to the spleen.
Cellular activation data in the spleen identified a number of significant differences 
between treatment groups. On day 0 of infection, significantly higher numbers of 
activated macrophages and B-cells were present in CpG-treated animals. It is unclear 
whether these cells were directly activated by CpG through TLR9 stimulation despite 
being reported to express TLR9 (Krieg et al, 1995; Suzuki et al, 2005). For this to 
happen, CpG-ODN would either have to cross the mucosal barrier of the lung to gain 
access to the blood for systemic transportation, or alternatively, CpGs may need to 
have been transported in phagocytic cells such as neutrophils to the spleen and then be 
released upon cellular necrosis or apoptosis. This is plausible given the significant 
increase in the number of C D llb+ expressing neutrophils in CpG-treated animals 
observed on day 0. However, it is also possible that the observed differences may be a 
result of these cell-types being stimulated in the lung and then having migrated to the 
spleen. Given the lack of cytokines detectable in the serum of CpG treated mice, it is 
also doubtful that these cell-types were activated as a result of systemic cytokine 
activation. Of particular interest is the prevalence of significant differences between 
treatment groups on days +7 and +9 of infection. In the animal model used throughout 
these studies, mice receiving CpG treatment typically begin to recover around this 
period of infection (day +7 to +9). Interestingly, all significant differences at these
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latter time-points revealed elevated numbers or increased activation in CpG-treated 
mice compared to those mice treated with PBS. This may be indicative of CpG- 
treated mice developing an appropriate immune response or a more sustained innate 
response. Alternatively, CpG-treatment may promote a more rapidly formed adaptive 
immune response as indicated by increased numbers of B and T-lymphocytes in the 
spleen.
The immunological differences described above in the lungs and spleens of VACV 
infected mice point towards a very significant role for the local lung environment in 
conferring CpG-mediated protection. Table 3.1 summarises the significant cellular 
differences between CpG-treated and untreated mice in the lung. These results show a 
large number of significant differences between treatment groups, particularly on day 
0 and day +1 of infection. Throughout this 24 hour period, the lungs of CpG-treated 
mice had higher numbers of activated macrophages, neutrophils, dendritic cells, NK 
cells, B-cells and CD4+ T-cells than untreated mice. In addition, significantly higher 
levels of pro-inflammatory and antiviral cytokines were present in CpG-treated mice 
during this time. In contrast, very few differences between CpG-treated and untreated 
mice were identified in the spleen during early infection (Table 3.2). This finding may 
emphasise the importance of local lung inflammation at the time of VACV challenge. 
The arrival of activated or primed effector cells into the lungs of CpG-treated mice 
prior to VACV challenge is likely to be one of the key contributors to CpG-mediated 
protection. Collectively, these cytokine and cellular responses are likely to attack 
VACV at the source, restricting its replication in the lung and severely hindering its 
ability to establish infection. This in turn may restrict local lung pathology and delay 
viral dissemination around the body. Significant differences between treatment groups
134
Day
0 +1 +3 +5 +7 +9 CpG-B 7909 
Treatment
Total macrophages +++ +++
F4/80+ CD54+ +++
F4/80* IA/IE+ +++ +++
% CD54+ + +
% IA/IE+ ++ ++ +
Total neutrophils +++ +++ +++
Ly6G+ CD54+ +++ +
Ly6G+ C D llb+ +++ +++ +++
% CD54+ ++ +
% CD1 lb+ +++ ++ + + +++
Total dendritic cells ++ +++
CD1 lc+ IA/IE+ +++ + + +++
CD1 lc+ CD80+ ++ ++ + +++
% IA/IE+ ++ ++ +++
% CD80+ +++ +++ +++ ++
Total NK cells +++ +++ +++
CD49b+ CD54+ ++ +
CD49b+ CD69+ + +++ + +++
% CD54+ + +
% CD69+
Total B-cells + + +++
CD19+ CD86+ ++ + +++
CD19+ CD80+ + + +++
% CD86+ +
% CD80+ + +++
Total CD4+T-cells ++ +++ +++
Total CD8+ T-cells ++
Table 3.1. Significant differences between CpG-B 7909 and PBS treatment 
groups in the lungs of mice during VACV infection. Significant differences are 
recorded for each immune cell type investigated via flow cytometry in the lungs of 
VACV infected mice. Differences between total and activated cell numbers are 
reported along with differences between the % of activated cell-types for days 0, +1, 
+3, +5, +7 and +9 post-infection. The overall effect of CpG treatment is also reported. 
Significance between treatment groups determined via two-way ANOVA with 
Bonferroni’s post-tests and represented as: + p<0.05; ++ p<0.01; +++ p<0.001.
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Day
0 +1 +3 +5 +7 +9 CpG-B 7909 
Treatment
Total macrophages ++ +++ ++
F4/80+ CD54+ ++ ++
F4/80+ IA/IE+ + +++ ++
% CD54+
% IA/IE+
Total neutrophils + ++
Ly6G+ CD54+
Ly6G+ C D llb+ + ++
% CD54+ +
% CD1 lb+ +++ ++
Total dendritic cells ++
C D llc+ IA/IE+ +
C D llc+ CD80+
% IA/IE+
% CD80+ +++
Total NK cells +++ ++
CD49b+ CD54+
CD49b+ CD69+
% CD54+ +++
% CD69+
Total B-cells +++ +++
CD19+ CD86+ +++
CD19+ CD80+ +++ +++
% CD86+ +++
% CD80+ +++
Total CD4+ T-cells +++ ++
Total CD8+T-cells +++
Table 3.2. Significant differences between CpG-B 7909 and PBS treatment 
groups in the spleens of mice during VACV infection. Significant differences are 
recorded for each immune cell type investigated via flow cytometry in the spleens of 
VACV infected mice. Differences between total and activated cell numbers are 
reported along with differences between the % of activated cell-types for days 0, +1, 
+3, +5, +7 and +9 post-infection. The overall effect of CpG treatment is also reported. 
Significance between treatment groups determined via two-way ANOVA with 
Bonferroni’s post-tests and represented as: + p<0.05; ++ p<0.01; +++ p<0.001.
136
were also found on day +9 of infection in both the lung and spleens of infected mice 
(Table 3.1 and Table 3.2). Here, higher numbers of activated cell types were present 
in mice treated with CpG-B 7909 than in control mice. Of particular interest are 
differences in numbers and activation status of T and B-lymphocytes. This implies 
that during the latter stages of infection, both the lung and the spleen may contribute 
significantly to the resolution of infection in CpG-treated mice, potentially through 
initiation of an adaptive response.
The role of B-cells and neutrophils in CpG mediated protection were investigated 
using B-cell KO mice and a neutralising antibody to a neutrophil cell marker. Results 
from the B-cell KO study revealed that B-cells were not fundamental in the protection 
elicited by CpGs against VACV as there was no significant difference in the survival 
of intact and B-cell KO mice treated with CpG (p=0.1970). In addition, no significant 
differences were determined between the average weights of wild-type and B-cell KO 
mice that received CpGs (p>0.05). This suggests that in an acute VACV infection, 
CpG-B 7909 is able to directly stimulate cell types other than B-cells and this 
stimulation is sufficient to generate a protective response. This is further suggested by 
the observation that both B-cell KO mice and wild-type mice that received CpG-B 
7909 tolerated infection equally, but significantly better than their equivalent PBS 
control groups (Figure 3.26b). These observations question the role of VACV specific 
antibody in the resolution of acute VACV infection in CpG mediated protection. 
Antibody secretion follows the recognition of antigen by receptors on B-cells and 
their subsequent differentiation into plasma cells. The generation of specific antibody 
is not possible in the absence of B-cells. In untreated intact mice, antibody is thought 
to play a significant role in the resolution of acute VACV infection through direct
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neutralisation and opsonisation of vims particles (Belyakov et al., 2003). In this 
present study, untreated B-cell KO mice were most susceptible to vims infection 
(Figure 3.26a). In addition, other studies have examined the role of B-cells in 
protection against VACV and suggested that mice deficient in B-cells fail to clear 
infection (Xu et al., 2004; Chaudhri et al., 2006). These observations support a role 
for antibody production in protection. However, in CpG-treated B-cell KO mice, it is 
possible that the strength of the Th-1 response generated by CpG-B 7909 compensates 
for the lack of neutralising antibody. Redundancy in the immune response is well 
reported and has been seen in studies where antibody to VACV was essential in CD4+ 
and CD8+ deficient mice, but not required when these cell-types were present 
(Belyakov et al., 2003). B-cell KO mice have also been used to study immunity to 
vaginal HSV-2 infection (Parr & Parr, 2000). In this study, the lack of B-cells did not 
significantly affect levels of protection, as has been reported here. However, the 
kinetics of the immune response and control of viral titres were found to differ 
between wild-type and B-cell KO mice suggesting that B-cells may still play a role in 
controlling viral infection. In other studies, B-cells have also been reported to be 
important in controlling secondary Francisella infection in a manner that does not 
involve antibody (Elkins et al., 1999a). These studies suggest that antibody may not 
always be required to confer protection against pathogens and that B-cells may 
provide significant contributions to the immune response in other ways.
The high expression of the cell surface marker Gr-1 on neutrophils enables in vivo 
depletion of neutrophils with the monoclonal antibody RB6-8C5 and has been used 
extensively to study the role of neutrophils in infection (Nathan, 2006). Neutrophils
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have previously been shown to play a significant role in HSV-1 and HSV-2 virus 
protection (Tumpey et al., 1996; Milligan, 1999) and have also been shown to 
phagocytose VACV particles (West et al., 1987). In this study, neutrophils were 
depleted on day -1 of challenge, i.e 24 hours prior to VACV challenge but 48 hours 
after CpG stimulation. Neutrophils were only depleted at this time-point to ensure 
neutrophils were not present during the initial infection with VACV. Survival analysis 
on CpG-treated and untreated groups found no significant differences between 
neutrophil depleted and neutrophil replete groups. These results initially suggest the 
absence of neutrophils at the time of VACV challenge does not affect CpG mediated 
VACV protection. However, this raises three clear points for discussion. Firstly, 
neutrophil numbers are constantly regenerated over time due to their short lifespan. 
Consequently, it is not known for certain at which point neutrophil numbers returned 
to baseline levels. In this data, the rate of weight loss in RB6-PBS mice over the first 
few days of VACV infection was greater than for other groups. This may suggest an 
important early role for neutrophils in the resolution of VACV infection and not 
necessarily a role in CpG-mediated protection. Regeneration of neutrophil numbers 
and subsequent activation after this point could explain the temporary stabilisation of 
weight loss seen between days +3 to +5 and ultimately contribute to the resolution of 
infection. Secondly, in addition to phagocytosis and release of lytic enzymes and 
reactive oxygen species into the surrounding areas, neutrophils also influence the 
behaviours of other cell types. For instance, neutrophils secrete chemotactic signals 
such as cathepsin-G, which attracts monocytes, and chemerin which attracts both 
immature DCs and pDCs to the site of inflammation (Bennouna et al., 2003; Chertov 
et al., 1997; Wittamer et al., 2005). In addition, neutrophils can also influence the 
properties of differentiated macrophages through secretion of cytokines such as TNF-
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a and IFN-y (Ethuin et al., 2004). Since neutrophils were present at the time of 
treatment in all groups, it is unclear whether they play an important role prior to 
VACV challenge. Thirdly, an unfortunate consequence of using the RB6 antibody is 
that Gr-1 is also expressed to a lesser extent on other cell types (Geissmann et al., 
2003; Matsuzaki et al., 2003). These include Gr-1+ CD8+ T-cells and some 
monocytes. The extent of unwanted cellular depletion was not determined in these 
studies and thus the effect of losing other Gr-1 expressing cells types in the early 
stages of infection cannot be accounted for. Other studies have suggested that up to 
85% of these additional Gr-1 expressing cell sub-sets may be depleted (Easton et al, 
2007). As expected, neutrophil depleted PBS mice were found to be most susceptible 
to infection and experienced the most severe weight loss of all groups tested (Figure 
3.27). Given the data obtained in this study, it is possible that neutrophils could be 
significant contributors to CpG mediated protection against VACV but may not be the 
main contributors to protection.
In conclusion, this chapter has sought to address the immunological basis behind the 
successful pre-treatment of mice with CpG-B 7909 prior to VACV infection. The 
results presented within this chapter demonstrate that intranasal delivery of the B- 
class CpG-B 7909 elicits a powerful immunological response in the local lung 
environment at the time of infection and that this response correlates strongly with 
protection. This response includes the secretion of pro-inflammatory cytokines such 
as IFN-a, IFN-y, TNF-a and IL-6 and the recruitment and activation of key effector 
cell types such as dendritic cells, macrophages, neutrophils and NK cells. 
Consequently, at the time of VACV challenge, the lung environment is loaded with 
elevated numbers of key effector cells that are primed for infection and are potentially
140
already in an antiviral state. Immune responses in the lungs and spleens of CpG- 
treated mice in the latter stages of infection may both play a significant part in virus 
clearance and alleviation of clinical signs of disease. This work has also suggested 
that B-cells and neutrophils may not be crucial cell types in protecting against VACV 
infection following CpG-B 7909 prophylaxis.
The ability of CpG-B 7909 to protect in this pre-exposure model correlates with its 
ability to induce a strong, local Th-1 inflammatory response. Whether CpG-B 7909 
can confer similar levels of protection when administered concomitantly with VACV 
challenge or post-challenge is currently unknown. The next chapter in this thesis will 
address this question and examine whether the immunological response generated by 
CpG-B 7909 is equally as effective when given after virus exposure.
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Chapter 4: The use of CpG-B 7909 as a post-exposure therapeutic against
VACV
4.1. Introduction
The timing of CpG delivery in the treatment against infectious disease has proven to 
be one of the most crucial aspects of CpG mediated therapy. The majority of studies 
reporting the successful use of CpGs as a monotherapy have involved a dosing 
regimen that begins prior to pathogen challenge. For instance, studies against 
intracellular bacteria such as Francisella tularensis and Listeria monocytogenes have 
achieved full protection when mice were pre-dosed with CpG up to 7 days before 
infection and partial protection when administered as early as 14 days prior to 
infection (Elkins et al., 1999b). Similar levels of protection have also been seen in 
CpG pre-treatment of Burkholderia pseudomallei infection where 100% protection 
against lethality was obtained when CpGs were administered up to 10 days prior to 
infection, and 57% protection was obtained when CpGs were given 15 days prior to 
infection (Wongratanacheewin et a l , 2004). However, CpG treatment on the day of 
infection saw protection drop to 33% in these studies and granted no protection at all 
if given 24 hours after challenge. Similarly low levels of protection (10%) were also 
reported in studies using Burkholderia mallei when CpGs were administered 24 hours 
post-challenge (Waag et a l, 2006). In contrast, treatment with CpG 48 hours prior to 
B.mallei challenge was able to confer full protection and provide 90% protection if 
treated at the time of challenge (Waag et a l, 2006). CpGs used as a post-exposure 
treatment for Mycobacterium tuberculosis have yielded more positive results. Here, 
CpGs administered to mice two weeks post-infection resulted in a significant drop in 
the number of bacteria in the lungs of infected mice and an increase in the IFN-y
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production by splenocytes when measured three weeks post-treatment (Juffermans et 
ah, 2002). Significant improvements in tuberculosis disease progression were also 
seen when CpGs were first given 2 hours pre- and then 6 hours post-challenge 
(Juffermans et al., 2002).
The effective post-exposure treatment of parasitic infection has also been reported by 
Zimmermann and colleagues. Single doses of CpG to mice infected with Leishmania 
major proved curative when given during the first 8 days of infection but failed to 
elicit protection if given as a single dose thereafter (Zimmermann et ah, 1998b). 
However, three consecutive doses of CpG were shown to control infection with 
L.major, starting as late as day +20 of infection (Zimmermann et ah, 1998b). 
Protection against the intracellular parasite Toxoplasma gondii has also been achieved 
using CpGs. Here, a single injection of CpG at the time of challenge was sufficient to 
confer long-term survival against toxoplasmosis (Zimmermann et ah, 1998a). This 
same study reported that CpG treatment was also able to reduce disease severity in 
mice given a sub-lethal dose of T.gondii by reducing the number of cysts found in the 
brain.
Against viral infection, successful CpG-mediated protection has been mostly reported 
when administered prior to or at the same time of infection, as has been seen in mouse 
models of HSV-2 (Harandi et ah, 2003; Sajic, et ah, 2003; Ashkar, et ah, 2003), 
VACV (Rees et ah, 2005) (Chapter 3) and TCAV (Pedras-Vasconcelos et ah, 2006). 
However, some viruses have also been successfully treated using CpGs post­
challenge. For instance, although pre-treatment of HSV-2 48 hours prior to infection 
with CpG was shown to confer 80% protection in a murine model (Harandi et ah,
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2003), treatment given 4 hours after challenge was still able to confer 66% protection 
against lethal infection. In another model of virus infection, CpG treatment +4, +9 and 
+14 days after infection with FLV in animal models has been shown to significantly 
increase disease recovery from 6% in control mice to 74% in mice treated with CpG 
(Olbrich et al., 2002).
4.2. Aims of this chapter
The pre-treatment of VACV infection with the B-class CpG-B 7909 has been shown 
to afford high levels of protection against VACV (Rees et al., 2005). However, the 
ability of the same CpG to confer protection when given post-challenge is unclear. 
This chapter examines the use of CpG-B 7909 as a post-exposure therapy following 
intranasal challenge with VACV and assesses the immunological impact of delayed 
treatment in mouse models of infection.
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4.3. Results
4.3.1. Selection of day and dose for post-exposure CpG delivery
Previous work by colleagues within Dstl and through personal communication with 
our collaborator AM Krieg, highlighted concerns over the toxicity of administration 
of high doses of CpG-B 7909 concurrent with VACV challenge. Consequently, an 
experiment was designed to examine the effect of lower doses of CpG-B 7909 than 
those used in the published pre-exposure model (Rees et al., 2005), following 
intranasal challenge with VACV. Given the previous success of treating VACV in the 
pre-exposure model, the intranasal route was again selected as the preferred route of 
treatment for post-exposure CpG-B 7909 delivery. Groups of mice (n=5) were 
challenged intranasally with 10 MLD VACV and then treated intranasally with PBS, 
or 15pg, 30pg or 50pg of CpG-B 7909 on day +1 or day +2 of challenge (Figure 4.1). 
Mice receiving either the 15pg or 50pg dose of CpG-B 7909 on day +1 were not 
protected from VACV challenge (Figure 4.1a). In contrast 60% of mice treated with 
30pg of CpG on day +1 survived infection. No protection was observed when 
treatment with CpG-B 7909 was withheld until day +2 of infection, regardless of dose 
used (Figure 4.1b).
4.3.2. Effect of multiple doses of CpG-B 7909 via the intranasal route
The previous experiment had demonstrated that a single 30pg dose of CpG-B 7909 
could provide protection against lethal VACV infection. The use of a second dose of 
CpG-B 7909 to improve protection further in the challenge model was examined. 
Groups of mice (n=4) were challenged intranasally with 10 MLD VACV and 
subsequently treated intranasally on day +1 and day +2, day +1 and day +3, or day +2 
and day +3 with 30pg of CpG-B 7909. Control mice were given PBS on the day of
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Figure 4.1. Different intranasal doses of CpG-B 7909 as a post-exposure 
treatment in mice infected with VACV. Graphs show survival data of mice (n=5) 
challenged intranasally on day 0 with 10 MLD VACV. Mice were treated intranasally 
on (a) day +1 or (b) day +2 with varying doses of CpG-B 7909 or PBS.
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challenge or 75pg CpG-B 7909 six days prior to challenge. In this experiment, 25% 
mice treated with CpG-B 7909 survived infection regardless of dosing regimen 
(Figure 4.2). Interestingly, all control mice survived infection, suggesting that all 
groups of mice may have received a sub-lethal dose of VACV (Figure 4.2). 
Regardless, these results suggest that the multiple dosing of mice with CpG-B 7909 
post-exposure using any of the regimens in this study, does not improve upon the 
levels of protection seen following a single treatment of CpG-B 7909.
4.3.3. Immunological impact of post-exposure CpG-B 7909 delivery
4.3.3.I. Experimental outline
The use of a single 30pg dose of CpG-B 7909 was selected for further immunological 
investigation in vivo. This experiment was run in parallel to that described in section 
3.3.1 to reduce the numbers of control mice required. Briefly, two groups of Balb/C 
mice were challenged intranasally with 10 MLD VACV. All mice receiving CpG-B 
7909 were treated on day +1 of infection with a single 30pg intranasal dose. All 
control mice were given lOpl of PBS 3 days prior to challenge. Groups of mice (n=4) 
from both treatment groups were humanely culled following infection on days +3, +5 
and +7, for comparative immune analyses. Cytokine analyses of lung and spleen 
preparations and sera, allowed for the pro-inflammatory cytokines TNF-a, IL-6, IFN- 
a and IFN-y, along with the chemokine CCL2 and anti-inflammatory cytokine IL-10 
to be determined throughout the course of the experiment. Flow cytometric analysis 
of mouse spleen and lung samples allowed for enumeration of macrophages, 
neutrophils, DCs, NK cells, B-cells and T-cells, along with characterisation of key 
cellular markers for particular cell types.
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Figure 4.2. Effect of multiple dosing with CpG-B 7909 as a post-exposure 
treatment in mice infected with VACV. Graph shows survival data of mice (n=4) 
challenged on day 0 with 10 MLD VACV. Mice were treated intranasally post­
infection with 30pg doses of CpG-B 7909 or PBS as shown.
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4.3.3.2. Cytokine responses in the lung
The levels of all pro-inflammatory cytokines and chemokines measured in the lungs 
of mice treated 24 hours post intranasal VACV challenge were shown to differ 
significantly from PBS treated mice at some time throughout the infection time- 
course (Figure 4.3). On day +3 post infection, levels of TNF-a (Figure 4.3a), IL-6 
(Figure 4.3b), IFN-a (Figure 4.3c), IFN-y (Figure 4.3d), CCL2 (Figure 4.3e), and IL- 
10 (Figure 4.3f), were all significantly higher (p<0.001) in CpG-B 7909 treated 
animals. By day +5, levels of IFN-y and IL-10 were no longer significantly different 
from PBS treated animals (p>0.05) whilst levels of TNF-a (p<0.01), IL-6 (p<0.05), 
CCL2 (p<0.01) and IFN-a (p<0.01) remained significantly elevated in CpG-B 7909 
treated mice. Thereafter on day +7, only levels of TNF-a (p<0.05) and IFN-a 
(p<0.001) remained significantly higher in CpG-treated mice than in those given PBS.
4.3.3.3. Cellular responses in the lung
4.3.3.3.I. Lung macrophage responses
Antibody specific to the mouse macrophage cell marker F4/80 was used to label 
macrophages from lung cell suspensions. The activation status of macrophages at 
each time point was determined using monoclonal antibodies to monitor changes in 
the cellular expression of the activation marker CD54 and the expression of MHC 
class II molecules (IA/IE) on the surface of F4/80 positive cells.
Figure 4.4 shows the numbers of F4/80+ cells in the lungs of mice treated with PBS or 
treated with CpG-B 7909 post intranasal VACV challenge. Total macrophage 
numbers in CpG-B 7909 treated mice were at their highest on day +3 and were 
elevated at each time point as shown in Figure 4.4a. Although total macrophage
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Figure 4.3. Measurement of lung cytokine levels in Balb/C mice treated with 
CpG-B 7909 or PBS post-infection with VACV. Mice were either treated on day +1 
post infection with CpG-B 7909 or pre-treated with PBS. Protein levels determined 
via CBA analysis or IFN-a elisa. Bars represent the geometric mean of four mice 
(Logio pg/ml) and error bars indicate 95% confidence intervals for cytokines (a) TNF- 
a; (b) IL-6; (c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05), ** (p<0.01) and ***
(p<0.001).
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Figure 4.4. Lung macrophage numbers during VACV infection in CpG-B 
7909 and PBS treated groups. Numbers of F4/80+ macrophages in the lungs of 
infected mice were examined over a seven day period in mice either pre-treated with 
PBS or treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) 
total number of F4/80+ macrophages; (b) macrophages expressing CD54; (c) 
macrophages expressing IA/IE. Graph represents geometric mean of four mice. 
Results shown include ± SEM. Statistical significance was determined using a two- 
way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as * (p<0.05).
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numbers never differed significantly at any individual time-point, CpG-B 7909 
treatment was found to have a significant effect on total macrophage numbers over 
the course of infection by two-way ANOVA (p<0.01). Similarly, the number of 
macrophages expressing CD54 was also found to be significantly increased over the 
course of the infection by CpG-B 7909 treatment (p<0.01), with CD54+ macrophages 
in CpG-B 7909 treated mice significantly higher (p<0.05) on day +3 (Figure 4.4b). 
Despite the apparent increase in IA/IE+ macrophage cell numbers in mice treated with 
CpG-B 7909 (Figure 4.4c), these levels failed to reach statistical significance 
(p>0.05). Throughout, total macrophage numbers and numbers of activated 
macrophages were at their highest on day +3 of infection. By day +5, significant 
differences between CpG-treated and control treated mice in the total number and 
CD54+ cells were lost.
The percentages of macrophages expressing CD54 are represented in Figure 4.5a. 
Here, no significant differences were observed between CpG and PBS treated groups 
on any day (p>0.05). In contrast, the percentage of macrophages expressing the co­
stimulation marker MHC II, were significantly lower (p<0.001) on day +3 in CpG- 
treated mice (Figure 4.5b). By day +5, the percentage of cells expressing MHC II had 
increased in CpG-B 7909 treated animals to levels comparable to control groups.
4.3.3.3.2. Lung neutrophil responses
Neutrophils were characterised using a monoclonal antibody to Ly6G as a cell 
marker. Activation of neutrophils was determined by monitoring expression of the 
activation makers CD54 and CD l ib  on Ly6G positive cells and through gating on 
neutrophil-rich areas on forward/side scatter plots.
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Figure 4.5. Activation of lung macrophages during VACV infection in CpG-B 
7909 and PBS treated groups. Lung macrophage activation was monitored by 
expression of activation marker CD54 (Figure 4.5a) and co-stimulation marker IA/IE 
(Figure 4.5b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as *** (p<0.001).
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Lung neutrophil numbers are represented in Figure 4.6. Total neutrophil numbers 
(Figure 4.6a), as well as the number of neutrophils expressing either CD54 (Figure 
4.6b) or CD1 lb (Figure 4.6c) were not found to differ significantly between treatment 
groups at individual time-points post-infection (p>0.05). In contrast, neutrophil 
numbers were found to alter significantly over the time course of infection (p<0.001). 
Whilst the actual number of neutrophils was not found to differ between treatment 
groups, significant differences in the percentage of cells expressing these activation 
markers were found. Specifically, the percentage of neutrophils expressing CD54 in 
mice treated with CpG-B 7909 post challenge were significantly lower (p<0.05) than 
PBS control mice on day +3 of infection (Figure 4.7a). In contrast, the percentage of 
neutrophils expressing CD l ib  was significantly higher in CpG-treated groups than 
PBS groups on days +3 and +5 post challenge (Figure 4.7b). The percentage levels of 
both CD54+ neutrophils and C D llb+ neutrophils altered significantly in different 
directions over the course of infection (p<0.001). This may suggest a role for 
activated neutrophils throughout VACV infection.
4.3.3.3.3. Lung dendritic cell responses
Dendritic cell responses were characterised using the cell differentiation marker 
C D llc to identify lung DCs and the activation status of cells was monitored via 
expression of MHC II (IA/IE) and the co-stimulation marker CD80.
Dendritic cell numbers altered significantly (p<0.001) over the course of infection. 
The total numbers of dendritic cells in both treatment groups did not differ 
significantly from each other, with total numbers in both groups climbing steadily 
over the course of infection (Figure 4.8a). Similar trends were also observed in the
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Figure 4.6. Lung neutrophil numbers during VACV infection in CpG-B 7909 
and PBS treated groups. Numbers of Ly6G+ neutrophils in the lungs of infected 
mice were examined over a seven day period in mice either pre-treated with PBS or 
treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total 
number of Ly6G+ neutrophils; (b) neutrophils expressing CD54; (c) neutrophils 
expressing CD lib . Graph represents geometric mean of four mice. Results shown 
include ± SEM. No statistical significance was determined using a two-way ANOVA 
and Bonferroni’s post-tests.
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Figure 4.7. Activation of lung neutrophils during VACV infection in CpG-B 
7909 and PBS treated groups. Lung neutrophil activation was monitored by 
expression of activation marker CD54 (Figure 4.7a) and diapedesis marker CD l ib  
(Figure 4.7b) on days +3, +5 and +7 of infection using flow cytometry. Graph 
represents geometric mean of four mice. Error bars represent ± SEM. Statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests. 
Significant findings between treatment groups are represented as * (p<0.05).
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Figure 4.8. Lung dendritic cell numbers during VACV infection in CpG-B 
7909 and PBS treated groups. Numbers of C D llc+ DCs in the lungs of infected 
mice were examined over a seven day period in mice either pre-treated with PBS or 
treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total 
number of C D llc+ DCs; (b) DCs expressing IA/IE; (c) DCs expressing CD80. Graph 
represents geometric mean of four mice. Results shown include ± SEM. Statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests. 
Significant findings between treatment groups are represented as ** (p<0.01).
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number of DCs expressing the co-stimulation markers MHC II (Figure 4.8b) and 
those expressing CD80 (Figure 4.8c). However, on day +3 of infection, the numbers 
of DCs expressing CD80 were significantly higher (p<0.01) in mice that had been 
treated with CpG-B 7909 than in controls (Figure 4.8c).
The percentage of DCs expressing MHC II also altered significantly over the course 
of infection (p<0.01) but no significant differences were found between treatment 
groups (p>0.05) (Figure 4.9a). The percentage of DCs positive for CD80 also 
fluctuated significantly over time (p<0.001) with the percentage of C D llc+ CD80+ 
DCs being significantly higher on day +3 in CpG-B 7909 treated mice compared with 
controls (Figure 4.9b).
4.3.3.3.4. Lung NK cell responses
The NK cell marker CD49b was used to distinguish NK cells in lung preparations. 
Activation of NK cells was determined using antibodies to CD54 and CD69.
Total NK cell numbers were significantly higher (p<0.01) on day +3 of infection in 
CpG-B 7909 treated mice than controls (Figure 4.10a). The number of NK cells 
positive for CD54 altered significantly throughout the infection time-course (p<0.001) 
but at no time-point were numbers significantly different between treatment groups 
(Figure 4.10b). The numbers of NK cells expressing CD69 differed significantly 
between treatment groups on day +3 as represented in Figure 4.10c where the lungs of 
CpG-B 7909 treated mice contained higher numbers of CD69+ NK cells (p<0.01).
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Figure 4.9. Activation of lung dendritic cells during VACV infection in CpG-B 
7909 and PBS treated groups. Lung DC activation was monitored by expression of 
co-stimulation markers IA/IE (Figure 4.9a) and CD80 (Figure 4.9b) over the course of 
infection using flow cytometry. Graph represents geometric mean of four mice. Error 
bars represent ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as ** (p<0.01).
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Figure 4.10. Lung natural killer cell numbers during VACV infection in CpG-B 
7909 and PBS treated groups. Numbers of CD49b+ NK cells in the lungs of infected 
mice were examined in mice either pre-treated with PBS or treated on day +1 with 
CpG-B 7909 over a seven day period using flow cytometry. Figure shows (a) total 
number of CD49b+ NK cells; (b) NK cells expressing CD54; (c) NK cells expressing 
CD69. Graph represents geometric mean of four mice. Results shown include ± SEM. 
Statistical significance was determined using a two-way ANOVA and Bonferroni’s 
post-tests. Significant findings between treatment groups are represented as **
(p<0.01).
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The percentage of activated NK cells expressing CD54 did not differ between 
treatment groups at any time nor did percentage levels alter significantly over the 
course of infection in either group (Figure 4.11a). In contrast, the percentage of cells 
expressing the early activation marker CD69 were significantly different between 
treatment groups on day +3 (Figure 4.11b). Thereafter, by day +5, the percentage of 
CD69+ NK cells had dropped significantly (p<0.001) in CpG-B 7909 treated mice to 
levels comparable with control mice.
4.3.3.3.5. Lung B-Cell responses
Antibody specific to CD 19, a pan B-cell marker was used to label B-cells in 
suspensions. The activation status of B-cells at each time point was determined via 
changes in the cellular expression of co-stimulatory molecules CD80 and CD86.
Total B-cell numbers in the lungs of control and CpG-B 7909 treated mice varied 
significantly (p<0.01) over the course of infection but did not differ significantly 
between one another at any time point (Figure 4.12a). Likewise, the numbers of 
activated B-cells expressing CD86 (Figure 4.12b) or those expressing CD80 (Figure 
4.12c) also fluctuated over the course of infection (p<0.001). Interestingly, numbers 
of CD19+ CD86+ cells appeared to dip on day +5 before returning to day +3 levels 
whereas the number of CD19+ CD80+ steadily increased over time. Throughout 
infection, increased numbers of activated B-cells were detected in all mice treated 
with CpG-B 7909. Consequently, whilst the differences in B-cell numbers did not 
differ significantly at any one time point, this overall trend resulted in a significant 
difference being found between treatment groups (p<0.05). No significant differences
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Figure 4.11. Activation of lung natural killer cells during VACV infection in 
CpG-B 7909 and PBS treated groups. Lung NK cell activation was monitored by 
expression of activation markers CD54 (Figure 4.11a) and CD69 (Figure 4.11b) over 
the course of infection using flow cytometry. Graph represents geometric mean of 
four mice. Error bars represent ± SEM. Statistical significance was determined using a 
two-way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as ** (p<0.01).
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Figure 4.12. Lung B-cell numbers during VACV infection in CpG-B 7909 and 
PBS treated groups. Numbers of CD19+ B-cells in the lungs of infected mice were 
examined in mice either pre-treated with PBS or treated on day +1 with CpG-B 7909 
over a seven day period using flow cytometry. Figure shows (a) total number of 
CD19+ B-cells; (b) B-cells expressing CD86; (c) B-cells expressing CD80. Results 
shown include ± SEM. No statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests.
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in the percentage of activated B-cells (Figure 4.13) were observed between treatment 
groups throughout infection (p>0.05).
4.3.3.3.6. Lung T-Cell responses
Antibody specific to CD3, a pan T-cell marker was used to identify T-cells in 
suspensions, whilst anti-CD4 and anti-CD8 antibodies distinguished between the two 
major T-cell sub-sets.
Lung CD4+ T-cell responses are represented in Figure 4.14a and lung CD8+ T-cells in 
Figure 4.14b. Throughout infection, the numbers of CD4+ and CD8+ T-cells were 
constantly higher in mice treated with CpG-B 7909 post VACV infection, than those 
given PBS. However, this observed increase failed to reach a level of statistical 
significance (p>0.05) which makes it unlikely to be a real effect of CpG treatment. 
Time was shown to have a significant effect on T-cell numbers, independent of CpG- 
B 7909 treatment, with both CD4+ T-cells and CD8+ T-cells significantly increasing 
between days +5 and +7 of infection (p<0.01 and p<0.001 respectively).
4.3.3.4. Cytokine responses in the spleen
Levels of all cytokines measured in the spleens of control and CpG-B 7909 treated 
mice are represented in Figure 4.15. With the exception of IFN-y, the levels of all pro- 
and anti-inflammatory cytokines and chemokines measured were not significantly 
affected by CpG-B 7909 treatment at any time-point. The exception to this was in the 
levels of IFN-y on day +3, which were found to be significantly lower (p<0.001) in 
CpG-B 7909 treated mice than those found in controls (Figure 4.15d).
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Figure 4.13. Activation of lung B-cells during VACV infection in CpG-B 7909 
and PBS treated groups. Lung B-cell activation was monitored by expression of 
activation markers CD86 (Figure 4.13a) and CD80 (Figure 4.13b) over the course of 
infection using flow cytometry. Graph represents geometric mean of four mice. Error 
bars represent ± SEM. No statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests.
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Figure 4.14. Lung T-cell numbers during VACV infection in CpG-B 7909 and 
PBS treated groups. Numbers of CD3+ T-cells in the lungs of infected mice were 
examined over a seven day period in mice either pre-treated with PBS or treated on 
day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total number of 
CD4+ T-cells; (b) total number of CD8+ T-cells. Graph represents geometric mean of 
four mice. Results shown include ± SEM. No statistical significance was determined 
using a two-way ANOVA and Bonferroni’s post-tests.
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Figure 4.15. Measurement of spleen cytokine levels in Balb/C mice treated with 
CpG-B 7909 or PBS post-infection with VACV. Mice were either treated on day +1 
post infection with CpG-B 7909 or pre-treated with PBS. Protein levels determined 
via CBA analysis or IFN-a elisa. Bars represent the geometric mean of four mice 
(Logio pg/ml) and error bars indicate 95% confidence intervals for cytokines (a) TNF- 
a; (b) IL-6; (c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical significance was 
determined using a two-way ANOVA and Bonferroni’s post-tests. Significant 
findings between treatment groups are represented as * (p<0.05), ** (p<0.01) and ***
(p<0.001).
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4.3.3.5. Cellular responses in the spleen
4.3.3.5.1. Spleen macrophage responses
Total macrophage numbers in the spleen altered significantly between day +3 and day 
+7 post-infection (p<0.01) (Figure 4.16a). No significant effects of CpG-B 7909 
treatment on macrophages expressing CD54 (Figure 4.16b) or MHC II (Figure 4.16c) 
were determined between control mice and CpG-B 7909 mice over the course of 
infection. This suggests that the macrophage egress observed in the spleen may be a 
consequence of VACV infection rather than CpG stimulation. Likewise, the 
percentages of activated macrophages (Figure 4.17) were not significantly different 
between treatment groups (p>0.05) but were significantly affected by time (p<0.01).
4.3.3.5.2. Spleen neutrophil responses
Total neutrophil numbers (Figure 4.18a) in the spleens of CpG-B 7909 treated mice 
were not significantly different from those in control PBS mice throughout the course 
of infection (p>0.05). Similarly, the numbers of activated neutrophils expressing 
either CD54 (Figure 4.18b) or CD1 lb (Figure 4.18c) did not differ between treatment 
groups. Neutrophil numbers fluctuated significantly over the course of infection 
(p<0.001) in both treated and untreated mice, presumably in response to VACV 
infection. The percentages of neutrophils expressing activation markers also varied 
significantly throughout infection but again, this happened irrespective of CpG-B 
7909 treatment as no significant differences between treatment groups were 
determined throughout (Figure 4.19).
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Figure 4.16. Spleen macrophage numbers during VACV infection in CpG-B 
7909 and PBS treated groups. Numbers of F4/80+ macrophages in the spleens of 
infected mice were examined over a seven day period in mice either pre-treated with 
PBS or treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) 
total number of F4/80+ macrophages; (b) macrophages expressing CD54; (c) 
macrophages expressing IA/IE. Graph represents geometric mean of four mice. 
Results shown include ± SEM. No statistical significance was determined using a 
two-way ANOVA and Bonferroni’s post-tests.
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Figure 4.17. Activation of spleen macrophages during VACV infection in CpG- 
B 7909 and PBS treated groups. Spleen macrophage activation was monitored by 
expression of activation marker CD54 (Figure 4.17a) and co-stimulation marker IA/IE 
(Figure 4.17b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. No statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests.
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Figure 4.18. Spleen neutrophil numbers during VACV infection in CpG-B 7909 
and PBS treated groups. Numbers of Ly6G+ neutrophils in the spleens of infected 
mice were examined over a seven day period in mice either pre-treated with PBS or 
treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total 
number of Ly6G+ neutrophils; (b) neutrophils expressing CD54; (c) neutrophils 
expressing CD lib . Graph represents geometric mean of four mice. Results shown 
include ± SEM. No statistical significance was determined using a two-way ANOVA 
and Bonferroni’s post-tests.
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Figure 4.19. Activation of spleen neutrophils during VACV infection in CpG-B 
7909 and PBS treated groups. Spleen neutrophil activation was monitored by 
expression of activation marker CD54 (Figure 4.19a) and diapedesis marker CD l ib  
(Figure 4.19b) over the course of infection using flow cytometry. Graph represents 
geometric mean of four mice. Error bars represent ± SEM. No statistical significance 
was determined using a two-way ANOVA and Bonferroni’s post-tests.
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4.3.3.5.3. Spleen dendritic cell responses
Figure 4.20 represents the numbers of DCs in the spleens of VACV-infected mice 
treated with either PBS or CpG-B 7909. No significant differences between treatment 
groups were found in the total number of DCs present (Figure 4.20a), nor in the 
number of DCs expressing MHC II (Figure 4.20b) or CD80 (Figure 4.20c). Dendritic 
cell numbers were found to alter significantly (p<0.001) over the course of infection 
independent of CpG-B 7909 treatment. The percentage of DCs expressing MHC II 
was also seen to alter throughout infection as seen in Figure 4.21a where levels 
decreased steadily over time in both PBS and CpG-B 7909 treated mice. This 
happened irrespective of CpG-B 7909 treatment as no significant differences were 
determined between treatment groups. In contrast, the percentage of DCs expressing 
CD80 in CpG-B 7909 on day +3 was significantly higher (p<0.05) than that found in 
PBS treated mice (Figure 4.21b). In both treatment groups, the percentage of DCs 
expressing CD80 decreased significantly (p<0.001) between days +3 and +5 to 
baseline levels.
4.3.3.5.4. Spleen NK cell responses
No significant differences in the total number or number of activated NK cells were 
determined between treatment groups at any stage throughout the infection time 
course (Figure 4.22). NK cell numbers altered significantly over the duration of 
infection but once again, as no significant effect of CpG-B 7909 was determined, this 
appeared to be a consequence of virus infection. Whilst the numbers of NK cells in 
the spleen appeared to be uneffected by CpG treatment, the actual percentage of NK 
cells expressing the early activation marker CD69 was significantly different (p<0.01) 
between treatment groups on day +3 (Figure 4.23b). By day +5, the percentage of
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Figure 4.20. Spleen dendritic cell numbers during VACV infection in CpG-B 
7909 and PBS treated groups. Numbers of C D llc+ DCs in the spleens of infected 
mice were examined over a seven day period in mice either pre-treated with PBS or 
treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total 
number of C D llc+ DCs; (b) DCs expressing IA/IE; (c) DCs expressing CD80. Graph 
represents geometric mean of four mice. Results shown include ± SEM. No statistical 
significance was determined using a two-way ANOVA and Bonferroni’s post-tests.
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Figure 4.21. Activation of spleen dendritic cells during VACV infection in 
CpG-B 7909 and PBS treated groups. Spleen DC activation was monitored by 
expression of co-stimulation markers IA/IE (Figure 4.21a) and CD80 (Figure 4.22b) 
over the course of infection using flow cytometry. Graph represents geometric mean 
of four mice. Error bars represent ± SEM. Statistical significance was determined 
using a two-way ANOVA and Bonferroni’s post-tests. Significant findings between 
treatment groups are represented as * (p<0.05).
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Figure 4.22. Spleen natural killer cell numbers during VACV infection in CpG- 
B 7909 and PBS treated groups. Numbers of CD49b+ NK cells in the spleens of 
infected mice were examined over a seven day period in mice either pre-treated with 
PBS or treated on day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) 
total number of CD49b+ NK cells; (b) NK cells expressing CD54; (c) NK cells 
expressing CD69. Graph represents geometric mean of four mice. Results shown 
include ± SEM. No statistical significance was determined using a two-way ANOVA 
and Bonferroni’s post-tests.
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Figure 4.23. Activation of spleen natural killer cells during VACV infection in 
CpG-B 7909 and PBS treated groups. Spleen NK cell activation was monitored by 
expression of activation markers CD54 (Figure 4.23a) and CD69 (Figure 4.23b) over 
the course of infection using flow cytometry. Graph represents geometric mean of 
four mice. Error bars represent ± SEM. Statistical significance was determined using a 
two-way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as ** (p<0.01).
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CD69+ NK cells in CpG-B 7909 treated mice dropped to levels seen in control mice 
and these remained comparable between groups for the remainder of the infection. 
The percentage of NK cells expressing CD54 did not differ significantly between 
treatment groups (Figure 4.23a).
4.3.3.5.5. Spleen B-cell responses
Total and activation marker-specific B-cell numbers are represented in Figure 4.24. 
B-cell numbers fluctuated significantly over time (p<0.001). However, no significant 
differences were observed between treatment groups in the total number of B-cells in 
the spleen (Figure 4.24a) or in the number of B-cells expressing the co-stimulation 
marker CD86 (Figure 4.24b). The numbers of B-cells expressing CD80 (Figure 4.24c) 
were significantly higher on day +7 in the spleens of mice that had been treated with 
CpG-B 7909 than in controls (p<0.05). Closer examination on day +7 revealed that 
the percentage of B-cells expressing CD80 in CpG-B 7909 treated mice was also 
significantly higher (p<0.01) than in control PBS mice (Figure 4.25b). In contrast, no 
significant differences were found between the percentages of B-cells expressing 
CD86 in CpG-B 7909 and PBS treated mice (Figure 4.25a).
4.3.3.5.6. Spleen T-cell responses
The number of CD4 positive T-cells in control and CpG-treated groups did not differ 
significantly from each other at any time-point (Figure 4.26a). However, there was a 
significant influence (p<0.05) of CpG treatment on CD4+ T-cell numbers over the 
time-course of infection. Similarly, the numbers of CD8+ T-cells were significantly 
lower in mice receiving CpG-B 7909 throughout the course of infection (p<0.01). In
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Figure 4.24. Spleen B-cell Numbers during VACV infection in CpG-B 7909 and 
PBS treated groups. Numbers of CD19+ B-cells in the spleens of infected mice were 
examined over a seven day period in mice either pre-treated with PBS or treated on 
day +1 with CpG-B 7909 using flow cytometry. Figure shows (a) total number of 
CD19+ B-cells; (b) B-cells expressing CD86; (c) B-cells expressing CD80. Results 
shown include ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as * (p<0.05).
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Figure 4.25. Activation of spleen B-cells during VACV infection in CpG-B 7909 
and PBS treated groups. Spleen B-cell activation was monitored by expression of 
activation markers CD86 (Figure 4.25a) and CD80 (Figure 4.25b) over the course of 
infection using flow cytometry. Graph represents geometric mean of four mice. Error 
bars represent ± SEM. Statistical significance was determined using a two-way 
ANOVA and Bonferroni’s post-tests. Significant findings between treatment groups 
are represented as ** (p<0.01).
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Figure 4.26. Spleen T-cell numbers during VACV infection in CpG-B 7909 and 
PBS treated groups. Numbers of CD3+ T-cells in the spleens of infected mice were 
examined in mice either pre-treated with PBS or treated on day +1 with CpG-B 7909 
over a seven day period using flow cytometry. Figure shows (a) total number of CD4+ 
T-cells; (b) total number of CD8+ T-cells. Graph represents geometric mean of four 
mice. Results shown include ± SEM. Statistical significance was determined using a 
two-way ANOVA and Bonferroni’s post-tests. Significant findings between treatment 
groups are represented as ** (p<0.01).
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particular, numbers of CD8+ cells in PBS control mice were significantly higher 
(p<0.01) than CpG-treated mice on day +7 (Figure 4.26b).
4.3.3.6. Cytokine responses in the sera
Cytokine and chemokine levels detectable in the sera of mice from both treatment 
groups are represented in Figure 4.27. No significant differences in the serum levels 
of pro-inflammatory cytokines TNF-a, IL-6 or IFN-y were seen between treatment 
groups throughout infection (Figure 4.27a, 4.27b, 4.27d), or for the chemokine CCL2 
(Figure 4.27e). Serum levels of the anti-inflammatory cytokine IL-10 were found to 
be significantly higher (p<0.05) in CpG-B 7909 treated mice than in control groups 
on day +3 of infection only (Figure 4.27f). Levels of IFN-a from both CpG-B 7909 
and PBS groups were only determined on day +3 of infection due to loss of sample. 
These samples did not differ significantly from each other (Figure 4.27e). Once again, 
serum levels of cytokines were substantially below those found in the lungs and 
spleens.
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Figure 4.27. Measurement of serum cytokine levels in Balb/C mice treated with 
CpG-B 7909 or PBS post-infection with VACV. Protein levels determined via CBA 
analysis or IFN-a elisa. Bars represent the geometric mean of four mice (Logi0 pg/ml) 
and error bars indicate 95% confidence intervals for cytokines (a) TNF-a; (b) IL-6; 
(c) IFN-a; (d) IFN-y; (e) CCL2; (f) IL-10. Statistical significance was determined 
using a two-way ANOVA and Bonferroni’s post-tests. Significant findings between 
treatment groups are represented as * (p<0.05).
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4.4. Discussion
In this chapter, the protective effects of CpG-B 7909 have been examined when 
administered as a post-exposure therapy for intranasal infection with VACV. Previous 
work has suggested that CpG-B 7909 can be extremely effective at providing 
complete protection against VACV infection, if given up to 7 days prior to VACV 
challenge, (Rees et a l, 2005). However, historically the effectiveness of CpGs as a 
post-exposure monotherapy has yielded mixed results as detailed in a variety of 
studies (Waag et al, 2006; Wongratanacheewin et a l, 2004; Olbrich et al, 2002). 
The use of CpG-B 7909 has not previously been tested as a potential post-exposure 
antiviral to poxvirus infection. Therefore, this work has attempted to address whether 
the protective immunomodulating properties induced by CpG-B 7909 in a pre­
exposure model, are similarly as effective when given after VACV challenge.
In initial studies, the local administration of a single 30pg dose of CpG-B 7909 
protected 60% of mice when administered one day after intranasal challenge with 
VACV. This level of protection proved significant (p<0.05), although it was less 
effective than CpG-B 7909 given prior to virus exposure where full protection has 
been obtained (Chapter 3) (Rees et a l, 2005). This dose of CpG-B 7909 was more 
protective than the 15pg and 50pg CpG doses which failed to confer any protection. 
This may be a consequence of the 15pg dose failing to stimulate a sufficient immune 
response to combat the ongoing VACV infection. In contrast, the failure of the 50pg 
dose to protect may have been a result of over-stimulation of the immune response 
resulting in a hastened time to death. The fact that the 30pg dose sits in the middle of 
this scale may suggest it causes an appropriate level of immune stimulation that is 
able to afford some protection from VACV infection.
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The drop in protection seen between CpG-B 7909 prophylaxis and post-exposure 
therapy of VACV infection is consistent with that seen by other groups in a variety of 
infection models. For instance, systemic delivery of CpG prior to intraperitoneal 
B.pseudomallei infection provided 100% protection against lethality, whereas only 
33% protection, or no protection has been observed if CpGs are given at the time of 
challenge or on day +1 respectively (Wongratanacheewin et al., 2004). Similarly, 
systemic CpG-B 7909 treatment prior to intranasal B. mallei infection afforded 90% 
protection, but only 10% if given 24 hours after challenge (Waag et al, 2006). 
Protection has also been completely abrogated in a pulmonary Klebsiella model of 
infection when CpGs were administered at the time of infection, whereas treatment 48 
hours prior to challenge resulted in 80% protection (Deng et al., 2004).
Reduced levels of protection have also been documented against viral infection by 
numerous groups. Pre-treatment intravaginally with CpG 1826 has given 100% 
protection against lethal HSV-2 infection but only 20% or 13% if given either 24 
hours or 72 hours post-challenge, respectively (Sajic et a l , 2003). Other groups have 
also reported reduced protection after post-exposure CpG treatment for HSV-2 
(Harandi et a l, 2003) although, in this study, CpG administration came 4 hours after 
challenge resulting in a drop from 80% protection in pre-exposure models to 66%. In 
all of these studies, the introduction of CpGs prior to viral challenge significantly 
restricted viral titres compared to control groups over the course of the experiments. 
However, delayed treatment with CpG failed to reduce viral titres in all of the post­
exposure models. For instance, HSV-2 viral titres in mice treated with CpG 24 or 72 
hours post-infection were no different from control mice and significantly higher than 
those seen in mice treated 4 hours post infection with CpG (Sajic et a l, 2003). The
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failure of CpGs in these models to limit the spread of infection correlates with disease 
severity and a loss of protection and has been linked to the timing of CpG delivery. In 
this current study, viral titres in post-exposure CpG-B 7909 treated mice could not be 
ascertained because lung and spleen cell suspensions were preserved for analysis by 
flow cytometry. However, as pre-treatment of mice with CpG-B 7909 has been shown 
to reduce VACV viral titres in the lungs, brain and spleen (Rees et al., 2005), it would 
be interesting to see how CpG-B 7909 treatment post-exposure affected the 
dissemination and growth of virus in this model. It is certainly possible that the drop 
in protection seen in this post-exposure virus model may also be due to the failure of 
the infected host to limit the spread of VACV during the early stages of infection. 
Indeed, experiments performed by colleagues here at Dstl investigating a 50pg dose 
of CpG-B 7909 given on day +2 of VACV infection, found no differences in viral 
titres between untreated and CpG-treated groups (Personal communication).
The results in this chapter suggest that the administration of CpG-B 7909 to the lung 
post VACV infection can induce significant changes to an already activated 
inflammatory response initiated by viral infection. In the pre-exposure model, 
protection correlated with a prominent immunological response to CpG treatment, 
characterised by the rapid release of pro-inflammatory cytokines and increased 
cellular traffic into the lung prior to VACV infection (Chapter 3). Here, CpG-B 7909 
treatment induced significant increases in the pulmonary levels of pro-inflammatory 
cytokines including TNF-a, IL-6, IFN-y and IFN-a. Once again, the exact origins of 
these cytokines are unknown although macrophages, dendritic cells, and NK cells are 
likely candidates as these cell types have all been shown to release these cytokines 
following CpG stimulation (Balias, Rasmussen, & Krieg, 1996; Platz et a l , 2004;
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Demedts et al., 2006; Katze, He, & Gale, 2002). Moreover, each of these cell-types 
expressed an activated phenotype on day +3 of infection. Consistent with direct CpG 
stimulation via TLR9, both the number and percentage of dendritic cells in the lung 
expressing the co-stimulatory marker CD80 were significantly higher in CpG-treated 
animals on day +3 of infection. Interestingly, given CpG-B 7909 is predominantly 
thought to activate B-cells, no significant differences were detected in either B-cell 
numbers or the percentages of activated B-cells at the site of CpG administration. This 
may be due to CpG stimulation being extremely rapid and inducing only transient 
effects on B-cells, as has been documented previously (Krieg et al., 1995). Likewise, 
the pro-inflammatory cytokine IL-12 which drives expression of IFN-y is also 
transient and is released rapidly following stimulation of dendritic cells and 
macrophages. This may also account for the lack of detectable levels of IL-12 
throughout infection as the first sample was taken 48 hours after CpG treatment.
Indirect CpG stimulation may account for the observed increases in the percentages of 
lung neutrophils expressing CD l ib  on days +3 and +5 of infection. Increases in 
CD1 lb expression are typically indicative of cellular egress and in this instance, may 
be a sign of recent recruitment of neutrophils to the site of stimulation (Ley et al., 
2007). Interestingly, the percentage of CD54+ neutrophils was significantly lower on 
day +3 of infection in CpG-treated mice than in control mice. Down-regulation of 
CD54 on neutrophils by anti-inflammatory cytokines such as IL-10 may be a strategy 
to retain neutrophils in the lung (Tomioka et al., 2004). NK cell activation after CpG 
stimulation has been well documented despite the absence of TLR9 which may 
emphasise the importance of indirect stimulation in CpG mediated protection (Sivori 
et al., 2006; Marshall et al., 2006). The total numbers of NK cells in the lung, along
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with those expressing the early activation marker CD69, were also significantly 
higher in the lungs of CpG-treated mice. Additionally, pulmonary levels of the 
chemokine CCL2 were significantly elevated in mice treated with CpG-B 7909 and 
this increase has also been reported in previous studies involving CpGs (Edwards et 
al., 2005). Consistent with CCL2 release, CpG-treated mice had a significantly higher 
number of activated macrophages in the lung as determined by CD54+ expression 
compared with control mice. Similar to that seen in Chapter 3, CpG stimulation 
appeared to reduce the percentage of macrophages expressing MHC II on day +3 in 
the lung, as has also been seen by other groups (Chu et al., 1999). Pulmonary levels of 
IL-10 were significantly higher on day +3 in CpG- treated mice. These increases in 
IL-10 may promote NK cell activity as has been previously described (Lauw et al, 
2000), or may counter-balance the inflammatory effects of other pro-inflammatory 
cytokines. It may be that the immune profiles reported here in this post-exposure 
system result from the host’s accommodation of the temporal nature of treatment and 
infection. Collectively, the immune responses at the site of infection may be crucial 
for protection against VACV.
In the spleens of infected mice, no differences between treatment groups were 
observed in the splenic levels of cytokines or chemokines measured over the course of 
infection. However, significant increases in the numbers and percentages of particular 
cell-types were found between treated and untreated groups suggesting that CpGs can 
have significant immunological effects at sites distal to their site of delivery. 
Specifically, increases in the percentages of CD80+ dendritic cells, CD69+ NK cells, 
and increased numbers of CD80+ B-cells were determined. The lack of enhanced 
cytokine production in CpG-treated mice, suggests that cytokine stimulation of cells
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alone is unlikely to account for these increases in CpG-treated mice. This opens the 
question as to whether the observed differences in CpG-treated mice may be a result 
of direct CpG stimulation via TLR9, particularly since DCs and B-cells are 
predominantly the cells activated. As described in Chapter 3, it is perhaps more likely 
that the observed differences may be a result of these cell-types being stimulated in 
the lung and then having migrated to the spleen where viral titres are likely to be high 
(Rees et al., 2005).
The immunological differences between CpG-treated and untreated mice in the lungs 
and spleens of VACV infected mice provide insight into the protective nature of CpG- 
mediated therapy. As observed with CpG prophylaxis, a strong local inflammatory 
response in the lungs of mice receiving CpG treatment may be key to protection. 
Following intranasal CpG-B 7909 delivery, levels of pro-inflammatory cytokines and 
innate effector cells in the lung such as macrophages, neutrophils, dendritic cells and 
NK cells are significantly boosted (Table 4.1). In contrast, very little effect of CpG 
stimulation is evident in the spleen throughout early infection (Table 4.2). The 
increases in the number of innate cells in the lung and the changes in their activation 
state may aid the ongoing immunological response to VACV infection. If so, 
additional recruitment and activation of cells such as macrophages, dendritic cells and 
NK cells may slow down the replication of VACV and give the immune system an 
opportunity to fight infection more effectively. This may also provide sufficient time 
for the adaptive response to form and resolve infection. Indeed, lymphocyte responses 
in the spleen of mice on day +7 reveal significant differences between CpG-treated 
and untreated mice (Table 4.2). Here, increased numbers of CD8+ T-cells and 
activated B-cells are present in CpG treated mice which may be indicative of the
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Day Overall
+3 +5 +7 CpG-B
7909
Treatment
Time
Total macrophages ++ +
F4/80+ CD54+ + ++ +
F4/80+ IA/IE+
% CD54+
% IA/IE+ +++ +++ +++
Total neutrophils +++
Ly6G+ CD54+ +++
Ly6G+ CD1 lb+ +++
% CD54+ + + +++
% CD1 lb+ + + ++ +++
Total dendritic cells +++
C D llc+ CD80+ ++ ++ +++
CD1 lc+ IA/IE+ +++
% CD80+ ++ ++ +++
% IA/IE+ ++
Total NK cells ++ +++
CD49b+ CD54+ +++
CD49b+ CD69+ ++ +++
% CD54+
% CD69+ + +++
Total B-cells ++
CD19+ CD86+ + +++
CD19+ CD80+ +++
% CD86+ +++
% CD80+ +++
Total CD4+T-cells ++
Total CD8+ T-cells +++
Table 4.1. Significant differences between CpG-B 7909 and PBS treatment 
groups in the lungs of mice during VACV infection. Differences between total and 
activated cell numbers are reported along with differences between the percentages of 
activated cell-types for days +3, +5 and +7 post-infection. The overall effect of CpG- 
B 7909 treatment for each parameter is also reported. Additionally, the overall 
significance of the variation between days for each parameter is reported under Time. 
Significance between treatment groups determined by two-way ANOVA using 
Bonferroni’s post-tests and represented as: + p<0.05; ++ p<0.01; +++ pO.OOl.
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Day Overall
+3 +5 +7 CpG-B
7909
Treatment
Time
Total macrophages ++
F4/80+ CD54+ ++
F4/80+ IA/IE+ ++
% CD54+ +++
% IA/IE+ ++
Total neutrophils +++
Ly6G+ CD54+ +++
Ly6G+ C D llb+ +++
% CD54+ +++
% C D llb+ ++
Total dendritic cells +++
C D llc+ CD80+ +++
C D llc+ IA/IE+ +++
% CD80+ + +++
% IA/IE+ +++
Total NK cells ++
CD49b+ CD54+ +++
CD49b+ CD69+ +++
% CD54+ ++
% CD69+ ++ + +++
Total B-cells +++
CD19+ CD86+ +++
CD19+ CD80+ + +++
% CD86+ +++
% CD80+ +++ +++ +++
Total CD4+ T-cells + +++
Total CD8+ T-cells ++ ++
Table 4.2. Significant differences between CpG-B 7909 and PBS treatment 
groups in the spleens of mice during VACV infection. Differences between total 
and activated cell numbers are reported along with differences between the 
percentages of activated cell-types for days +3, +5 and +7 post-infection. The overall 
effect of CpG-B 7909 treatment for each parameter is also reported. Additionally, the 
overall significance of the variation between days for each parameter is reported 
under Time. Significance between treatment groups determined by two-way ANOVA 
using Bonferroni’s post-tests and represented as: + p<0.05; ++ p<0.01; +++ p<0.001.
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formation of a VACV specific adaptive response. This implies that as with CpG 
prophylaxis, the immediate response of cells in the lung to CpG delivery and the latter 
involvement of cells in the spleen may be crucial to CpG-mediated protection.
A significant factor of VACV infection is the wealth of immunomodulatory proteins 
available at its disposal to disrupt the host response to infection (Haga & Bowie, 
2005) (Section 1.3.2). Many of these genes are synthesised early during the VACV 
lifecycle making the delayed administration of immunomodulatory CpGs less likely 
to work. Collectively, these proteins could contribute significantly to the drop in 
protection observed in the post-exposure model of infection. Many VACV proteins 
such as A46R and A52R, function to disrupt TLR signaling (Stack et al., 2005) and 
their presence prior to CpG delivery may severely dampen the ability of CpGs to 
stimulate cells through TLR9. Other immunomodulatory proteins such as VACV 
IFN-yR or TNF-a receptors (crmB-E) may bind these cytokines and prevent them 
from stimulating receptors on their intended target cells. The potential of these 
individual VACV proteins to limit the protective efficacy of CpG-B 7909 was not 
addressed during this work and remains to be elucidated in this post-exposure model.
The use of multiple doses of CpG treatment post-exposure has been successful in the 
treatment of pathogens in a number of model systems such as FLV, L.monocytogenes 
and F.tularensis (Olbrich et al., 2002; Klinman et al., 1999). However, against 
VACV, multiple doses of CpG-B 7909 seemed to exacerbate infection. This was 
evident from the observations showing mice that received two separate doses of CpG 
succumbed to infection before the control group and rapidly showed signs of 
intolerance to CpG treatment (Figure 4.2). In addition to the cytopathic effects caused
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by poxvirus infection, a role for excessive inflammation in the pathogenesis of disease 
has long been cited as a significant contributor to disease pathology (Stanford et al., 
2007). Consequently it is possible that multiple doses of CpG during a pre-established 
acute poxvirus infection could provoke a pro-inflammatory immune response leading 
to exacerbated disease pathology and a hastened time to death. This may also explain 
why lower doses of CpG-B 7909 (30pg) prove more protective than higher doses in a 
post-exposure system.
Currently, CpG treatment administered at the time of challenge or post infection has 
only been successful in the control of slower growing pathogens that establish chronic 
infection. For instance, treatment of M.tuberculosis at the time of infection or even 2 
weeks after infection significantly reduces bacterial loads in the lung and causes a 
reduction in lung pathology (Juffermans et al., 2002). CpG treatment five days after 
intranasal infection with C.neoformans has also been shown to be effective, 
preventing bacterial dissemination and reducing lung eosinophilia (Edwards et al., 
2005). In a viral model, CpG post-exposure treatment of mice infected with FLV was 
also able to reduce viral titres with 74% mice not going on to develop leukaemia 
(Olbrich et al, 2002). In this instance, the onset of disease recovery was not apparent 
until after the final treatment with CpG and was suggested to be highly reliant on the 
generation of specific CD8+ T-cells. Therefore, in the more acute models of infection, 
like VACV, the delayed use of CpGs in a post-exposure therapy may be severely 
restricted in providing protection.
In summary, the use of CpG-B 7909 as a post-exposure therapy can provide a 
significant degree of protection if administered 24 hours after an otherwise lethal dose
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of VAC V. Intranasal delivery of CpG was shown to induce significant changes to the 
immune response in both the lungs and spleens of infected mice. In particular, CpG 
treatment resulted in significant changes to lung macrophages, neutrophils, dendritic 
cells and NK cells and resulted in elevated levels of TNF-a, IL-6, IFN-a and IFN-y. In 
the spleens of infected mice, fewer significant changes in the numbers of cells or 
expression of cellular activation markers were observed following CpG treatment. 
Here, significant differences were determined later during infection with increases in 
B and T-lymphocyte numbers. Additionally, only levels of IFN-y in the spleen were 
found to differ significantly between treatment groups with control mice having 
higher levels than CpG-treated mice. Collectively, these changes are likely to have 
contributed to the partial protection observed in mice treated with CpG. The failure of 
CpGs to provide complete protection against VACV, as has been observed in pre­
exposure systems, may be a combination of allowing the virus to replicate to high 
titres, the release of immunomodulatory proteins, and the establishment of a firm 
foothold prior to administration of CpG therapy. In addition, it is also possible that the 
administration of CpGs during an already established VACV infection may result in 
overwhelming levels of inflammatory cytokines such as IL-ip which were not 
examined in this work. Together, each of these factors may play a role in limiting the 
efficacy of CpG treatment in the post-exposure model.
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Chapter 5: Macrophage responses to different classes of CpG
5.1. Introduction
5.1.1. Defences at the lung surface
The previous chapters have assessed the host response to VACV in vivo in 
conjunction with CpG-B 7909 prophylaxis or therapy. These results have suggested 
that protection correlates with a prominent pro-inflammatory response, resulting in 
the activation and recruitment of a variety of innate immune cell types in the lung. 
CpG treatment against VACV has proven most effective when administered prior to 
challenge, making the cell-types that respond to CpG stimulation key to 
understanding how protection is conferred. B-cells, the cell-type thought most 
responsive to CpG-B stimulation, are present in the lung in low numbers, and results 
presented in 3.3.8 using B-cell KO mice suggest that B-cells may not be crucial in 
conferring CpG-B mediated protection against VACV. Similarly, protection against 
VACV was still conferred by CpG-B 7909 stimulation in neutrophil depleted Balb/C 
mice (3.3.9). This makes understanding the lung environment and the initial 
interactions between CpGs and other TLR9-expressing cells in the lung extremely 
important.
The lungs of air-breathing animals are constantly bombarded with antigenic material 
and need to be maintained by a variety of innate immune mechanisms. The mucosal 
lining of the lung epithelium provides a first-line of defence against inhaled antigens. 
Here, ciliated and non-ciliated epithelial cells, basal cells and goblet cells provide a 
mechanical barrier to particles, and secrete soluble constituents that comprise the 
airway surface fluid that covers the respiratory epithelium (Fokkens & Scheeren,
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2000). This airway surface fluid is rich in complex glycoproteins called mucins and 
antimicrobial compounds such as lysozymes (Dajani et al., 2005), P-defensins 
(Lehrer, 2004), and lactoferrin (Kruzel et al., 2006) that prevent the colonisation of 
the epithelial surfaces by invading organisms. Bacteria and virus particles that are 
carried towards the alveolar surface also interact with opsonising components of the 
alveolar fluids such as IgG, and complement (Martin & Frevert, 2005), and 
surfactant/surfactant-associated proteins (SPs) such as SP-A and SP-D (Woodworth et 
al., 2007). Micro-organisms may also be neutralised by IgA secreted mainly from the 
bronchial-associated lymphoid tissue (BALT) (Pilette et al., 2001). Organisms that 
are able to bypass these defences are then met by cells of the immune system that 
reside in the alveolar space. These cell types may include T-cells, B-cells, neutrophils, 
eosinophils, mast cells and dendritic cells, but by far the most predominant cell type 
found in the alveolar spaces are the alveolar macrophages (AMs) (Bingisser & Holt,
2001). AMs account for approximately 95% of leukocytes in the alveolar spaces, 
making them the sentinel phagocytic cell in the lung and the first cell type to 
encounter foreign antigens (Sibille & Reynolds, 1990). Consequently, this also makes 
them very likely to be one of the first TLR9 expressing immune cells that encounter 
CpGs after intranasal delivery.
5.1.2. The role of alveolar macrophages
Alveolar macrophages are thought to play a dual role in maintaining lung 
homeostasis. Beyond their potent phagocytic capability, they are known to express a 
wide range of PRRs permitting recognition of foreign antigen and processing of 
danger signals leading to NF-kB activation and pro-inflammatory gene transcription 
(Oshikawa & Sugiyama, 2003). This has been demonstrated through TLR-mediated
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release of pro-inflammatory cytokines such as IL-6, IL-1, IL-12 and TNF-a (Ogle et 
a l, 1994) and chemokine release of IL-8 resulting in rapid neutrophil recruitment into 
the alveolar spaces (Holt, 1986). The release of leukotrienes and reactive oxygen 
intermediates such as nitric oxide (NO) has also been well documented (Bingisser & 
Holt, 2001) and the expression of immunoglobulin receptors (fcR), complement and 
mannose receptors, as well as a range of scavenger receptors and antigenic markers 
have also been well characterised (Laskin et a l, 2001). These data suggest AMs 
possess a number of mechanisms for direct pathogen killing to complement their 
ability to promote cellular recruitment from the pulmonary vasculature and clearance 
of infectious material. However, the lung has been shown to be a predominantly 
immunosuppressive environment that prevents over-zealous inflammatory responses 
to inhaled antigen (Bonfield et a l, 1995). AMs have been implicated in the down- 
regulation of the immune response through suppression of pulmonary DC APC 
function (Holt et a l, 1993) and through regulation of T-cell functions (Strickland et 
a l, 1993). These studies suggest AMs function poorly as accessory cells for T-cell 
activation and also modulate the presentation of antigen through dendritic cells to 
prevent an inflammatory response.
5.1.3. Varieties of lung macrophages and heterogeneity
A number of studies have shown the macrophage to be an extremely heterogeneous 
cell population (Gordon & Taylor, 2005). Differences relating to morphology, 
expression of surface markers and the release of specific products such as enzymes 
and cytokines have all been cited between macrophages that are found in different 
tissues (Laskin et a l, 2001; Dorger et a l, 2001). Within the lung itself, clear 
functional and morphological differences have been reported between alveolar and
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interstitial macrophages in both murine (Crowell et a l, 1992) and human (Fathi et al.,
2001) tissues. Interstitial macrophages are found in the connective tissues of the lung, 
are not exposed to airborne particles (unlike AMs) and are thought to comprise about 
40% of total macrophage numbers in the lung (Crowell et a l, 1992). These 
macrophages combat organisms that colonise or infiltrate the epithelial surfaces and 
secrete a diverse array of soluble mediators in the immediate vicinity of the lung 
matrix and pulmonary connective tissues. Studies also report the presence of another 
type of lung macrophage, the pulmonary macrophage, which differs from its alveolar 
and interstitial counterparts, adhering tightly to the lung endothelial cells to remove 
bacteria from the lung (Dehring & Wismar, 1989). Alveolar macrophages exhibit sub­
populations (Sandron et a l, 1986) and studies show certain sub-populations are more 
prevalent during particular disease states. This is clear when comparing the 
phenotypes of AMs during acute and chronic infections, with the former having a 
prevalence of smaller, less mature ‘monocyte-like’ macrophages compared to a larger, 
more mature macrophage phenotype found in the latter (Brannen & Chandler, 1988). 
Likewise, interstitial macrophages exhibit considerable heterogeneity with respect to 
antigen expression, morphology and function (Kobzik et a l, 1988). These findings 
suggest that the response of macrophages during infection depends significantly on 
the type of macrophage encountered by the invading organism. Likewise, macrophage 
responses to therapeutic agents such as CpG could also vary according to the type of 
macrophage stimulated.
5.1.4. Macrophage responses to CpG
As described in Chapter 1, macrophages possess a variety of PRRs to facilitate a rapid 
response to pathogens. Macrophages have been shown to ingest, and be activated by,
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bacterial DNA (Stacey et al., 1996) and the expression of TLR9 on murine 
macrophages and their response to CpG stimulation has been investigated by several 
groups in vitro. CpG activation of macrophages alters the expression of a wide variety 
of genes (Gao et al., 2002) and induces a prominent pro-inflammatory effect, 
governed by NF-kB activation, cytokine release and up-regulation of TLRs including 
TLR9 (An et al., 2002). TLR9 stimulation on both peritoneal and alveolar 
macrophages through CpG has been shown to inhibit signaling through the IL-10R 
and to negate the effect of IL-10 stimulation (Fernandez et al., 2004). Other studies 
have reported that CpGs enhance mouse macrophage uptake of Burkholderia 
pseudomallei, Salmonella enterica serovar Typhi and E.Coli (Utaisincharoen et al.,
2003) and promote the survival of bone marrow-derived macrophages in a TLR9 and 
PI3-K-Akt dependant manner (Sester et al., 2006). The expression of chemokines 
including MIP-la, MIP-lp, RANTES, and IP-10 have all been shown to be 
upregulated by the murine macrophage cell line RAW 264.7 and macrophages 
isolated from spleen and lung tissue fractions following CpG stimulation (Takeshita et 
al., 2000). CpGs have also been shown to release pro-inflammatory cytokines and 
induce the production of NO and the inducible nitric oxide synthase (iNOS) enzyme 
in RAW 264.7 cells (Utaisincharoen et al., 2002). Additionally, both NO and IL-ip 
mRNA synthesis has been observed in avian macrophages in a sequence specific 
manner following CpG stimulation (He et al., 2003). Other studies also suggest that 
the degree of macrophage activation by CpG may vary according to the class of CpG 
used and the chemical content of the ODN backbone (Roberts et al., 2005). 
Collectively, all these studies indicate the macrophage can be directly activated by 
CpGs to release a multitude of inflammatory factors.
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5.1.5. Viral infections in the lung
Viral infections of the upper respiratory tract and lung are extremely common with a 
wide variety of viruses being able to colonise the lung surfaces. The positioning and 
prevalence of macrophages throughout the lung, along with their repertoire of PRRs, 
make them key cell-types in the initiation of the anti-viral response (Malmgaard et a l, 
2004). Recently, AMs have been identified as the primary source of IFN-a following 
infection with the RNA virus Newcastle disease virus in a RIG-I dependent manner 
(Kumagai et al, 2007). Interestingly, removal of AMs led to pDCs becoming the 
dominant IFN-a producers further suggesting that AMs typically suppress the 
functions of other cell-types (Kumagai et al., 2007). Still, the role of AMs in viral 
infection may vary according to the virus itself and the interaction between viral 
PAMPs and PRRs. In addition, differences in the virus’ ability to fuse to host cells, 
replicate and counteract the immune response may also affect the role of AMs (Van 
Reeth & Adair, 1997). This is supported by studies that find AMs promote 
inflammation when infected with influenza A virus (Lehmann et a l , 1996) and 
adenovirus (Zsengeller et a l , 2000) whereas they may act to suppress the immune 
response to VACV strain WR (Rivera et a l, 2007). HSV-2 infected macrophages can 
be activated through TLR-dependent and independent pathways and studies show 
active viral replication inside the cell boosts the IFN-a/p response (Malmgaard et a l,
2004). This work suggests that interactions between the virus and the cell surface of 
macrophages may not be enough to induce a full inflammatory response and thus the 
role of the AM may also vary due to virus cell tropism. Studies have not shown the 
role of the AM during infection with VACV strain IHD, nor examined how intranasal 
delivery of CpGs may affect the function of AMs prior to infection with VACV. 
However, studies have suggested that mice depleted of macrophages are unable to
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control VACV infections due to impaired virus clearance and antigen presentation 
(Karupiah et al., 1996).
5.1.6. CpG-B 7909 and CpG-B 10103
The in vivo studies detailed in Chapters 3 and 4 of this thesis were all conducted using 
the B-class CpG-B 7909. However, the progression of CpG-B 7909 into phase III 
clinical trials for cancer research in September 2005 resulted in the withdrawal of 
CpG-B 7909 from the majority of these studies. Consequently, CpG-B 10103 was 
used as an alternative B-class CpG throughout the in vitro work detailed in this 
chapter.
5.2. Aims of this chapter
The intranasal delivery of CpG in the VACV model has had a marked protective 
effect. As alveolar macrophages are one of the first cell types to encounter inhaled 
material, their response to the delivery of CpGs may be key to the initiation of this 
protective response. This chapter examines the effect of CpG stimulation on different 
macrophage populations using both primary cells and in vitro cell lines and different 
classes of CpGs. In addition, the growth of VACV in two macrophage cell lines is 
investigated in the context of pre-stimulation with CpGs.
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5.3. Results
5.3.1. TLR9 is present on primary macrophages
To assess whether TLR9 is present on mouse AMs, bronchoalveolar lavage samples 
from Balb/C mice were obtained using the protocol detailed in section 2.6.4. In an 
initial experiment, BAL samples from 2 mice were taken and analysed separately for 
the presence of TLR9. Briefly, lavage samples were aliquoted onto a 96-well plate 
and left to adhere overnight in RPMI medium supplemented with 10% (x volume) 
FCS and 1% (x volume) PSG. The following morning, supernatants were carefully 
removed to leave only adherent cells. These remaining cells were processed for RT- 
PCR. Results from this experiment revealed that TLR9 transcript was clearly 
detectable in both mouse samples (Figure 5.1).
In a follow-up experiment to re-affirm expression of TLR9 on primary alveolar 
macrophages, BAL samples were taken from 4 Balb/C mice and then pooled. A small 
aliquot of crude BAL was then taken away for immunohistological staining using the 
Hema ‘Gurr’ rapid stain set which suggested that approximately 90% of cells 
recovered were alveolar macrophages (Figure 5.2a; Figure 5.2b). The remainder of 
the BAL sample was plated onto a 96-well plate, supplemented with medium and 
incubated overnight at 37°C. The following morning, any non-adherent cells were 
removed to leave only macrophages, and wells replenished with either fresh medium 
or stimulated in triplicate with 75 pg/ml CpG-B 10103 or 75 pg/ml CpG-sC 10109 for 
five hours. After five hours stimulation, supernatants were removed and cells 
analysed for expression of TLR9 and TNF-a via RT-PCR. Expression of TLR9 was 
once again clearly detected (Figure 5.3a) and interestingly, the expression of TNF-a 
was found to differ between unstimulated and CpG-stimulated samples (Figure 5.3b).
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Figure 5.1. Expression of TLR9 on primary alveolar macrophages. Figure 
illustrates the expression of TLR9 and the endogenous control gene 18s RNA, 
analysed via RT-PCR on an ABI Taqman 7000 machine. Samples analysed in 
triplicate from two separate BAL samples obtained from Balb/C mice.
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Figure 5.2. Immunohistological staining of BAL samples. Crude lavage 
preparations were stained using eosin and methylene blue. Approximately 90% of 
cells were assessed as being alveolar macrophages, (a) x400 (b) xlOOO magnification.
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Figure 5.3. Primary alveolar macrophages are responsive to CpG. (a) TLR9 
was detectable on primary alveolar macrophages from pooled Balb/C mouse BAL 
samples via RT-PCR analysis, (b) Expression of both TLR9 and TNF-a were found to 
increase relative to unstimulated controls (baseline) after 5 hours stimulation with 
75pg/ml CpG-B 10103 and CpG-sC 10109.
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Here, CpG-B 10103 was able to induce a five-fold increase in the expression of TNF- 
a relative to medium control wells, whilst CpG-sC induced more than an 18-fold 
increase in expression relative to medium. This suggested the administration of CpGs 
to primary AM cultures could induce a pro-inflammatory response. In addition, the 
expression of TLR9 on these cells differed from unstimulated samples, so that cells 
stimulated with CpG-10109 induced an approximate 2-fold increase in TLR9 
expression (Figure 5.3b).
5.3.2. TLR9 expression in MH-S and J774 macrophage cell-lines upon 
stimulation with CpG
The difficulty of obtaining high numbers of AMs from BAL preparations resulted in 
the testing of two in-vitro cell-lines as potential models for ex-vivo AMs. Two 
different cell-lines, an alveolar macrophage cell-line (MH-S), and a blood 
monocyte/macrophage cell-line (J774), were obtained from ECACC (HPA, UK). 
Initially, the expression of TLR9 on these two cell-lines was examined via RT-PCR. 
MH-S and J774 macrophages were seeded onto 96-well plates at a concentration of 
lx l0 6/ml, incubated overnight and stimulated in triplicate with a variety of different 
classes of CpG. Total RNA was extracted from cells after 1, 2, 5 and 24 hours 
stimulation with 75 pg/ml CpG. This experiment was then repeated twice, giving a 
total of three separate experiments for each time-point. RT-PCR analysis of samples 
confirmed the expression of TLR9 on both cell-lines. Results also suggested that 
expression of TLR9 was unaffected by CpG stimulation at any individual time-point 
(Figure 5.4). Interestingly, statistical analysis suggested that expression of TLR9 did 
vary significantly between time-points (p<0.05). However, since expression never
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Figure 5.4. Changes in expression of TLR9 mRNA. MH-S (M) and J774 (J) 
macrophages were stimulated with 75pg/ml CpG and analysed via RT-PCR. Graphs 
show changes in TLR9 gene expression relative to unstimulated medium control wells 
after (a) 1 hour (b) 2 hours (c) 5 hours (d) 24 hours CpG stimulation. Experiments 
performed in triplicate, values represent geometric mean of three separate 
experiments. Error bars ± SEM.
No significant differences between CpGs and cell-line specific non-CpG 2137 
determined by three-way ANOVA with Bonferroni’spost-tests.
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shifted more than 2-fold in either direction relative to unstimulated samples, the 
biological significance of this variance is uncertain.
Having established both in vitro macrophage cell-lines possessed transcripts for 
TLR9, the physical expression of TLR9 protein on these cell-lines was investigated. 
Intracellular expression of TLR9 was assessed via flow cytometry using a polyclonal 
FITC conjugated antibody for TLR9 and a rat IgG2a isotype control. Both MH-S and 
J774 cells were stimulated in 24-well plates for 24 hours with the two different CpGs, 
CpG-B 10103 or CpG-sC 10109. Results confirmed expression of TLR9 protein and 
failed to show any noticeable shift in TLR9 expression following CpG stimulation 
(Figure 5.5a-b). Expression of CD54 on both cell-lines was examined during these 
experiments as a positive control for cellular activation. Stimulation with either CpG 
resulted in a prominent shift in CD54 fluorescence consistent with cellular activation 
(Figure 5.5c-d).
5.3.3. The in vitro stimulatory properties of CpG-B 7909 are comparable to 
CpG-B 10103
The expression of TLR9 on both MH-S and J774 macrophage cell-lines suggested 
that these cells may be suitable for modelling the response of primary macrophages to 
CpG stimulation. To examine whether the properties of CpG-B 10103 were 
comparable to CpG-B 7909, a comprehensive analysis of cytokine/chemokine 
expression and NO release from both MH-S and J774 macrophages was undertaken. 
Results suggested that CpG-B 7909 and CpG 10103 stimulated macrophages equally 
as determined by RT-PCR, CBA and NO release (p>0.05). Statistical interaction plots 
for the analysis of cytokine data obtained from RT-PCR and CBA are represented in
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Figure 5.6. Here, average values obtained from MH-S and J774 macrophages 
following CpG-B 10103 or CpG-B 7909 stimulation are seen to overlap almost 
completely indicating very close similarity between them. Similarly, Figure 5.7 
illustrates the near identical effects of CpGs 7909 or 10103 on NO output from MH-S 
and J774 macrophages. Collectively, these results suggest that CpG 10103 is a 
suitable substitute for examining the stimulatory effects of CpG-B 7909 on 
macrophages in vitro.
5.3.4. Release of NO by MH-S and J774 macrophages following stimulation 
with CpG
The release of oxygen intermediates and nitrogen derivatives such as NO, are well 
characterised killing mechanisms employed by macrophages. Following activation, 
NO is released into the local environment and is readily detectable by quantification 
of nitrite levels as detailed in section 2.1.2. MH-S and J774 macrophages were seeded 
onto 96-well plates at a concentration of lx l0 6/ml, incubated overnight and stimulated 
in triplicate with a variety of different classes of CpG at a range of concentrations (5- 
100 pg/ml). Measurements of NO were taken at 24, 48 and 72 hour time-points. This 
experiment was then repeated twice, giving a total of three separate experiments for 
each time-point.
5.3.4.I. A-class and semi-soft C-class CpGs stimulate greater NO responses than 
B-class and C-class CpGs in MH-S but not J774 macrophages
MH-S and J774 macrophages were stimulated with different CpGs and analysed for 
NO release 24 hours post-stimulation via Griess reaction (Figure 5.8). CpG-A (2336) 
and CpG-sC (10109) induced significantly more NO in MH-S macrophages than
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responses in macrophages. Macrophage cell-lines MH-S and J774 were treated with 
either CpG 10103 or CpG-B 7909 and assessed for cytokine output via: (a) CBA (b) 
RT-PCR.
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Figure 5.8. Release of NO as determined by nitrite measurement using the 
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CpG-C (10101) and CpG-B (10103) and non-CpG control 2137 (p<0.001) (Figure 
5.8a). Levels of NO induced by ODNs CpG-B, CpG-C and non-CpG 2137 were 
comparable with un-stimulated medium control wells. Maximum release of NO in 
these experiments was achieved irrespective of CpG concentration for all CpGs with 
the exception of CpG-A 2336 which induced maximum NO at higher concentrations. 
J774 macrophages did not share the same profile of NO production following CpG 
stimulation as that seen in MH-S macrophages. A-class CpG 2336 failed to induce 
significantly more nitric oxide than 10101, 10103 or 2137. However, 10109 was still 
able to induce modest levels of NO production, albeit significantly less than that 
produced by MH-S macrophages (p<0.001). This pattern was identical in experiments 
left to run for 48 hours (Figure 5.8b) and 72 hours (Figure 5.8c).
5.3.4.2. Lower concentrations of CpG do not induce higher concentrations of NO
Some classes of CpG have been reported to stimulate cells in a concentration 
dependent manner resulting in a bell-shaped response curve (Jurk et a l , 2004). 
Therefore, lower concentrations (75 pg/ml-0.625 pg/ml) of CpG were investigated 
using NO as a measurement of macrophage stimulation. Lower concentrations of CpG 
did not result in any enhanced NO production (Figure 5.9). These findings also 
confirmed results seen in earlier experiments that saw greater responses induced by 
CpG-A 2336 and CpG-sC 10109 in MH-S macrophages. The prominent release of 
NO induced by CpG-A and CpG-sC in earlier experiments prompted the inclusion of 
an additional control non-CpG 2243 which unlike control-ODN 2137, contains a 
mixed phosphorothioate-phosphodiester backbone. Previous studies have observed a 
non-specific stimulatory effect of oligonucleotide backbone chemistry on the 
activation of macrophages (Roberts et a l , 2005). No NO response was induced by
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Figure 5.9. Release of NO by MH-S and J774 macrophages following 
stimulation with low concentrations of CpG. Macrophage cell lines (a) MH-S and 
(b) J774 were stimulated in vitro with varying concentrations (75-0.625 pg/ml) of 
different classes of CpG-ODNs. Fresh medium was used as a negative control. Non- 
CpG control ODNs 2137 and 2243 were assessed against CpGs to determine the non­
specific effect of ODN backbone chemistry. Assays performed in triplicate and graphs 
represent an average of at least 2 experiments. Error bars ± 95% CL *Significance 
(p<0.001) between CpG-ODNs and control non-CpG 2243.
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control non-CpG 2243 in either MH-S or J774 cells suggesting the responses initiated 
by CpG-A 2336 and CpG-sC 10109 were not due to the chemical composition of the 
oligonucleotide backbone.
5.3.5. Chemokine and cytokine production by MH-S and J774 macrophage 
cell-lines after stimulation with different classes of CpGs
The activation of macrophages can be characterised by the secretion of pro- 
inflammatory cytokines and chemokines (Sibille & Reynolds, 1990). This experiment 
studied the mRNA synthesis and secretion of the chemokine CCL2, as well as the 
pro-inflammatory cytokines TNF-a and IL-6 in vitro in MH-S and J774 macrophage 
cell-lines following stimulation with CpG. Cells were grown to a concentration of 
lx l0 6 cells/ml, incubated overnight and stimulated in triplicate with different classes 
of CpG at a concentration of 75 pg/pl. At times 1, 2, 5 and 24 hours, supernatants for 
each time-point were merged and frozen for analysis of protein by CBA. Total RNA 
was extracted immediately from cells as detailed in Section 2.3.1 for analyses by RT- 
PCR. This experiment was then repeated twice, giving a total of three separate 
experiments.
5.3.5.I. CCL2
Expression of CCL2 mRNA in MH-S cells and J774 cells after CpG stimulation is 
represented in Figure 5.10. Here, CCL2 mRNA was found to be significantly 
upregulated over time relative to un-stimulated control wells in both MH-S and J774 
cells (p<0.001). Stimulation with CpG-A 2336 or CpG-sC 10109 resulted in the most 
prominent induction of CCL2 expression (p<0.001), inducing a rapid up-regulation of 
CCL2 as seen at the 2 hour and 5 hour time-points (Figure 5.10b and 5.10c). No
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Figure 5.10. Changes in chemokine CCL2 mRNA expression. MH-S (M) and 
J774 (J) macrophages were stimulated with 75pg/ml CpG and analysed via RT-PCR. 
Graphs show changes in gene expression relative to unstimulated medium control 
wells after (a) 1 hour (b) 2 hours (c) 5 hours and (d) 24 hours CpG stimulation. 
Experiments performed in triplicate, values represent geometric mean of three 
separate experiments. Error bars ± SEM.
Significant differences between CpGs and cell-line specific non-CpG 2137 determined 
by three-way ANOVA with Bonferroni’spost-tests and represented as:
* p<0.05, * * p<0.01, * * * p<0.001.
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significant difference in the synthesis of CCL2 was found between the two cell-lines 
in response to CpG stimulation (p>0.05).
Figure 5.11 illustrates the levels of CCL2 protein in the supernatants from CpG 
stimulated MH-S macrophages and J774 macrophages as determined by CBA 
analysis. Both cell-lines secreted very high levels of CCL2 and no significant 
difference between the amounts of CCL2 produced was determined statistically 
(p=0.487). Macrophages stimulated with CpGs 2336 or 10109 did not secrete more 
CCL2 than any other CpG as was seen at the level of mRNA transcription. 
Unstimulated medium control released equivalent amounts of CCL2 as CpG 
stimulated macrophages. This suggests macrophages do not require stimulation with 
CpG to secrete CCL2 in vitro.
5.3.5.2. TNF-a
Changes in the expression of TNF-a mRNA in MH-S cells and J774 cells following 
stimulation with CpG can be seen in Figure 5.12. Expression of TNF-a altered 
significantly over time (p=0.017) with CpGs 2336 or 10109 increasing the expression 
of TNF-a mRNA most significantly throughout the first 5 hours of stimulation 
(Figure 5.12 a-c). The effects of CpG stimulation on TNF-a expression were 
comparable between MH-S cells and J774 cell-lines (p=0.627).
Figure 5.13 illustrates the detection of TNF-a protein levels in MH-S and J774 
macrophages. These results show clear differences between MH-S and J774 secretion 
of TNF-a with J774 cells secreting significantly more TNF-a over time (p<0.001).
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Figure 5.11. Changes in chemokine CCL2 protein release. MH-S (M) and J774 
(J) macrophages were stimulated with 75 pg/ml CpG and analysed via CBA. Graphs 
show levels of CCL2 (pg/ml) in supernatants of macrophage wells stimulated with 
CpGs 2336, 10103, 10101, 10109 and 2137 alongside unstimulated medium control 
wells after (a) 1 hour (b) 2 hours (c) 5 hours (d) 24 hours stimulation. Experiments 
performed in triplicate, values represent geometric mean of three separate 
experiments. Error bars ± SEM.
No significant differences between CpGs and cell-line specific non-CpG 2137 
determined by three-way ANOVA with Bonferron ’sipost-tests.
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Figure 5.12. Changes in pro-inflammatory TNF-a cytokine mRNA expression.
MH-S (M) and J774 (J) macrophages were stimulated with 75pg/ml CpG and 
analysed via RT-PCR. Graphs show changes in gene expression relative to 
unstimulated medium control wells after (a) 1 hour (b) 2 hours (c) 5 hours and (d) 24 
hours CpG stimulation. Experiments performed in triplicate, values represent 
geometric mean of three separate experiments. Error bars ± SEM.
Significant differences between CpGs and cell-line specific non-CpG 2137 determined
by three-way ANOVA with Bonferroni’spost-tests and represented as:
* p<0.05, **p<0.01, ***p<0.001.
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Figure 5.13. Changes in pro-inflammatory TNF-a protein release. MH-S (M) 
and J774 (J) macrophages were stimulated with 75 pg/ml CpG and analysed via CBA. 
Graphs show levels of TNF-a (pg/ml) in supernatants of macrophage wells stimulated 
with CpGs 2336, 10103, 10101, 10109 and 2137 alongside unstimulated medium 
control wells after (a) 1 hour (b) 2 hours (c) 5 hours (d) 24 hours stimulation. 
Experiments performed in triplicate, values represent geometric mean of three 
separate experiments. Error bars ± SEM.
Significant differences between CpGs and cell-line specific non-CpG 2137 determined
by three-way ANOVA with BonferronVspost-tests and represented as:
* p<0.05, **p<0.01, * * * p<0.001;
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CpGs 2336 or 10109 stimulation resulted in significantly more TNF-a release than 
other CpGs (p<0.001) and this was true for both cell types.
5.3.5.3. IL-6
IL-6 mRNA expression in MH-S and J774 macrophages differed significantly 
following CpG-stimulation. Stimulation of J774 macrophages with CpG resulted in 
the up-regulation of significantly more IL-6 than that induced in MH-S macrophages 
(p<0.001) (Figure 5.14). Over the course of the experiment, the up-regulation of IL-6 
was most significantly induced by CpG-A 2336 or CpG-sC 10109 (p<0.001) and 
peaked after 5 hours stimulation.
Protein levels of IL-6 are represented in Figure 5.15. Very little IL-6 was detectable 
within the first 2 hours of CpG stimulation (Figure 5.15 a-b). By 5 hours, release of 
IL-6 was most significant (p<0.001) in macrophages stimulated with CpG-A 2336 or 
CpG-sC 10109 (Figure 5.15c) and this was observed after 24 hours (Figure 5.15d). 
Analysis of IL-6 protein levels revealed that J774 cells secreted significantly more IL- 
6 than MH-S cells (p<0.05).
5.3.6. Replication of VACV in unstimulated MH-S and J774 macrophages
Previous experiments have shown that MH-S and J774 macrophages responded 
differently to CpG stimulation as measured by cytokine and NO production. To 
determine how CpG-treated macrophages responded to infection with VACV, it was 
first necessary to establish whether MH-S or J774 macrophages possessed an intrinsic 
ability to restrict VACV replication. An initial experiment was performed to assess 
the replication of VACV in unstimulated macrophages. Macrophages were incubated
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Figure 5.14. Changes in pro-inflammatory cytokine IL-6 mRNA expression.
MH-S (M) and J774 (J) macrophages were stimulated with 75pg/ml CpG and 
analysed via RT-PCR. Graphs show changes in gene expression relative to 
unstimulated medium control wells after (a) 1 hour (b) 2 hours (c) 5 hours and (d) 24 
hours CpG stimulation. Experiments performed in triplicate, values represent 
geometric mean of three separate experiments. Error bars ± SEM.
Significant differences between CpGs and cell-line specific non-CpG 2137 determined
by two-way ANOVA with Bonferronipost-tests and represented as:
* p<0.05, **p<0.01, * * * p<0.001;
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Figure 5.15. Changes in pro-inflammatory IL-6 protein release. MH-S (M) and 
J774 (J) macrophages were stimulated with 75 pg/ml CpG and analysed via CBA. 
Graphs show levels of IL-6 (pg/ml) in supernatants of macrophage wells stimulated 
with CpGs 2336, 10103, 10101, 10109 and 2137 alongside unstimulated medium 
control wells after (a) 1 hour (b) 2 hours (c) 5 hours (d) 24 hours stimulation. 
Experiments performed in triplicate, values represent geometric mean of three 
separate experiments. Error bars ± SEM.
Significant differences between CpGs and cell-line specific non-CpG 2137 determined
by two-way ANOVA with Bonferronipost-tests and represented as:
* p<0.05, **p<0.01, * * * p<0.001;
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overnight in 24-well plates at a concentration of 1 x 106 cells/ml and infected the 
following morning with 5 x 106 pfu VACV. Virus titres were then determined at time 
1, 2, 5, 8, 12, 15, 18, 24 and 36 hours post infection as detailed in Section 2.2. VACV 
growth curves in each cell-line are represented in Figure 5.16 with each time-point 
representing the mean of three independent experiments. These studies found no 
significant difference in the ability of VACV to replicate in either macrophage cell- 
line over a 36 hour period (p=0.84) (Figure 5.16).
5.3.7. Replication of VACV in pre-stimulated MH-S and J774 macrophages
Replication of VACV in both MH-S and J774 macrophages was assessed following 
pre-stimulation of cells with a down-selected group of CpGs. As the most 
immunostimulatory CpG in our initial studies, CpG-sC 10109 was compared against 
CpG-B 10103, a similar CpG to CpG-B 7909 which conferred protection in the pre­
exposure work in vivo (detailed in Chapter 3). Briefly, both MH-S and J774 
macrophages were seeded at a concentration of lx l0 6 cells/ml onto 24-well plates and 
left to adhere overnight. The following morning, cells were stimulated in triplicate 
with 75 pg/ml of either CpG-sC 10109 or CpG-B 10103 for 24 hours prior to 
infection the following day with 5x106 pfu VACV. Viral titres were then calculated at 
6, 12 and 24 hours and three independent experiments performed. Stimulation of cell- 
lines 24 hours prior to viral infection significantly effected the growth of VACV 
(Table 5.1). The extent of VACV inhibition was found to vary dramatically between 
cell-types and the class of CpG used to stimulate macrophages. Stimulation of MH-S 
macrophages with CpG-B 10103, and particularly CpG-sC 10109, resulted in 
significantly lower titres of VACV at both 12 and 24 hour time-points compared to 
unstimulated control samples (Figure 5.17a.). Here, stimulation with CpG-sC was
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Figure 5.16. Growth of VACV in MH-S and J774 macrophage cell lines. Growth 
of VACV was determined at times 1, 2, 5, 8, 12, 15, 18, 24 and 36 hours. Data shown 
represents the geometric mean titre of three separate experiments. Error bars indicate 
± SEM. No significant difference determined between cell-lines as determined by 
Two-way Anova with Bonferroni’s post-tests.
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Cell Comparison Time 
1 6 12 24
MH-S Medium: 10103 _ * * * *
MH-S Medium: 10109 - *** ***
MH-S 10103:10109 - - **
J774 Medium: 10103 - - *
J774 Medium: 10109 - - ***
J774 10103:10109 - - -
MH-S and J774 Medium: Medium - - -
Table 5.1. Both CpG-B 10103 and CpG-sC 10109 significantly restrict the 
growth of VACV in MH-S and J774 macrophages. Table indicates level of 
significance as determined by pair-matched two-way ANOVA of titres calculated 
from three separate experiments. Level of significance indicated by (-) n/s, (*) p<0.05, 
(**) p<0.01, (***) pcO.OOl.
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Figure 5.17. Growth of VACV in MH-S and J774 macrophage cell lines pre­
stimulated with CpG. Growth of VACV was determined at time 6, 12 and 24 hours 
after pre-stimulation with 75pg/ml CpG-B 10103 and CpG-sC 10109 in (a) MH-S 
and (b) J774 macrophages. Data shown represents geometric mean of three separate 
experiments. Error bars indicate ± SEM. Significance determined by pair-matched 
two-way ANOVA of titres calculated from three separate experiments.
f  10103:Medium p<0.05; § 10109:Mediump<0.05; $ 10103:10109 p<0.05.
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found to be significantly more effective at limiting the growth of VACV than CpG-B 
10103 (p<0.01). Both CpG-B 10103 and CpG-sC 10109 were also able to reduce 
VACV viral titres significantly in J774 cells compared to medium controls although 
more modestly than in MH-S cells (and only at the 24 hour time-point) (Figure 
5.17b). Interestingly, no significant differences were found between CpGs 10103 and 
10109 in their ability to restrict the replication of VACV in J774 cells. Overall, these 
results indicated that at 24 hours post VACV-infection, viral titres were most 
significantly restricted in MH-S macrophages when stimulated with CpG-sC 10109. 
No significant differences were observed in VACV titres between stimulated and un­
stimulated MH-S or J774 macrophages during the first six hours of infection (Table
5.1). This suggests the reduction in viral titres at 12 and 24 hours was unlikely to be a 
result of VACV failing to infect cells that had been pre-stimulated with CpG and was 
instead a result of CpG stimulation.
5.3.8. The effect of NO inhibition on VACV replication in MH-S and J774 
macrophages
The initial investigation into differences between MH-S and J774 macrophages 
indicated the release of NO, following stimulation with CpG-sC 10109, was perhaps 
the most striking difference between the two cell-lines (Figure 5.8). As MH-S 
macrophages pre-stimulated with 10109 released significantly more NO than J774s, 
and 10109 pre-stimulated MH-S cells could restrict the growth of VACV, the effect of 
nitric oxide on VACV was investigated.
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5.3.8.1. The inhibition of NO from MH-S macrophages
To assess whether the release of NO was responsible for limiting the growth of 
VACV in MH-S cells, it was first necessary to optimise the inhibition of NO synthesis 
in MH-S cells using the global nitric oxide synthetase inhibitor L-NMMA. Therefore, 
initial experiments were performed to determine the optimum time at which to 
introduce the inhibitor to MH-S cells, and the most effective dose to use. Figure 5.18 
illustrates the inhibition of NO release from MH-S macrophages as determined by 
Griess reaction at 24 hours post-stimulation with CpG-sC 10109. Results show that 
the introduction of L-NMMA at the same time as CpG stimulation was most effective 
at inhibiting the synthesis of NO (Figure 5.18a). The optimum dose of L-NMMA was 
determined from three separate experiments introducing L-NMMA at the same time 
as CpG-sC 10109, and again measuring NO release at 24 hours (Figure 5.18b). From 
these experiments, an optimum concentration of 4000 pMol was determined.
5.3.8.2. Inhibition of NO does not alter the growth of VACV in CpG stimulated 
macrophages
The effect of NO inhibition prior to macrophage infection with VACV was 
investigated in MH-S cells. Macrophages were seeded onto 24-well plates at a 
concentration of lx l0 6 cells/ml and left to adhere overnight. Cells were then 
stimulated in triplicate with 75 pg/ml CpG-sC 10109, or co-incubated with 75 pg/ml 
CpG-sC 10109 and 4000 pMol NMMA for 24 hours. These wells were run alongside 
macrophages that were incubated alone with 4000 pMol L-NMMA, or replenished 
with fresh medium. After 24 hours, an aliquot of medium was removed from each 
well for analysis of NO levels to confirm NO inhibition. All wells were then infected 
with 5xl06 pfu VACV and titres calculated at 1, 12 and 24 hours post-infection.
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Figure 5.18. Effect of NO inhibitor L-NMMA on release of nitric oxide in MH- 
S macrophages following 24 hour stimulation with CpG-sC 10109. (a) 0-2000 
pMol L-NMMA was added to wells in triplicate either 24 hours prior, 2 hours prior or 
concomitant to 75 pg/ml CpG-sC 10109 stimulation, (b) Complete dose range of L- 
NMMA 0-4000 pMol. Cells were replenished with fresh medium or were stimulated 
with 75 pg/ml CpG-sC 10109 for 24 hours. Graph representative of three independent 
experiments. Error bars represent ± 95% confidence limits.
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VACV titres in macrophages supplemented with L-NMMA and CpG-sC 10109 did 
not differ significantly from macrophages given CpG alone (p>0.05) (Figure 5.19). 
Addition of CpG in both of these groups significantly reduced VACV titres compared 
to unstimulated control wells (p<0.001) suggesting that the restriction of VACV titres 
in CpG stimulated MH-S macrophages is not a result of NO production.
5.3.9. CpGs prevent apoptosis in both MH-S and J774 macrophage cells lines
NO has previously been shown to induce apoptosis in macrophages that have been 
stimulated with IFN-y and LPS (Sarih et al., 1993). Given the strength of the NO 
response generated in MH-S macrophages by CpG-sC 10109, an experiment was 
planned to investigate whether the reduction in VACV titres seen in MH-S 
macrophages was a result of CpG-induced apoptosis prior to viral infection due to a 
high concentration of CpG. Therefore, both MH-S and J774 macrophages were 
stimulated with either CpG-B 10103 or CpG-sC 10109 for 24 hours and analysed 
using Annexin-V as a marker of apoptosis via flow cytometry. Stimulation of both 
macrophage cell-lines with CpG significantly reduced the percentage of cells that 
were either in the end stages of apoptosis, undergoing necrosis or already dead, 
relative to unstimulated samples (p<0.001) (Figure 5.20). No significant difference 
between class of CpG or cell-line was found in the percentages of apoptotic 
macrophages after 24 hours of stimulation (p>0.05).
5.3.10. CpG-sC 10109 is protective against VACV
The identification of CpG-sC 10109 as a potent stimulator of macrophages led to the 
examination of its ability to protect in the pre-exposure model of VACV infection. 
Groups of mice (n=6) were pre-treated with 75 pg CpG-sC 10109 on day -7, -3, or -1
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Figure 5.19. Effect of L-NMMA NO inhibition on growth of VACV in MH-S 
cells. Prior to infection with VACV, macrophages were incubated for 24 hours with 
RPMI medium (VACV), CpG-sC 10109 (VACV + 10109), CpG-sC 10109 and L- 
NMMA (VACV + 10109 + L-NMMA) or L-NMMA alone (VACV + L-NMMA). 
Growth of VACV was determined at time 1, 12 and 24 hours post-infection. Data 
shown represents geometric mean of three separate experiments. Error bars indicate ± 
SEM. Significance determined by pair-matched two-way ANOVA of titres calculated 
from three separate experiments.
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Figure 5.20. CpGs prevent apoptosis in both MH-S and J774 macrophages.
I
Staining of Annexin-V, a Ca -dependent phospholipid-binding protein, allows for 
identification of cells within a population that are actively undergoing apoptosis. MH- 
S macrophages were stained for Annexin-V and 7-AAD 24 hours after (a) fresh 
medium replacement (b) 75pg/ml CpG-B 10103 stimulation (c) 75 pg/ml CpG-sC 
10109 stimulation. Apoptosis in J774 macrophages was also examined 24 hours after 
(d) fresh medium replenishment (e) 75pg/ml CpG-B 10103 stimulation (f) 75pg/ml 
CpG-sC 10109 stimulation. Values in quadrants represent % of cells gated ± SEM. 
Figures representative of three separate experiments.
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relative to intranasal infection with 10 MLD VACV. A separate group of mice were 
treated with CpG-sC 10109 and challenged with VACV concomitantly on day 0. 
Control groups included mice treated with CpG-B 7909 on day -3 and a group given 
PBS. Results represented in Figure 5.21 show that pre-treatment with CpG-sC 10109 
provided complete protection when given 7 days prior to challenge and 80% 
protection when given on days -3 or -1. Treatment given on the day of challenge 
failed to confer any protection against virus infection. Mice given CpG-B 7909 on day 
-3 of infection as a positive control were fully protected.
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Figure 5.21. CpG-sC 10109 confers protection against VACV. Graph shows 
survival data of mice (n=6) treated intranasally with 75 pg doses of CpG or PBS, prior 
to challenge on day 0 with 10 MLD VACV infection.
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5.4. Discussion
A number of studies have suggested that the response of macrophages during 
infection depends significantly on the type of macrophage encountered by the 
invading organism (Gordon & Taylor, 2005; Laskin et a l , 2001; Dorger et a l, 2001). 
This makes the comparison of different macrophage responses important in 
understanding their likely contribution to the immune response. The development of 
in vitro macrophage cell-lines has enabled researchers to model the role of primary 
macrophages without the need for extensive animal use. Hence, the use of the MH-S 
macrophage cell-line has become a well-established tool for studying the alveolar 
macrophage (Mbawuike & Herscowitz, 1989; Sankaran & Herscowitz, 1995). Using 
this cell-line as a model for primary alveolar macrophages, the studies presented 
herein have highlighted a number of differences between MH-S macrophages and the 
non-alveolar macrophage cell-line J774 following stimulation with different classes of 
CpG. In addition, the investigation of CpGs that combine the characteristic features of 
individual classes has identified the newly designed semi-soft CpG 10109 as a potent 
stimulator of macrophages with antiviral properties.
Macrophages actively participate in the inflammatory response by releasing 
cytokines, chemokines and a range of other inflammatory mediators such as reactive 
oxygen and nitrogen species. Studies using alveolar macrophages (AMs) have shown 
them to be quiescent cells that are functionally regulated by alveolar epithelial cells 
through the expression of the TGF-p, activating integrin avP6 and the constitutive 
release of anti-inflammatory cytokines such as IL-10 (Fernandez et al., 2004; 
Takabayshi et al., 2006). Once activated, AMs play a fundamental role in regulating 
lung inflammation by being able to act as both initiator and suppressor of
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inflammatory responses (Holt, 1986; Oshikawa & Sugiyama, 2003; Ogle et al., 1994; 
Holt et al., 1993; Strickland et al., 1993). Whilst, many macrophage sub-types 
recognise and respond directly to CpG stimulation (Stacey et al., 1996), the ability of 
alveolar macrophages to respond to CpGs has been a subject of some controversy. 
Several groups have documented the successful activation of primary alveolar 
macrophages using CpG alone or in combination with IFN-y or LPS (Huang et al., 
2005; Fernandez et a l, 2004), whilst others have suggested TLR9 expression on 
alveolar macrophages may be impaired and incapable of responding fully to binding 
of CpG (Suzuki et al., 2005).
The results within this chapter have shown that primary AMs from Balb/C mice 
express TLR9 and suggest that they can be induced to up-regulate synthesis of TNF-a 
following stimulation with CpGs. In addition, both alveolar and non-alveolar 
macrophage cell-lines were found to express TLR9 and could be induced to secrete 
NO and up-regulate expression of pro-inflammatory cytokines following CpG 
stimulation. The release of NO by macrophages is a key effector mechanism for the 
killing of pathogens. NO also serves a dual role in the regulation of macrophage 
apoptosis and cell death (Bosca et a l, 2005). Here, results suggest a marked 
difference in the ability of different classes of CpG to induce NO release from 
macrophage cell-lines. CpG-A 2336 and CpG-sC 10109 were found to induce potent 
NO responses from the MH-S macrophage cell-line compared to all other classes of 
CpG investigated. These two CpGs induced comparable amounts of NO over the 
three time-points investigated although the earlier kinetics of NO production was not 
investigated. Previously, Sester and colleagues found that phosphorothioate (PS) 
CpGs were more potent than their phosphodiester (PO) counterparts in the induction
238
of pro-inflammatory cytokines such as IL-12 from murine Raw 264.7 macrophages 
and IFN-primed bone marrow derived macrophages (Sester et a l, 2000). In these 
studies, ODNs with a pure PS-backbone (CpG-B, CpG-C), were less capable of 
activating macrophages than those with a mixed PS-PO backbone. The presence of a 
complete PS-backbone within a CpG increases nuclease resistance and enhances 
cellular binding and uptake (Zhao et a l, 1993; Stein et a l, 1988). Of the CpGs 
investigated here, it is worth noting that CpG-A 2336 and CpG-sC 10109 did not have 
a complete PS backbone, and yet treatment with these CpGs resulted in enhanced 
stimulation.
The frequency and spacing of CpG motifs within a CpG, as well as the regions 
peripheral to the CpG motifs, are factors that contribute to the stimulatory effects of 
individual ODNs. Mixed ODN backbones are predominantly built with a PO 
backbone and modified 5’ and 3’ PS ends which are typically palindromic or 
complemented with poly-G motifs (Krieg, 2002). The inclusion of these regions 
peripheral to the central CpG motif has been shown to facilitate interactions between 
homologous regions on adjacent ODNs, promoting duplex formation that contributes 
to IFN-a induction (Kerkmann et a l, 2005; Vollmer et a l, 2004). Collectively, these 
properties have also been shown to improve cellular uptake and may help explain the 
ability of CpGs 2236 and 10109 to activate macrophages so effectively. This finding 
is not unique to macrophages, as ODNs with a mixed PS-PO backbone have also been 
reported to be more stimulatory for NK cells than pure PS or PO-backbones (Boggs et 
a l, 1997). Previous studies have observed a non-specific stimulatory effect of 
oligonucleotide backbone chemistry on the activation of macrophages (Roberts et a l,
2005). The inclusion of a control non-CpG with a mixed PS-PO background in these
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assays failed to induce NO from cells suggesting that enhanced NO production was 
unlikely to be a non-specific effect of a mixed PS-PO oligonucleotide backbone.
Interestingly, the extent of NO release was found to differ significantly between MH- 
S and J774 macrophages. Here, only CpG-sC 10109 was able to induce a mild NO 
response from the J774 macrophage cell-line. The reason for this difference in NO 
production between the two cell-lines is currently unclear. The release of NO from 
AMs has been well documented and has been shown to facilitate the down-regulation 
of immune responses via suppression of T-cell proliferation and pulmonary dendritic 
cell functions (Strickland et a l, 1993; Holt et al., 1993). Furthermore, it has been 
shown to exert a very strong influence on its own and other cells’ apoptotic pathways 
(Bingisser & Holt, 2001). The induction of apoptosis via NO is thought to involve the 
release of cytochrome c from the mitochondria and targeting of members of the BCL- 
2 family (Bosca et al., 2005). However, studies have suggested that macrophages are 
more resistant to the anti-apoptotic effects of NO than other cell-types which may 
prolong their ability to phagocytose invading organisms or prolong their influence on 
the outcome of infection. As such, stronger NO responses by alveolar macrophages in 
vivo and MH-S cells in vitro, may be a strategy to preserve macrophage numbers and 
cellular integrity. Previous studies have also indicated that AM preservation may act 
to control inflammation by phagocytic clearance of other local apoptotic or necrotic 
cells such as neutrophils (Haslett, 1999; Knapp et al., 2003). Here, stimulation of 
MH-S and J774 cells with CpG-sC 10109 and CpG-B 10103 prevented onset of 
apoptosis equally following 24 hours incubation despite differences in NO release. In 
contrast to previous studies, it was not possible to induce NO production from J774 
cells using B or C-class CpGs (Ghosh et al., 2001). This may be a result of the CpG
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motifs in our study being optimally designed to stimulate human cells (GTCGTT), 
rather than those motifs used in other studies that are characteristically more 
stimulatory for mouse cells (GACGTT) (Hartmann & Krieg, 2000).
No CpG class investigated throughout these studies was capable of altering the 
expression of TLR9 more than 2-fold on macrophage cell-lines over a 24 hour period. 
This suggests the immunostimulatory properties of CpG-A 2336 and CpG-sC 10109 
were not a result of TLR9 up-regulation or its cellular re-distribution. However, a 
limited examination of CpG-stimulated primary AMs suggested that CpG-sC 10109 
could induce a 2-fold increase in expression. This finding was the result of a single 
experiment using a pool of four BAL samples and would be strengthened by 
obtaining similar results in repeat experiments.
CpGs 2336 and 10109 were also found to promote more vigorous IL-6 responses than 
other CpGs in macrophage cell-lines. Statistical analysis revealed MH-S macrophages 
were induced to express significantly lower amounts of IL-6 than that from J774 
macrophages at both the level of mRNA transcript and quantity of translated protein. 
IL-6 is a potent inflammatory cytokine that has been suggested to regulate the 
transition from neutrophil to monocyte recruitment during the early stages of 
inflammation (Kaplanski et al., 2003). Given the proposed anti-inflammatory nature 
of alveolar macrophages, the weaker induction of IL-6 in MH-S cells, an alveolar 
macrophage cell line, may be a result of these cells limiting the degree of 
inflammation they evoke. As such, the release of IL-6 from non-alveolar macrophages 
(modelled here by J774 cells) in response to CpG stimulation may model monocyte 
recruitment to the site of infection in vivo or promote a more potent pro-inflammatory
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response. The MH-S cell-line secreted significantly less TNF-a protein than the J774 
macrophage cell-line, despite having synthesised comparable levels of TNF-a mRNA. 
TNF-a is a pleiotropic pro-inflammatory cytokine with a variety of diverse 
immunological functions which can promote cellular proliferation and activation or 
contribute to the onset of septic shock if over-expressed (Rahman & McFadden,
2006). If also true in an in vivo setting, the muted release of TNF-a from alveolar 
macrophages could help prevent an undesirable or excessive inflammatory response 
in the lung.
Phagocytic cells of the immune system such as macrophages play a central role in the 
control of virus infection and the replication of VACV in a number of these cell-types 
has been investigated (Humlova et a l , 2002; Rivera et al, 2007). Replication of 
VACV in both MH-S and J774 macrophages was comparable over the duration of 
repeated time-course experiments which indicated that these cells were equally 
permissive of VACV. Stimulation of both cell-lines with CpG was found to restrict 
viral titres over a 24 hour period, although this effect was far more pronounced in 
MH-S macrophages when stimulated with CpG-sC 10109. As both CpG-B 10103 and 
CpG-sC 10109 restricted apoptosis equally in both cell-lines, it is unlikely that the 
reduction of VACV titres in CpG-sC 10109 primed MH-S macrophages was due to 
enhanced macrophage apoptosis prior to VACV infection. As CpG-sC 10109 induced 
greater quantities of NO in MH-S and J774 cells, a role for NO in the inhibition of 
VACV replication was investigated using a global NO synthase inhibitor. Inclusion of 
the NO inhibitor failed to restore growth of VACV despite almost complete 
prevention of NO release. This suggested that CpG induced suppression of VACV 
replication was unrelated to NO production. Previous studies investigating the growth
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of VACV in macrophages have shown that IFN-y induced NO release from RAW 
264.7 macrophages can limit VACV replication and that its inhibition can restore 
VACV growth (Harris et a l, 1995; Karupiah & Harris, 1995; Karupiah et a l, 1993). 
The difference in these findings may be a consequence of CpGs and IFN-y activating 
different signaling pathways upon receptor binding or alternatively a difference in the 
ability of RAW 264.7 and MH-S macrophages to control VACV infection following 
stimulation. In these models, this is perhaps unlikely to involve enhanced 
phagocytosis of virus particles as no differences in VACV titres were found between 
cell-types in the early stages of infection. It is possible that the restriction of VACV 
replication following CpG stimulation could be a result of IFN-a production. IFN-a is 
a potent antiviral cytokine and its induction has been shown previously to restrict 
VACV replication in macrophage cell lines (Liu et a l , 2004). CpG-C ODNs are 
hybrids of CpG-A and CpG-B ODNs and are known to induce more potent IFN-a 
responses from pDCs than CpG-B (Jurk et al, 2004). A similar ability to induce IFN- 
a from macrophages may explain the enhanced ability of CpG-sC 10109 to restrict 
VACV replication over CpG-B 10103. Recently, Rivera and colleagues have also 
reported that MH-S macrophages can limit the replication of VACV in vitro, as well 
as demonstrating an essential role for primary AMs in vivo (Rivera et al, 2007).
Finally, the immunostimulatory properties of CpG-sC 10109 and its ability to restrict 
VACV replication in MH-S macrophages made it a candidate for testing in an in vivo 
model of VACV infection. Pre-treatment of Balb/C mice intranasally prior to an 
intranasal challenge with 10 MLD VACV was able to confer complete protection. 
Interestingly, protection with CpG-sC 10109 was optimal when given 7 days prior to 
challenge. This differs from the protection afforded by CpG-B 7909 which requires
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administration three days prior to challenge for optimum efficacy (Rees et al., 2005). 
These findings are not so surprising given the structural and immunomodulatory 
differences between the two classes of CpG. Here, significant differences between the 
two classes of CpG and their effects on macrophages have been presented. The effect 
of CpG-sC 10109 on cell-types other than macrophages has yet to be published by 
Coley Pharmaceuticals or any other group. However, it is conceivable that other 
significant differences exist between CpG-B and CpG-sC in the effects they exert on 
particular cell-types. Theoretically, the mixed oligonucleotide backbone of CpG-sC 
10109 is likely to induce a much stronger IFN-a response from cells such as pDCs 
than CpG-B 7909 (Kerkmann et al., 2005). In addition, CpG motifs present in CpG- 
sC 10109 that resemble those found in CpG-B ODNs, may stimulate B-cells to secrete 
pro-inflammatory cytokines and non-specific levels of IgM in a manner similar to 
CpG-B 7909 (Vollmer et al., 2004). Collectively, these effects are likely to contribute 
to a different, yet equally effective immune response to VACV infection. Recently, 
the use of CpG-sC 10109 as an adjuvant in anthrax studies has been investigated and 
reported to significantly boost the immunogenicity of the BioThrax® vaccine (Gu et 
al., 2007).
The results presented within this chapter suggest that primary alveolar macrophages 
do express TLR9 which makes them potential candidates for direct stimulation in 
vivo. The stimulation of an alveolar macrophage cell-line using CpGs results in the 
release of a variety of pro-inflammatory cytokines and chemokines as well as the 
secretion of NO and a reduction in macrophage apoptosis. In addition, pre-stimulation 
of MH-S macrophages in vitro with CpG establishes an antiviral state that restricts the 
replication of VACV independently of NO production over a 24 hour period. It is
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possible that some or all of these in vitro observations may also occur in vivo and 
contribute to the development of the protective immune response against VACV 
infection observed during infection of mice.
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Chapter 6: Summary Discussion
The threat of a new smallpox epidemic has dramatically increased efforts to identify 
new antiviral compounds against orthopoxviruses. Currently, the smallpox vaccine is 
cited by most countries as the post-exposure therapeutic of choice for use in the event 
of a smallpox epidemic. In this case, the vaccine would need to be administered 
within the first few days of infection to be effective. This may be problematic due to 
the incubation period of variola virus and delayed onset of characteristic symptoms 
(Stanford et al, 2007). More importantly, this vaccine carries with it a small but 
significant risk of serious complications (Fulginiti et al., 2003) which emphasises the 
need for new therapies. The restrictions placed upon research using variola virus, 
along with its exquisite host specificity, have led to the development of a variety of 
animal models to study smallpox pathogenesis and assess potential treatments. These 
have often used closely related viruses such as VACV in mouse models of infection, 
as has been used throughout this thesis.
The initiation of the inflammatory response requires recognition by host cells of a 
perceived threat from invading organisms. This recognition is often facilitated by 
PRRs of which the TLR-family are the best studied. Synthetic agonists have been 
developed that can initiate this inflammatory response and prove to be of huge 
therapeutic value (Krieg, 2006). One group of such synthetic TLR9 agonists, are CpG 
oligodeoxynucleotides which mimic immunostimulatory motifs present in prokaryotic 
DNA. A variety of classes of CpGs have been developed over recent years, each with 
unique characteristics and immunostimulatory properties (Vollmer et al., 2004). This 
thesis has investigated the therapeutic efficacy of CpGs as both a pre- and post-
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exposure antiviral against VACV. In doing so, insight has been provided into the type 
of immune response generated by VACV infection in naive mice. In addition, the 
immunomodulatory effects of CpGs have been examined to understand how these 
responses may contribute to a protective response against VACV.
6.1. The immune response to VACV in naive mice
This work has provided insight into the immune response of naive mice following 
intranasal VACV challenge. Intranasal administration of VACV leads to an acute 
infection and a wide spread immune response in both the lungs and spleens of 
infected mice. Following infection, the cell numbers of various immune effector cells, 
including neutrophils, macrophages, DCs and B-cells, increase in the lung and 
become activated (Figure 6.1). During this time, the release of cytokines such as IFN- 
y contribute to an antiviral immune response and chemokines like CCL2 recruit cells 
such as macrophages to the site of infection. The influx of immune effector cells into 
the lung attempts to control VACV replication and limit viral dissemination around 
the body. In the spleen, immune cells are alerted to the presence of infection, either 
through migration of cells from the infected lung or recognition of viral ligands from 
VACV itself. In response, pro-inflammatory cytokines such as TNF-a, IL-6 and type I 
and type II interferons are released, further amplifying the immune response (Figure
6.2). Throughout the remainder of infection, immune cells in the lungs and spleen 
continue to exhibit an activated phenotype and an adaptive response involving B and 
T-lymphocytes develops. Occasionally, this immune response enables mice to survive 
infection and recover from clinical signs of disease. Studies suggest that humoral and 
cell-mediated immunity are important at this stage to promote virus clearance 
(Reading & Smith, 2003b). In addition, the roles of complement and pox-virus
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Figure 6.1. Increased inflammatory responses in the lungs of untreated VACV 
infected mice. Figure shows increased immune activity in the lungs of mice 
following intranasal infection with VACV.
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VACV infected mice. Figure shows increased immune activity in the spleens of mice 
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specific antibodies, although not examined in this work, are thought to play a major 
role in combating orthopoxvirus infection (Smith & Kotwal, 2002).
Data presented by Rees and colleagues suggests VACV rapidly establishes itself in 
the lungs of infected mice, reaching a peak on day +3 of infection (Rees et al, 2005) 
(Figure 6.3b). At this stage, viral titres also peak in the spleen and significant levels of 
VACV can be isolated from the brain (Rees et al., 2005) (Figure 6.4b and Figure 6.5). 
By day +5, viral titres begin to decrease in the lungs and spleen, although titres in the 
brain increase. By day +9 of infection, titres in the spleen are very low but high titres 
persist in both the lung and the brain. This titration data correlates with the 
immunological data obtained throughout this thesis. Increases in VACV titres during 
early infection results in a strong local inflammatory response in the lung. The arrival 
of VACV in the spleen also initiates a strong inflammatory response, characterised by 
very high levels of IFN-y. As the inflammatory response amplifies in the lungs, viral 
titres stabilise, and begin to reduce steadily over the remainder of infection. This 
implies that the immune response in the lung is eventually able to control local VACV 
replication. In the spleen, viral titres begin to drop post-day +3 of infection when the 
inflammatory response is at its strongest. The clearance of VACV from the spleen 
may be due to the antiviral effects of IFN-y and the involvement of B and T- 
lymphocytes as the adaptive immune response develops. Ultimately in this model, 
these responses fail to prevent lethality and mice succumb to infection. This may be a 
consequence of high viral titres in the brain. The role of the immune response in 
controlling VACV titres in the brain is unclear and may involve resident immune cells 
such as astrocytes and microglial cells.
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6.2. The effect of CpG-B 7909 on the immune response to VACV
The intranasal administration of CpG-B 7909 has previously been shown to 
completely protect mice from a subsequent intranasal challenge with VACV (Rees et 
al, 2005). Here, viral titres in the lungs of CpG-treated animals were found to be 
significantly lower than in mice that had not received any CpG treatment. This 
suggested that pre-treatment with CpG may result in a more effective inflammatory 
response capable of controlling virus infection. The work presented in Chapter 3 of 
this thesis provides an immunological assessment of the lungs and spleens of mice 
given CpG or PBS prior to VACV challenge. Stimulation with CpG-B 7909 resulted 
in the release of pro-inflammatory cytokines such as IFN-a, IFN-y, TNF-a and IL-6 
along with chemotactic messengers such as CCL2 as has been shown in a number of 
other studies (Schwartz et a l , 1997; Klinman et a l , 1996; Krieg, 2002; Deng et a l ,
2004). In addition, effector cells such as macrophages, neutrophils, dendritic cells and 
NK cells were identified in high numbers in the lungs of CpG-treated mice. 
Consequently, at the time of VACV challenge (day 0), the lungs of CpG-treated mice 
had elevated numbers of activated immune effector cells and increased levels of 
powerful pro-inflammatory and antiviral cytokines (Figure 6.3a). In addition, the 
strength of immune response in the lungs of CpG-treated animals persisted over the 
first three days of infection compared to the more muted response observed in control 
animals. It is likely that the strength of this response restricted the growth and 
dissemination of VACV, as has been shown in other studies using CpGs as a 
prophylactic against viruses and bacteria (Ashkar et al, 2003; Sajic et al, 2003; 
Waag et al, 2006; Wongratanacheewin et al, 2004; Elkins et al, 1999b). Figure 6.3b 
is recreated with kind permission from the authors of the Rees study (Rees et al,
2005). Here, pre-treatment of mice with CpG-B 7909 resulted in significantly lower
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Figure 6.3. Immunological impact of CpG-B 7909 in the lung and effect on 
viral titres. (a) CpG-B 7909 delivery results in increased immune responses in the 
lung, (b) Prophylactic CpG-B 7909 delivery can significantly affect viral titres in the 
lung. Statistical significance determined by two-way ANOVA and Bonferroni’s post­
tests. Significance denoted by *** p<0.001. Error bars indicate ± SEM.
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titres of VACV in the lung on day +3 than those from control animals. This reduction 
in viral replication seems to be a direct result of a pre-formed and primed local 
inflammatory response at the site of infection. In this sense, the pre-positioning of 
effector cells in the lung prior to challenge provides the immune response with a 
critical “head-start” in the race between host response and pathogen. As a 
consequence, VACV titres in the lungs of CpG-treated mice do not reach as high a 
level as those in un-treated mice. In addition, whilst viral titres persist in untreated 
animals, they are almost cleared in CpG-treated mice. This clearance may be related 
to a second-wave of inflammation evident on day +9 of infection in CpG-treated mice 
(Figure 6.3a). Here, DCs, NK cells and B and T-lymphocytes may contribute 
significantly to this reduction in viral titres.
Few immunological differences were identified in the spleens of CpG-treated and un­
treated groups at the time of VACV challenge. Prior to VACV challenge, small 
increases in neutrophil numbers, B-cell activation and IFN-y were detected (Figure 
6.4a). In the days following VACV infection, little additional immune activity beyond 
that caused by VACV infection was identified in the spleen. Interestingly, this 
correlates with splenic VACV titres obtained in the Rees study (Rees et al., 2005) 
(Figure 6.4b). Here, viral titres reach a peak on day +3 of infection whereas titres in 
CpG-B 7909 treated animals are significantly lower. This is likely to be a direct 
consequence of the successful immune response launched in the lung, slowing the 
dissemination of VACV to distal sites like the spleen. This effect on viral 
dissemination may be the key factor to CpG-mediated protection. For instance, viral 
titres obtained from the brain in the Rees study show that CpG-treatment prevented 
VACV from reaching the brain in the majority of animals (Figure 6.5). In comparison,
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Figure 6.4. Immunological impact of CpG-B 7909 in the spleen and effect on 
viral titres. (a) CpG-B 7909 delivery results in increased immune responses in the 
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high titres were determined in the brains of untreated mice and studies have suggested 
this contributes significantly to lethality (Hayasaka, Ennis & Terajima, 2007).
This data may suggest that the success of CpGs as a prophylactic relies on the 
generation of a powerful but local response at the site of pathogen challenge. This 
ensures the creation of a hostile environment for any invading pathogen. In support of 
this, other studies have lost the prophylactic effect of CpGs when delivered at sites 
distal from infection (Pedras-Vasconcelos et al., 2006; Ashkar et al, 2003; Sajic et 
al., 2003). However, it is possible that the immune response to VACV in the spleen 
becomes important later in infection. This is suggested by the observation from day 
+7 of infection, the numbers of activated cell-types in CpG-treated animals, including 
macrophages, neutrophils, DCs, NK cells and CD4+ and CD8+ T-cells, become 
significantly higher than those from untreated groups (Figure 6.3a). It is at this time 
that clinical signs begin to alleviate in the animal model used throughout this study or, 
conversely, the time when control mice succumb to infection. Further studies using 
VACV could investigate the importance of local CpG delivery in a pre-exposure 
system and examine how the kinetics of the immune response alters if given by 
different routes.
How the protective immune response against VACV is launched by CpG-B 7909 in 
this pre-exposure system is unclear. CpG-B ODNs are predominantly thought to 
activate B-cells most potently (Krieg et al., 1995). Here, B-cell stimulation could 
result in enhanced antigen presentation and antibody release as well as cytokine 
release such as IL-6 which in turn cascades the inflammatory signal throughout the 
lung. In this sense, it may well be that B-cells do facilitate the initiation of this
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protective response. However, it is apparent from these studies using a B-cell KO 
mouse model that protection against VACV is still induced by pre-treatment with 
CpG-B 7909. This suggests that CpG-B 7909 can also stimulate other TLR9 
expressing cell types in the lung and that this stimulation is sufficient to induce 
protection. Candidates for this direct stimulation include cells such as pDCs, myeloid 
DCs and alveolar macrophages. In addition it suggests that CpG-mediated protection 
does not rely upon the generation of VACV specific antibodies.
Studies that depleted neutrophils during the initial stages of infection did not affect 
the outcome of VACV infection. However, the role of neutrophils as a mediator of the 
protective response following CpG stimulation remains a question of interest. 
Although absent during the initial stages of infection, neutrophils may respond to 
CpG stimulation and recruit cells to the lung through release of chemotactic 
compounds like chemerin and cathepsin-G (Bennouna et al., 2003; Chertov et al., 
1997; Wittamer et al., 2005). In addition, neutrophils may prime other cells types 
through release of cytokines such as TNF-a and IFN-y (Ethuin et al., 2004) prior to 
VACV challenge and the importance of this is also a question that could be addressed 
in future work. In this present study, neutrophils were only depleted 24 hours prior to 
challenge. Repeated doses of neutralising antibody are usual in studies investigating 
the complete loss of neutrophils throughout infection. Thus, it would be interesting to 
examine whether the loss of neutrophils throughout the duration of the infection 
significantly affected the hosts ability to resolve VACV infection. The use of the 
RB6-85 monoclonal antibody remains the preferred method of depleting neutrophils 
by investigators despite the unavoidable loss of other Gr-1 expressing cell-types 
including CD8+ T-cells and some monocytes. Studies have suggested that the extent
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of this collateral depletion can be limited by altering the dose and timing of antibody 
treatment (Seilier et al., 2003). Other studies have induced neutropenia using low 
doses of cyclophosphamide (Zuluaga et al., 2006) or prevented neutrophil recruitment 
by blocking CXCR2 (Tsai et al., 2000). Both of these approaches have problems 
though as cyclophosphomide also depletes monocytes and lymphocytes, and because 
neutrophils can also be recruited in response to stimuli not involving CXCR2.
6.3. Post-exposure treatment of VACV with CpG-B 7909
In a post-exposure model of VACV infection, CpG-B 7909 was found to be less 
protective against VACV than in the pre-exposure model. This drop in protection 
(100% to 60%), is consistent with a wide range of studies which have also seen 
protective levels fall if treatment with CpG is withheld (Wongratanacheewin et al., 
2004; Waag et al., 2006; Deng et al., 2004; Sajic et al., 2003; Harandi, Eriksson, & 
Holmgren, 2003). In other studies, the host response failed to control the growth and 
replication of pathogens such as Klebsiella in the lung, Burkholderia, and HSV-2 in 
the genital mucosa. It may be that in this system, VACV rapidly reaches high titres in 
the lung and quickly disseminates to other sites of the body which future studies could 
confirm.
The post-exposure administration of CpG-B 7909 was still found to have a significant 
effect on the inflammatory response initiated by VACV. CpG-B 7909 delivery 
resulted in increased cellular recruitment and activation of macrophages, neutrophils 
and DCs in the lung (Figure 6.6a). In addition, NK cell activity on day +3 was 
increased and significant increases in cytokine and chemokine levels were also 
determined. Beyond this initial effect, no significant cellular differences between
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CpG-treated and untreated mice were determined throughout the remainder of 
infection. In the spleen, it appears only NK cells and DC numbers were bolstered by 
CpG delivery (Figure 6.6b). Interestingly, B-cell and T-cell numbers on day +7 were 
significantly higher in CpG-treated mice which may suggest CpG-treatment 
contributed to the development of an adaptive response. Despite these effects, it 
appears that post-exposure delivery of CpG-B 7909 can not orchestrate an immune 
response that can undo the “damage” already caused by VACV infection. The 
absence of the pre-formed immune response, which protects in a pre-exposure model, 
enables VACV to replicate rapidly and establish systemic infection. Therefore, the 
delayed administration of CpG-B 7909 may provide a degree of “damage-limitation”, 
sufficient to grant protection in some but not all of those infected. This is supported 
by the fact that as a post-exposure therapy, CpGs have only yielded success against 
slow growing organisms such as M. tuberculosis, C.neoformans and FLV (Juffermans 
et al, 2002; Edwards et al, 2005; Olbrich et al, 2002). These results suggest that 
CpGs alone as a monotherapy may struggle to protect against pathogens such as 
VACV which replicates rapidly, or variola, which can also replicate to high titres 
quickly in key organs during infection.
Results reported here also support the requirement for local delivery of CpG to the 
site of infection as intraperitoneal, subcutaneous or intramuscular delivery of CpG 
failed to offer equivalent protection in a post-exposure model. In addition, the use of 
multiple doses of CpG was not found to be of therapeutic benefit. It is possible that 
other dosing regimens or a combination of optimised CpG doses may grant more 
success in this area. However, given the inflammatory nature of CpGs, it may be that 
multiple doses of CpG could enhance host tissue damage and accelerate time to death
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due to an over-zealous immune response. CpG toxicity has been reported in the 
literature. Here, liver necrosis and lymphoid tissue disruption were reported following 
repeated CpG doses in a mouse model (Heikenwalder et al., 2004). As such, 
investigations of this type need to proceed with caution. It is of note that toxicity 
studies of this type may not transition directly to humans given the more limited 
repertoire of human immune cells that express TLR9. Thus it is possible that these 
studies may over-estimate any negative effect of repeated CpG stimulation.
The role of VACV immunomodulatory proteins in infection was not investigated in 
these studies. However, this is an area of particular interest and one that may 
contribute significantly to the loss of protection in a post-exposure system. 
Poxviruses, such as VACV, possess a wealth of proteins that aim to disrupt many 
different arms of the host immune response (Haga & Bowie, 2005). Many of these 
proteins are synthesised early during infection and their release into the surrounding 
area prior to CpG delivery may allow the virus to obtain a vital foothold and 
subsequently hinder the effectiveness of the innate immune response. Many of these 
proteins have been shown to increase virulence in in vivo studies (Stack et al, 2005; 
Reading & Smith, 2003) which makes their targeted disruption by siRNA or other 
technologies of potential therapeutic benefit. It would be interesting to see whether 
protection with CpG-B 7909 was boosted in systems where selected 
immunomodulatory proteins were disabled, possibly as part of a combination therapy 
approach. Maybe then, the inflammatory response induced by CpG-B 7909 may be 
stronger and more effective at combating VACV infection.
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Collectively, these analyses find CpGs are more protective when given pre-exposure 
than when given after the event of VACV infection. This is likely to be a direct result 
of the initiation of a prominent local pro-inflammatory response pre-exposure, which 
primes the host immune system prior to infection. Of equal significance is the location 
of this response. Intranasal delivery of CpG ensures the effects of CpG are most 
strongly felt in the lung (Figure 6.7a). This ensures when VACV arrives in the lung, it 
is swiftly controlled and efficiently contained by the immune system. This ultimately 
enables the control of VACV infection and restriction of the lethal dissemination 
throughout the host. In addition, immune activity in the spleen is also boosted prior to 
VACV arrival (Figure 6.7b). In a post-exposure system, the addition of CpGs 
exacerbates an on-going pro-inflammatory response in both the lung and the spleen. 
This response seems sufficient to protect mice in some cases but insufficient in others. 
This suggests the necessary immune response initiated by CpG delivery is typically 
initiated too late. Consequently, the failure of CpGs to protect in this instance results 
from the inability of the host to control virus spread to multiple organs. These 
findings re-affirm the importance of local delivery of CpG to ensure activated cells 
are very much in the right place at the right time.
6.4. CpGs activate macrophages and restrict VACV titres in vitro
Studies using B-cell KO mice and neutrophil ablating antibodies (Section 3.3.7/8) 
suggested that neither B-cells nor neutrophils were crucial in conferring CpG 
mediated protection against VACV. This led to the investigation of other cell-types 
that may be important in mediating defence against VACV. Macrophages were 
identified in Chapter 3 as cells that were both highly activated and present in high 
numbers in the lungs of CpG-treated mice. The prevalence of alveolar macrophages in
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the lung and reports that they also express TLR9 (Huang et al., 2005) made them a 
prime candidate cell-type to investigate. In addition, other studies have suggested that 
macrophages actively ingest and respond to CpG stimulation (Stacey et al., 1996; 
Sester et al, 2000; Roberts et al, 2005). The expression of TLR9 on primary AMs 
was confirmed using RT-PCR and these studies suggested that CpG stimulation could 
enhance levels of TNF-a transcription in AMs. This observation makes them potential 
candidates for direct CpG stimulation in vivo. Reports that macrophages exhibit 
considerable heterogeneity (Gordon & Taylor, 2005) led to the investigation of CpG 
responses by AMs using an in vitro cell-line (MH-S) alongside a commonly studied 
non-alveolar macrophage cell-line (J774).
The degree of macrophage stimulation was found to vary dramatically according to 
the class of CpG used. In all studies, CpG-A 2336 and CpG-sC 10109 were identified 
as the most potent activators of macrophages. Here, stimulation with these CpGs 
typically induced significantly stronger NO, cytokine and chemokine responses than 
other CpGs. Interestingly, CpG-B 10103 (substituted for CpG-B 7909) was unable to 
stimulate strong pro-inflammatory cytokine and chemokine responses in either cell- 
line. However, stimulation of macrophages with CpG-B 10103 increased expression 
of the activation marker CD54 suggesting that incubation with CpG-B 10103 did 
activate both macrophage cell-lines. In addition, CpG-B 10103 significantly reduced 
levels of apoptosis in both MH-S and J774 macrophages further suggesting it can 
stimulate macrophages. Apoptosis is often a significant component of the host 
immune response and in an in vivo setting, prevention of apoptosis may prolong the 
ability of macrophages to secrete cytokines, phagocytose pathogens or necrotic 
neutrophils and present antigen to naive T-cells (Haslett, 1999). The role of
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macrophage apoptosis in an in vivo VACV infection has not been fully defined but it 
is known that VACV encodes a number of anti-apoptotic proteins such as v-GAAP, 
SPI-2, crmE (Dobbelstein & Shenk, 1996; Gubser et al, 2007), which suggests 
cellular apoptosis may play a significant role in VACV infection. Therefore, 
determining whether apoptosis plays a significant role in CpG mediated protection 
and how VACV may modify this response would be a valid area to investigate.
The growth of VACV in MH-S and J774 macrophages did not identify any difference 
in the ability of VACV to replicate within either cell-line. However, pre-stimulation 
of macrophages with CpG-B 10103 or CpG-sC 10109 identified a significant 
difference in the ability of VACV to grow in pre-stimulated macrophages. Here, CpG- 
sC 10109 restricted growth of VACV significantly more than CpG-B 10103. The 
mechanism for this inhibition was found to be unrelated to NO release as has been 
suggested in other studies (Harris, Buller, & Karupiah, 1995; Karupiah & Harris, 
1995; Karupiah et al, 1993), as inhibition of NO did not significantly affect viral 
titres. Importantly, these studies suggest that pre-stimulation of macrophages with 
CpG-B can restrict growth of VACV. This may have important implications for the 
role of macrophages in understanding the mechanistic nature of CpG-B prophylaxis.
Investigation of the ability of CpG-sC 10109 to protect against VACV in vivo 
suggested that pre-treatment could provide full protection. Optimum protection was 
achieved when CpG-sC 10109 was administered 7 days before challenge, compared 
to three days before for CpG-B 7909. This result, along with the in vitro observations 
made, suggests that these two CpGs may confer protection against VACV via 
different means. If so, the role of the macrophage in this model would be worth
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investigating. Studies using clodronate liposomes to deplete macrophages in vivo have 
suggested that macrophages may be crucial to resolving VACV infection (Karupiah et 
al, 1996; Rivera et al, 2007). If macrophages are key to providing defence against 
orthopoxvirus infection, it is possible that a more potent macrophage stimulator such 
as CpG-sC 10109 may be able to provide enhanced protection against VACV in a 
post-exposure model of infection.
Collectively, these studies also identified significant differences between MH-S and 
J774 macrophage responses to CpG stimulation. MH-S macrophages were found to 
transcribe less IL-6 than J774s and secrete significantly less TNF-a and IL-6 
following CpG stimulation. These in vitro cytokine observations concur with the view 
that AMs are typically quiescent cells that limit inflammation in the lung environment 
(Takabayshi et a l, 2006; Holt, 1986; Holt et a l , 1993). It may be that this controlled 
release of pro-inflammatory cytokines by AMs contributes to a protective immune 
response against pathogens such as VACV. MH-S macrophages were found to secrete 
significantly more NO than their J774 counterparts when stimulated with CpG. NO is 
thought to play a dual role in inflammation, being toxic to invading pathogens but 
also being capable of suppressing T-cell and DC functions and promoting apoptosis 
(Strickland et a l, 1993; Holt et al, 1993). In this sense, high NO release by MH-S 
macrophages may model an in vivo situation whereby AMs cause the destruction of 
invading pathogens whilst restricting overall levels of inflammation. This could help 
preserve lung integrity and homeostasis.
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6.5. Concluding remarks
The investigation into CpGs as candidates to fill the current void in available 
antivirals against orthopoxvirus, has resulted in a number of key observations. CpG-B 
and CpG-sC classes of CpG are capable of protecting mice against a lethal dose of 
VACV if given at an optimum time prior to challenge. This protection is thought to be 
a direct result of the release of pro-inflammatory and antiviral cytokines that promote 
the recruitment of an array of host effector cells. This in turn prevents the invading 
virus from establishing itself and restricts its dissemination around the host. Key to 
this response may be macrophages and their ability to modulate the host response 
through release of pro-inflammatory cytokines and chemokines. In addition, activated 
macrophages infected with VACV may be able to restrict viral growth and limit virus 
dissemination. Despite the effectiveness of CpGs as a prophylactic, in reality, pre­
empting orthopoxvirus infection is unlikely to ever prove a workable solution. Of 
greater interest is the ability of antivirals to protect after virus infection. In this case, 
therapy with CpG-B falls some way short of other antivirals such as ST-246, which 
are currently leading the way in research trials (Yang et al, 2005a). Potentially, the 
key factor in CpGs failing to confer protection in a post-exposure setting is their 
inability to orchestrate an immune response rapidly enough to control VACV growth. 
Whether investigation of other CpG classes such as CpG-sC could improve in this 
area, is unclear. However, it is perhaps doubtful that any improvement will be 
improvement enough. Antiviral compounds such as ST-246 target the virus itself and 
prevent its maturation (Yang et al, 2005b). This may slow the replication of virus 
sufficiently for the host immune system to mount an appropriate and protective 
response. In addition, these newly formulated drugs are highly effective in an orally 
available format which makes them extremely desirable. In contrast, the loss of
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protection observed when CpGs are not delivered to the site of infection further 
detracts from their applicability.
Whilst the mono-therapeutic use of CpGs may not be the solution to viral infection, 
CpGs are proving valuable immunomodulatory agents in other medically important 
areas. Although recently withdrawn from non-small cell lung cancer trials (Schmidt, 
2007), CpGs are proving effective against other types of malignancies (Murad et al., 
2007) and still have the potential to be invaluable as allergy treatments or as adjuvants 
to new vaccines (Krieg, 2006; Jurk & Vollmer, 2007). Furthermore, the use of CpGs 
in a combined antiviral approach is something that could prove to be of benefit. 
Combination approaches currently lead the way in the treatment of HIV and in other 
viral infections. It is feasible that where current antiviral compounds target the virus 
but are not fully effective, CpG therapy could help promote an immune response that 
resolves infection and generates adaptive immunity. Ultimately, understanding the 
differing kinetics of the immune response following CpG stimulation may allow for a 
more tailored approach to CpG mediated therapy in many areas.
Finally these studies have helped underpin our knowledge of the host response to 
VACV infection and response to CpG stimulation. Characterisation of the immune 
response during pathogen infection is paramount to understanding disease pathology 
and in determining correlates of protection in treatment studies. These studies have 
highlighted the importance of a rapid immune response to infection and revealed that 
the host response to VACV infection involves a diverse array of cell-types including 
macrophages, neutrophils, DCs and NK cells, in addition to B and T-lymphocytes. 
This response is likely to be orchestrated through the involvement of a wide variety of
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pro-inflammatory cytokines and chemokines and release of NO. Understanding this 
response may enable a more tailored approach to immunomodulatory therapy and 
make the development of new and effective antiviral therapies a more likely prospect.
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